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CHAPTER 1. INTRODUCTION 
1.1. Background and Significance 
Infectious bacteria are becoming progressively more resilient to existing antibiotic drugs. 
It has been estimated that multi-drug resistant bacterial diseases are directly responsible for 
23000 deaths annually in the United States and more than 25000 in the European Union.1-2 These 
multi-drug resistant diseases are also estimated to cause economic loses of $55 billion dollars 
annually in the United States.1 Despite the need for new antibiotics to overcome the huge loses in 
lives and money, the development pipeline is constrained (Figure 1).1, 3 Pharmaceutical 
companies are unwilling to develop novel antibiotics because of risky market failures. Therefore 
many incentive strategies have been proposed to encourage research facilities and 
pharmaceutical companies to develop new antibiotics.4  
 
Figure 1. A graphical representation showing the number of antibacterial 
approvals from 1980 till 20121 
 
Antibiotics "opposing life" are compounds that are produced by microorganisms that 
selectively inhibit the growth of or kill other microorganisms. Antibiotics can be classified 
according to their chemical structure, mechanism of action, spectrum of activity or their source. 
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Based on their mechanism of action, antibiotics are classified into four main categories: cell wall 
synthesis inhibitors; protein synthesis inhibitors; DNA/RNA replication and repair inhibitors; 
and folate coenzyme biosynthesis inhibitors (Figure 2).   
 
Figure 2. A graphical representation showing the classification of antibiotics according to 
their mode of action 
Aminoglycoside antibiotics, which are classified as protein synthesis inhibitors, were 
among the first "weapons" against bacterial warfare revealed to mankind. Their history began 
when Waksman discovered streptomycin 1 (Figure 3),5 the first useful antibiotic isolated from a 
bacterial source, in 1944. Streptomycin was the first effective therapeutic for tuberculosis, a 
disease that for centuries caused human morbidity and mortality unsurpassed by wars or any 
other pestilence.6-7 Streptomycin 1 opened the door for the successive introduction of a series of 
milestone aminoglycosides which definitively established the usefulness of this class of 
antibiotics in the treatment of serious life-threatening bacterial infections.8 Unfortunately, as the 
use of AGAs in clinical practice became widespread, resistance came to be observed more 
frequently. This expanding bacterial resistance together with adverse effects, in particular 
ototoxicity and nephrotoxicity, decreased the use of AGAs in clinics and led to them being 
progressively replaced broad-spectrum antibiotics with fewer side effects, such as 
fluoroquinolones, carbapenems, and cephalosporins. Consequently, AGAs share in the 
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antibiotics market declined to only 2.7% in 2010.9 Recently, with the ever-growing bacterial 
resistance to the newer classes of antibiotics, many researchers decided to revisit AGAs with 
renewed emphasis on chemical modification, which includes structural modifications,10-11 
dimerization,12  and conjugation to other antibiotics13 or biomolecules.14  
 
Figure 3. Streptomycin (1) 
1.2. Structural features and classifications 
Structurally aminoglycosides are low molecular weight (300-800 Dalton) 
pseudosaccharide molecules consisting of a central aminocyclitol ring, mostly a 2-
deoxystreptamine (2-DOS) ring, linked to one or more amino sugars by glycosidic bonds. The 
most prominent features of AGAs are the presence of multiple amines attached to their rings. 
These amines together with the various hydroxyl groups gave them high water solubility and 
basic characteristics. As a result of their high polarity, AGAs are poorly absorbed orally with less 
than 1% reaching the blood stream through the gastrointestinal tract, which makes parenteral 
injections the common mode of administration for systemic diseases. Moreover, their high 
polarity prevents them from crossing the blood-brain barrier and reaching the central nervous 
system.15  
Aminoglycosides are classified according to the linkage type with the 2-
deoxystreptamine ring into two major classes: 4,5-aminoglycosides and 4,6-aminoglycosides in 
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which the 2-deoxystreptamine ring is disubstituted at the positions 4 and 5, or 4 and 6 (Figure 4). 
Although most of the aminoglycosides fit to this classification, some others have unusual 
structures (Figure 5) such as bicyclic rings (e.g. apramycin 9), mono-substitution of the 2-DOS 
ring (e.g. apramycin 9 and garamine 10) or incorporation of a streptamine ring instead of 2-DOS 
(e.g. streptomycin 1). In addition, aminoglycosides that are derived from bacteria of the 
Streptomyces genus are named with the suffix mycin, whereas those that are derived from 
Micromonospora are named with the suffix micin.  
 
Figure 4. Classification of aminoglycosides 
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Figure 5. Unusual aminoglycoside structures 
1.3. Mechanism of action of aminoglycosides 
Aminoglycosides are of outstanding value as they are highly active broad-spectrum 
antibiotics that act against a wide range of bacteria including Gram-positive, and especially 
Gram-negative bacteria, as well as various parasites such as plasmodiums. They are also 
bactericidal in that they kill the bacteria, rather than simply stopping their growth. Early studies 
showed that protein synthesis is the primary target of AGAs, as production of labeled protein by 
cell-free extracts of Mycobacterium tuberculosis was blocked by streptomycin 1.16 Today there 
is significant knowledge of all the different stages of AGAs action from uptake until bacterial 
death. 
1.3.1. AGA uptake 
The large size of aminoglycosides excludes their penetration through bacterial porin 
channels. However, AGAs with their several basic amine groups are protonated, and have 
cationic nature, which results in nonspecific electrostatic interactions between the positively 
charged AGAs and the negatively charged lipopolysaccharides (LPS) in the outer bacterial 
membrane.17-18 This electrostatic interaction is followed by two energy-dependent uptake phases: 
energy-dependent phase I (EDPI) and energy-dependent phase II (EDPII). 
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Energy-dependent phase I (EDPI) is a slow rate uptake to the cytosol and depends on 
AGA concentration. Inhibitors of oxidative phosphorylation or electron transport can halt this 
phase (Figure 6). In the energy-dependent phase II (EDPII), aminoglycosides bind to the 30S 
ribosomal subunit through a rapid process, and this binding perturbs the translational accuracy 
(misreading) and leads to defective proteins. The so-formed defective cell membrane proteins 
eventually alter cell membrane permeability, stimulating further aminoglycoside influx and 
leading to an autocatalytic cycle of AGA uptake and protein synthesis disruption, followed by 
cell death.19 
 
Figure 6. Schematic diagram showing the stages of AGAs uptake 
1.3.2. Protein synthesis and AGA binding to the ribosomes  
Normal protein synthesis starts by producing a mRNA copy of the genetic information in 
the DNA in a process called transcription. This process is followed by the translation process in 
which the ribosomes translate mRNA-encoded genetic information to proteins. RNA is 
assembled as a single-stranded chain of nucleotides that fold upon themselves, rather than as 
paired double-strands as in the DNA. Ribonucleotides consist of three parts: the phosphate 
backbone, ribofuranose sugars, and nucleobases. There are four nucleobases found in RNA: 
adenine, guanine, cytosine and uracil. Adenine and guanine are purine bases while cytosine and 
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uracil are pyrimidine bases. The bases usually pair together according to the Watson-Crick rule 
in which adenine associates with uracil by two hydrogen bonds, and guanine pairs with cytosine 
by three hydrogen bonds (Figure 7). 
 
Figure 7. The four fundamental nucleotides found in RNA and their Watson-Crick base 
pairs. 
The high accuracy of protein translation, with errors estimated at only 4 × 10−4 per 
codon,20 suggested that fidelity does not simply come from mRNA-codon/tRNA-anticodon 
recognition, but that ribosomes also play a crucial role in translation accuracy and do not just act 
as an inert platform. The fidelity of protein synthesis requires the binding of a correct tRNA to 
the A-site, which is a small loop in the small ribosomal subunit that serves as aminoacyl-tRNA 
acceptor site. tRNA interacts with the ribosomal A-site containing three unpaired adenines 
(A1408, A1492 and A1493) and makes it adopt a “flipped-out” conformation.  This leads to a 
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faster step in which other conformational changes occur, and results in tight binding of the 
cognate tRNA to the A-site.21 The amino acid that the tRNA was carrying is transferred and 
bonds to the growing polypeptide chain (Figure 8). The ribosome then moves one codon step 
along the mRNA to accept the new tRNA, which codes to the next codon. 
 
Figure 8. Schematic diagram showing ribosomes in protein synthesis 
Aminoglycoside bactericidal activity is attributed to their binding of aminoacyl-tRNA 
acceptor site A-site in the bacterial 16S rRNA.22-27 Recognition and binding of aminoglycosides 
to their target is due to two primary types of interactions. The most prominent interaction comes 
from the electrostatic interaction between the cationic aminoglycosides and the negatively 
charged backbone of rRNA. Other interactions mainly arise from hydrogen bonding of 
aminoglycosides with rRNA bases. The location of these hydrogen bonds differs between 
aminoglycosides, but some are common. For example, the 2-DOS ring (ring II) of paromomycin 
interacts with bases A1406, U1495 and G1494 by hydrogen bonds.23 Moreover, hydrogen bonds 
are formed between the paromomycin ring 1 and A1408, A1492, A1493 and G1491 in the 
bacterial rRNA (Figure 9). On the other hand, neither rings III nor IV have any direct interaction 
with rRNA.23  
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Figure 9. a) Crystal structure of paromomycin binding to the bacterial A site (PDB code: 
1FJG). b) Schematic diagram showing the binding of paromomycin (3) with rRNA 
nucleobases. 
When bound to the A-site, AGAs stabilize the conformation of the internal loop with 
A1492 and A1493 "flipped out" (Figure 10). This reduces the energetic cost for both cognate and 
noncognate tRNA to bind, thereby reducing the ability of the ribosome to recognize the correct 
tRNA, and leads to misreading of the mRNA and synthesis of defective proteins (Figure 11).28-30 
In addition, this "flipped out" conformation increases the affinity of the tRNA for the A site, thus 
stabilizing the pre-translocation state and increasing the energy barrier for translocation.31-32 
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Figure 10. Schematic diagram showing a) the equilibrium of A-site between "flipped in" 
and "flipped out" conformations in protein translation and b) aminoglycoside bound to 
ribosome A site stabilizing the "flipped out" conformation 
The connection between the resulting faulty proteins and bacterial cell death is a subject 
of debate. One hypothesis is that the damaged protein can insert in the bacterial inner membrane 
and cause its destabilization and so cell death.33-34 Another hypothesis suggests that defective 
metabolic and respiratory enzymes lead to oxidative stress and production of toxic free 
radicals.35  
 
Figure 11. Schematic diagram showing aminoglycoside bound to ribosome and causing 
codon misreading. 
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1.4. Aminoglycoside resistance and toxicity 
The excellent characteristics of AGAs as broad-spectrum antibacterial agents, with 
desirable bactericidal activity against difficult-to-treat Gram-negative bacteria and mycobacteria, 
are counterbalanced by two major problems, namely resistance and toxicity (ototoxicity, i.e., 
damage to the inner ear, and nephrotoxicity, i.e., damage to the kidney).36 Due to these problems 
the importance of AGAs has waned, but a deep understanding of these problems may help to 
overcome them. 
1.4.1. Aminoglycoside resistance 
AGAs are isolated from soil-dwelling bacteria in particular Streptomyces and 
Micromonospora species. However, their bacterial origins also are the source of most of the 
resistance problems encountered today, as most of the AGA producing species have established 
strategies to prevent the deleterious effects of the antimicrobial metabolites they produce 
themselves.9 Resistance problems also arise because of the frequent use of AGAs against human 
and animal pathogens. Improper and incomplete treatment with AGAs will allow mutant 
resistant bacteria to flourish. Thus, establishment of regulations to address proper use of 
antibiotics, promotion of public awareness of rational administration of antibiotics, and 
encouragement of the development of new antibiotics are three strategies that Food and Drug 
Administration (FDA) is pursuing to solve bacterial resistance problems.37  
Resistance mechanisms can be categorized into three types (Figure 12). First, bacteria can 
reduce the internal concentration of AGAs by decreasing the drug uptake (influx) or increasing 
the drug expulsion (efflux). Second, some bacteria are able to modify their ribosomal A-site so 
that AGAs can no longer bind to it. Finally, the most common mechanism for bacterial resistance 
arises from the structural modification of the aminoglycosides themselves by specific enzymes 
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expressed by resistant strains. There are three classes of these aminoglycoside modifying 
enzymes (AME): aminoglycoside phosphotransferases (APHs), aminoglycoside 
acetyltransferases (AACs) and aminoglycoside nucleotidyltransferases (ANTs).38-39 
 
Figure 12. Schematic diagram showing different resistance mechanisms 
1.4.1.1. Reduction of aminoglycoside internal concentration  
Bacteria can reduce aminoglycoside concentration by decreasing the drug uptake (influx) 
or by increasing the drug expulsion (efflux). As discussed in the previous section AGA uptake 
goes through three stages. While the first step is electrostatic attraction between AGAs and the 
bacterial cell surface, the other two steps are energy and oxygen dependent which give anaerobic 
bacteria an inherent resistance to AGAs.40  Also mutations to the ATP synthases of E. coli, S. 
aureus, and P. aeruginosa have been shown to decrease their susceptibility to AGAs.41 
The other strategy of decreasing AGA concentration in the bacterial cells is by increasing 
the drug expulsion (efflux). This is done by efflux energy-dependent active pumps. There are 
many types of transporters, such as the resistance nodulation cell division (RND)-type 
transporter superfamily,42-43 which plays an important role in Gram-negative bacteria like P. 
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aeruginosa. Another example is the major facilitator superfamily (MFS) of transporters which 
contributes to aminoglycoside resistance of E. coli.44 
1.4.1.2. Ribosomal binding site modifications 
Alteration of the aminoglycosides target, the 16S RNA by bacteria, is another mode of 
resistance. There are two types of target modifications: nucleotide mutation and nucleotide 
methylation. The most common example of nucleotide mutations is the A1408G mutation in the 
ribosomal A-site. This mutation gives bacteria resistance to the 6’-NH2 aminoglycosides by 
interrupting key interactions with the AGAs.45  
Many aminoglycoside-producing bacteria (Streptomyces and Micromonospora) protect 
themselves from their own AGAs by producing rRNA methylases, which can methylate the 16S 
rRNA.46-47 Examples of these methylase enzymes that are now well known include RmtA, in P. 
aeruginosa,48 the RmtB that was found to be responsible for aminoglycoside resistance in 
Serratia marcescens,46 and ArmA, that was first found in a Klebsiella pneumoniae clinical 
isolate.49 These mutations are of low clinical importance at present, but they pose a potential 
threat because of the almost complete resistance they bring against AGAs, especially 4,6-
disubstituted AGAs. The mono-substituted 2-DOS AGA apramycin (9), on the other hand, is not 
susceptible to the ArmA methylation mechanism due to its unusual bicyclic structure.50 
1.4.1.3. Aminoglycoside modifying enzymes (AMEs) 
Aminoglycoside modifying enzymes catalyze covalent modification at hydroxyl or amino 
groups of both the 2-deoxystreptamine nucleus and the sugar moieties. The modified drugs fail 
to properly bind to the ribosomes. As AMEs are encoded on plasmids they are highly mobile and 
are easily spread between bacterial species. There are three classes of aminoglycoside modifying 
enzymes (AME): aminoglycoside acetyltransferases (AACs), aminoglycoside 
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phosphotransferases (APHs) and aminoglycoside nucleotidyltransferases (ANTs). Typical 
positions for structural modification by AMEs in kanamycin 6, neomycin 2, netilmicin 11 and 
apramycin (9) are shown in (Figure 13).51 The common nomenclature of these enzymes 
identifies their class by three capital letters followed by a number in parentheses that indicates 
the site of modification. Sometimes there is a roman numeral that describes a particular 
resistance profile and then a lower-case letter that acts as an individual identifier (e.g. AAC(3)-
IIa). 
 
Figure 13. Target sites of aminoglycosides modifying enzymes on a) kanamycin B b) 
neomycin B c) netilmicin and d) apramycin 
1.4.1.3.1. Aminoglycoside acetyltransferases (AACs) 
AACs belong to the GCN5-related N-acetyltransferase (GNAT) superfamily of proteins. 
They are acetyl-CoA-dependent and catalyze the acetylation of amino groups in 
aminoglycosides. Over 50 members of the AAC family have been identified that are sub-
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classified to AAC(1), which has no further subclasses, AAC(3)-I to X, AAC(2′)-I, and AAC(6′)-I 
and -II. AAC(1) enzymes do not cause a substantial drop in antibiotic activity and are of little 
importance as they are rarely found in clinical isolates.52 AAC(3) enzymes are found only in 
Gram-negative bacteria where AAC(3)-IIa are found in a large variety of genera, AAC(2′)-I 
confers resistance to neomycin, kanamycin, and gentamicin and is found in Gram-negative 
bacteria and mycobacteria.53 AAC(6′) enzymes are present in Gram-negative as well as Gram-
positive bacteria and are by far the most common of all AMEs as acetylation of the 6’-amino 
group blocks a crucial interaction with A1408 and renders the AGA inactive.54 
1.4.1.3.2. Aminoglycoside phosphotransferases (APHs)  
APHs are ATP-dependent enzymes that catalyze the regiospecific transfer of the -
phosphoryl group of the ATP to hydroxyl groups of AGAs. This phosphorylation introduces a 
negative charge into the molecule, which decrease the ability to bind to the A-site in the 
ribosome. APHs are often found on multidrug-resistant R plasmids leading to problems of gene 
transfer between Gram-positive and Gram-negative bacteria. Seven classes of such enzymes, 
APH(3’), APH(2’’), APH(3’’), APH(4), APH(7’’), APH(6), and APH(9) have been identified in 
clinical isolates of which the APH(3′) class is the most common.55 
1.4.1.3.3. Aminoglycoside nucleotidyltransferases (ANTs) 
ANTs are another class of ATP-dependent enzyme that catalyze the transfer of an AMP 
group to a hydroxyl group in the AGA. Different classes of ANTs, the ANT(6), ANT(9), 
ANT(4′), ANT(2″), and ANT(3″), are now known. Although they are the smallest AME family 
by number, ANTs are of significant clinical importance because of the ability of ANT(2″) to 
neutralize tobramycin 12 and amikacin 13 as well as gentamicin 7 (Figure 14).56  
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Figure 14. Structures of tobramycin (12) and amikacin (13) 
1.4.1.3.4. Avoiding AME resistance  
There are two viable ways to avoid the resistance from AMEs. One way is to develop 
inhibitors of the modifying enzymes that can be co-administered with the AGA. Alternatively, a 
better way is to synthesize analogs of natural aminoglycosides resistant to the modifying 
enzymes. In comparison to kanamycin B (6), netilmicin (11) suffers from fewer resistance 
enzymes as the installation of the N1-ethyl group sterically protects it from aminoglycoside 
modifying enzymes at this position (Figure 13).  Netilmicin (11) is also protected from several 
AMEs, such as APH(3′) and ANT(4′), by the absence of the 3′- and 4′-OH groups in ring I. 
Aminoglycoside modifying enzymes for apramycin also are rare, with only AAC(3) known thus 
far. This absence of resistance makes apramycin (9) a candidate for human use and a good 
candidate for modification and development.57 
1.4.2. Adverse effects of aminoglycosides 
The adverse effects of AGAs are one of the main problems that prevent their wide use in 
clinics. The main side effects a patient can encounter when given AGAs are nephrotoxicity, or 
kidney damage, and ototoxicity, or hearing loss. Along with these main side effects, there are 
minor acute side effects like neuromuscular blocking action that can be referred to as curare-like 
activity. The mechanism of this latter effect was confirmed to be action as a calcium channel 
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blocker; subsequently AGAs have been used as chemical tools to explore the functions of 
calcium channels.58  
1.4.2.1. Nephrotoxicity 
Nephrotoxicity is kidney damage cause by AGAs and is clinically presented as non-
oligouric kidney injury. Kidney damage can lead to the inability of the body to clear urine and 
other wastes. Its manifestations include aminoaciduria, glycosuria, enzymuria, hypomagnesemia, 
hypocalcemia, and hypokalemia. Although nephrotoxicity is reversible, if it is untreated it causes 
increased electrolyte levels in the body and may lead to permanent kidney damage and 
eventually kidney failure.27 This toxicity can be explained by the accumulation of AGAs in the 
renal cortical tissue especially the proximal tubules. AGAs are absorbed by endocytosis and once 
transferred to the lysosome, the positively-charged AGAs strongly bind to the negatively-
charged phospholipids resulting in a decrease of lysosomal phospholipase activity.59 An 
abnormal increase in size and number of lysosomes was found with decreased lysosome stability 
can lead eventually to cell death.60 
Several strategies have been used to prevent nephrotoxicity including: 1) hydration 
therapy, which can often decrease the symptoms of aminoglycoside-induced nephrotoxicity. 2) 
The use of a once daily large dose as opposed to the same daily dose taken as separate three 
doses or by continuous infusion.61 This latter is explained by the finding that uptake by the renal 
cells will be saturable at relatively low concentrations such that the excess drug passes the 
lumen, is not reabsorbed, and is excreted without causing toxicity. 3) Aminoglycoside 
modifications in which the N-1 atom has been made non-ionizable (i.e., by acylation) decrease 
AGA basicity and thus reduce binding to acidic phospholipids, and decrease inhibition of the 
lysosomal phospholipases.39 4) Co-administration of polyaspartic acid prevents aminoglycoside 
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binding to negatively charged phospholipids bilayers and thereby prevents the drug from 
inhibiting the activities of lysosomal phospholipases.62 Overall, nephrotoxicity is reversible, can 
be easily monitored and can largely be prevented.   
1.4.2.2. Ototoxicity 
Unlike nephrotoxicity, ototoxicity is irreversible and difficult to monitor. It is reported to 
affect as much as 20% of the patient population, which makes it the main concern.63 Ototoxicity 
includes damage to the vestibular system, resulting in imbalance disorders, and damage to the 
cochlea, resulting in tinnitus and hearing loss. There is no apparent correlation between 
nephrotoxicity potential or with the concentrations reached in the inner ear by different 
aminoglycosides with the magnitude of their ototoxic potential.63 However, longer AGA 
treatments, kidney malfunction and the nutritional state of the patient may also contribute to the 
magnitude of ototoxicity.64 While some AGAs (e.g. gentamicin) are more vestibulotoxic than 
cochleotoxic, which can be used for vestibular chemical ablation, others (e.g. amikacin and 
neomycin) can be more cochleotoxic than vestibulotoxic. 
AGAs quickly penetrate to the inner ear within minutes of parenteral administration, and 
although the half-life of the AGAs in the plasma ranges from 3-5 h, their half-lives in the inner 
ear can reach 30 days. This long resident time was earlier misinterpreted as accumulation of 
AGAs in the inner ear, but this was ruled out by the fact the concentration of the drug in the 
inner ear was the same as in other organs and never reached the plasma concentration.65 
AGAs cause damage to hair cells in the cochlea located in the inner ear. The cochlear 
hair cells function is to convert sound waves to electric impulses, which are transferred to the 
brain to give the hearing sensation. AGAs affect first the cochlear hair cells in the basal part that 
are responsible for the higher frequency (high pitched) sound, and so causing higher frequency 
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deafness, before they affect the cochlear hair cells in the apical part that are responsible of the 
lower frequency (low pitched) sound.66 The fact that the damaged hair cells do not regenerate 
makes ototoxicity irreversible.  
 
Figure 15. A schematic representation of the mechanisms of aminoglycoside ototoxicity. 
Ototoxicity caused by AGAs involves the formation of reactive oxygen species (ROS) in 
the inner ear tissues that lead to ultimate cell death (Figure 15).  The mode of formation of ROS 
has not been clear,67-69 but some hypothesis will be outlined: 1) a non-catalytical pathway, in 
which AGAs binds to iron and mediate the formation a reactive oxygen species from arachidonic 
acid. Electrospray Ionization Mass Spectrometry (ESIMS) confirmed the existence of ternary 
complexes between Fe2+/3+, gentamicin 7, and arachidonic acid.70 2) A catalytical pathway, in 
which AGAs activate Rho-GTPase (Rac-1), which in turn activates the NADPH oxidase 
complex to form  superoxide radicals.71 However, recent evidence suggests that inhibition of 
mitochondrial protein synthesis is the main reason.24, 72-74 The potency of a series of AGAs in 
inhibiting mitochondrial hybrid ribosome function correlated with the relative cochleotoxicity of 
the respective compounds in humans.75 The molecular rationale for the increased affinity to 
mitochondrial rRNA is that its A site retains the critical A1408 residue, similar to the bacterial A 
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site (Figure 16). This rationale is bolstered by the hyper-susceptibility of individuals with 
mutations in mitochondrial rRNA to ototoxicity, in particular the transition mutation A1555G in 
the A-site of the mitoribosomal small subunit which renders such A sites even more similar to 
the bacterial A site.73, 75 The problem of efficient genetic tools to study the interaction between 
eukaryotic rRNA with aminoglycosides has been overcome by the pioneering work of the 
Böttger group. They replaced the bacterial drug binding site in 16S rRNA with its eukaryotic 
counterpart, resulting in bacterial hybrid ribosomes with a fully functional eukaryotic rRNA 
decoding site (Figure 17).76 This technique allows the fast screening of aminoglycosides 
derivatives in vitro to evaluate their potential ototoxicity in addition to evaluation of their 
bactericidal activity against wild type and clinically resistant strains. It is one of the key 
techniques in this collaborative project with the Böttger group. 
 
Figure 16. Secondary-structure comparison of decoding-site rRNA sequences in the small 
ribosomal subunit. (A) Decoding region of 16S rRNA helix 44 in wild-type ribosomes of M. 
smegmatis. (B) Homologous 18S rRNA sequence in human ribosomes. (C) Homologous 12S 
rRNA sequence in human mitochondrial ribosomes. (D) Mitochondrial 12S rRNA sequence 
with mutation A1555G conferring hypersusceptibility to AGA ototoxicity.  
Ototoxicity side effects can be reduced by concurrent administration of antioxidants 
which act as radical scavengers to neutralize any ROS formed and prevent their delirious actions. 
Antioxidants do not affect the serum concentration or the antibacterial efficacy of 
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aminoglycosides.77 Indeed, salicylic acid, which acts as both an antioxidant and an iron-chelator 
has been shown to reduce the gentamicin-induced auditory threshold from more than 60 dB to 
less than 20 dB.78 
  
Figure 17. Bacterial hybrid ribosomes with fully functionally eukaryotic rRNA A site 
1.5. Recent advances  
In the last few years, several research groups have begun to develop aminoglycoside 
derivatives that can be more active, less toxic, and suffer less resistance from bacteria. The Crich 
and Vasella groups collaborated to synthesize modifications on the 4',6'- and 4’-positions of 
paromomycin 3. These derivatives were more selective toward bacterial ribosomes over human 
mitoribosomes, with a concomitant decrease in ototoxicity but not in antibiotic activity (Figure 
18). 10, 79-80 
 
Figure 18. Examples of 4',6'-O-alkylidene (14) and 4'-O-alkyl paromomycin (15) derivatives 
that showed increased selectivity for bacterial ribosomes over human mitoribosomes. 
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Apramycin (9) is considered to be one of the least ototoxic AGAs, which this can 
possibly be attributed to its unique bicyclic aminosugar moiety.81 Considerable work has been 
done by the Crich group in an effort to increase apramycin activity as well as it's selectivity by 
modification of  6' and 7'-positions.82 These studies, however, showed these positions to be 
essential for activity as most manipulations of them decreased the activity. 
 
Figure 19. The structure of plazomicin [6'-N-(2-hydroxyethyl)-1-N-(4-amino-2(S)-
hydroxybutyryl) sisomicin] (16) 
 
Plazomicin, 16 (Figure 19) developed by the Achaogen company, is a semisynthetic 
aminoglycoside antibiotic currently in phase 3 clinical trials for complicated urinary tract 
infections.83-84 Like netilmicin, plazomicin is prepared from the readily available sisomicin.83-84  
Plazomicin 16 was designed to thwart the most common aminoglycoside modifying enzymes 
(AMEs) by the judicious positioning of substituents and so to respond to the ever-growing 
problem of drug-resistant infectious diseases.85 The placement of the 4-amino-2(S)-
hydroxybutyryl (L-HABA) unit on the 1-position not only protect the drug against enzymes 
acting on position 1 [AAC(1) enzymes], but also on both position 3 [AAC(3) enzymes] and 
position 2'' [ANT(2’’) and APH(2’’)]. L-HABA substitution also serves to decrease the drug 
nephrotoxicity as discussed before. The inclusion of a 2-hydroxyethyl group on the 6'-position 
protects the drug against enzymes acting on position 6’. 
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1.6. Overall goals  
Toward the goal of preparing next generation AGAs two sub-projects were defined: 1) 
examining the effects on 4’-modification in the 4,6-series on the netilmicin skeleton 11. 
Netilmicin 11 was chosen as substrate for this investigation because its ototoxicity is low, which 
makes it ideal for further investigation.86-88  Likewise, the knowledge that modification of the 4’-
position of paromomycin10, 79-80 reduces its ototoxicity but not it’s antibiotic activity, suggested 
derivatization of netilmicin at that position.  
2) Improvement of apramycin 9 by hybridization: A number of reports have described the 
synthesis and evaluation of hybrid AGAs combining fragments from both the 4,5- and 4,6-series 
of 2-deoxystrptamine AGAs.89-92  Our attention was captured by an early report on the 
moderately increased activity of the 5-O-(β-D-ribofuranosyl) derivative of apramycin against 
selected Gram-negative organisms,93 suggesting derivatization at the 5-position of apramycin 9 
and apramycin-paromomycin hybrids; the goal being to combine paromomycin’s high activity 
with apramycin’s low ototoxicity as a possible avenue for further improving the profile of this 
promising antibiotic. 
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CHAPTER 2. INVESTIGATIONS IN THE 4,6-CLASS OF AGAs 
2.1. Mode of binding of netilmicin to the bacterial ribosomal A-site  
Netilmicin 11 is a N1-ethyl semisynthetic analog of sisomicin, an antibiotic extracted 
from Micromonospora inyoensis.94 Netilmicin was developed and marketed in the United States 
as Netromycin® by the Schering Corporation.95 Netilmicin belongs to the 4,6-disubstituted class 
of aminoglycosides and is active against most Gram-negative and some Gram-positive bacteria, 
including many gentamicin-resistant strains.96 The N1-ethyl modification protects netilmicin 
from both adenylating and phosphorylating enzymes and consequently maintains its activity 
against most strains of bacteria that harbor these enzymes.97 It is also reported to be less ototoxic 
than amikacin and gentamicin in in vivo rabbit studies.87  
Although a crystal structure of the rRNA A-site bound to netilmicin has yet to be 
determined, it is assumed that netilmicin has the same binding mode as its congener sisomicin, 
which specifically binds to the deep/major groove of the bacterial A site and makes 11 hydrogen 
bonds to base and phosphate oxygen atoms (Figure 20).98 Sisomicin 8 has a double bond 
between the C4′ and the C5′ atoms, which force ring I to adopt a flattened conformation with the 
possibility of classical π-stacking with the G1491 base.  This is in contrast to AGAs with a 
saturated carbohydrate ring I, which adopt a chair conformation that interacts with the aromatic 
of G1491 through CH/π interactions.98 Ring I also forms a pseudo base-pair interaction with 
A1408 in which the ring oxygen of ring 1 accepts a hydrogen bond from N6-adenine and the 
protonated 6'-amino group donates a hydrogen bond to adenine N1. The C3-amine in ring II 
makes hydrogen bonds with the phosphate oxygen atoms of A1493 and A1494 so that A1492 
and A1493 can take flipped-out conformations. Ring III binds to the upper side of the A-site 
helix through four hydrogen bonds.98  
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Figure 20. a) Crystal structure of sisomicin bound to the deep/major groove of the bacterial 
A site showing π-stacking with G1491 base and pseudo base-pair interaction with A1408 
(PDB code: 4F8U), b) a schematic diagram showing the pseudo base-pair interaction of 
ring I with A1408 and c) detailed interaction of sisomicin with the bacterial A site.  
2.2. Synthesis of netilmicin 
Netilmicin 11 was first synthesized in one step by reductive alkylation of sisomicin95 
without the conventional protection of the other amine groups (Scheme 1). The synthesis took 
advantage of the fact that the 1-amino group is the least basic and under acidic conditions (pH = 
5), all other amines are protonated and so unreactive. The only problem with this direct synthesis 
was its low yield (25%). Subsequently, several papers and patents were published that describe 
improved overall yields albeit employing three main steps.99-101  In these sequences the first step 
was selective protection of the 3,2’,6’-amino groups mediated by transition metal acetates such 
as zinc, copper or cobalt acetates to give 17.  This was followed by reductive alkylation of the 
N1-amine to afford compound 18 and finally deprotection; the best overall yield (73%) was 
obtained using zinc acetate in the first step  (Scheme 1).101 
 
G1491 
A1408 
a) b) 
c) 
26 
 
 
 
 
Scheme 1. Synthesis of netilmicin 
2.3. Modifications of netilmicin 
Modification of netilmicin was done primarily by deoxyfluorination102 of the 5-position 
and acylation of N6’-position.103 The synthesis of 5-deoxy-5,5-difluoro-netilmicin 23 started by 
Cbz-protection of the sisomicin amines and was followed by cyclization using sodium hydride to 
provide the 3’’,4’’-oxazolidinone 19 in 87% yield (Scheme 2). Selective benzoylation was done 
at the 2’’-position to give 20, which was oxidized to give the ketone 21, followed by 
difluorodeoxygenation using diethylaminosulfur trifluoride (DAST) to give 22. Birch reduction 
removed the Cbz-groups and gave the product 23.102 
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Scheme 2. Synthesis of 5-deoxy-5,5-difluoro-netilmicin (23) 
The synthesis of 5-deoxy-5-fluoronetilmicin 29 started by tosyl protection of the 
sisomicin amines to give the pentatosyl derivative 24, which was benzoylated at the N1’ and 2’’-
positions to afford 25 (Scheme 3). Inversion of configuration of the 5-hydroxyl group and 
adjustment of the protecting groups was done by a sequence of the following steps: mesylation 
of the 5-hydroxyl group, substitution of the mesylate with sodium acetate, cleavage of acetate 
and benzoate esters, and finally benzoylation at the N1’ and 2’’-positions to give the 5-epi-
netilmicin derivative 27. Deoxyfluorination then was done using DAST to afford the 5-fluoro-
netilmicin derivative 28 in 25%, which upon deprotection with sodium in liquid ammonia 
yielded the desired product 29. In the same fashion, 27 was deprotected to afford 5-epi-netimicin 
30 in 72% yield. 5-Deoxy-5-fluoronetilmicin 29 and 5-epi-netimicin 30 showed higher 
antibacterial activity than the parent, while 5-deoxy-5,5-difluoro-netilmicin 23 was slightly less 
active. Moreover, in acute toxicity studies, compound 30 showed less toxicity that netilmicin.102  
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Scheme 3. Synthesis of 5-deoxy-5-fluoronetilmicin 29 and 5-epi-netilmicin 30 
6’-N-Glycyl-netilmicin 32 was synthesized in two steps (Scheme 4): first, netilmicin was 
selectively acylated at the 6’-position with 2-azidoacetyl-N-hydroxysuccinimide to form 
derivative 31, and this was followed by Staudinger reaction, which reduced the azide into the 
corresponding amine 32. 6’-N-Glycyl-netilmicin showed less antibacterial activity than 
netilmicin. 
 
Scheme 4. Synthesis of 6’-N-glycyl-netilmicin 32  
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2.4. Rational 
As discussed in the previous chapter, because modification of the 4’-position of 
paromomycin10, 79-80 reduces its ototoxicity but not its antibiotic activity, it was of interest to 
examine if these effects on 4’-modification in the 4,5-series (i.e. paromomycin) extends to 4,6-
series (i.e. netilmicin).  Netilmicin was chosen as substrate for modification in this manner 
because it is considered to be one of the least ototoxic aminoglycosides, which makes it ideal for 
further investigation.86-88   
2.5. Chemistry 
2.5.1. Triazenes as a selective protecting group for secondary amines  
Modification of netilmicin at the 4'-position 
requires prior protection of the amino and hydroxyl 
groups present. Work initially proceeded with a benzyl 
carbamate protection route, however, severe rotamer 
problems prevented sharp NMR spectra from being obtained (Scheme 5). High temperature 
NMR was done to facilitate rotamer exchange to give average peaks and hence sharper spectra, 
but unfortunately to no avail – presumably because of the number of carbamates present. 
The use of triazenes as protecting groups104 was considered to be a possible solution to 
the problem. A search of the literature105-106 showed that this protecting group is only used for 
secondary amines. Triazenes derived from primary amines are unstable and are more commonly 
exploited as nucleophiles in the capture of a range of electrophiles, either inter- or 
intramolecularly.107-108  Taking an advantage of this feature it was possible to protect secondary 
amines selectively in the presence of primary amines (Scheme 6).109 
Scheme 5. Rotamers of secondary 
amine carbamates 
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Scheme 6.  General protocol for selective protection of secondary amines as the N-phenyl 
triazenes 
2.5.2. Aryl triazenes 
Trisubstituted triazenes have been widely employed in organic synthesis for the 
protection and/or derivatization of aryl amines.104-105, 109-110 As a protecting group, aryl triazenes 
are compatible with oxidizing agents (e.g. pyridinium dichromate (PDC)) and reducing agents 
(e.g. LiAlH4 and NaBH4) as well as with basic conditions, acylating and alkylating reagents 
(Schemes 7 and 8). The free amine can be easily regenerated by treatment with trifluoroacetic 
acid.105, 111  
 
Scheme 7.  Literature reactions showing the compatibility of phenyltriazenes with 
oxidizing, reducing and alkylating agents 
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Scheme 8.  Literature reactions showing the compatibility of phenyltriazenes with acylating 
reagents and basic conditions 
Triazenes are also used as linkers to solid supports in solid-phase organic synthesis 
(SPOS) (Scheme 9). After functionalization on the bead, the triazene linker can be easily cleaved 
from the solid support using acidic conditions. Triazenes can also act as concealed diazonium 
salts upon cleavage from the resin and as such are used for conversion of aryl amines to many 
functionalized arenes as well as in cyclizations to generate various heterocyclic structures, 
namely, benzoannelated nitrogen heterocycles.104, 110 
 
Scheme 9.  Uses of triazenes in solid-phase organic chemistry (SPOS) 
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Figure 21.  Resonance structures of aryl triazenes and the coalescence temperatures of 
triazene N-methyl protons  
Aryl triazenes contain an extended  system in which there is considerable delocalization 
of charge density and so can be presented by two resonance structures (A) and (B) (Figure 21). 
An observable effect of this resonance is an increase in the effective barrier to rotation about the 
N(2)-N(3) bond due to the double bond character contribution of the 1,3-dipolar resonance form 
(B). The barriers to rotation about the N(2)-N(3) bond, which are determined by variable 
temperature NMR, show that the more electron-withdrawing the substituent attached at the para-
position, the more important the 1,3 dipolar form (B) of these compounds and hence the higher 
the rotation barrier about the N(2)-N(3) bond (Figure 21).112-113 In the p-NO2 derivative, the 
coalescence temperature (Tc) is higher than room temperature and the two methyl groups appear 
as distinct resonances at room temperature in the NMR spectra. The barrier to rotation for 
trialkyltriazenes was found to be about 10.5-11 kcal/mol, approximately 3 kcal/mol lower than 
that of most aryldialkyltriazenes, due to absence of stabilization of the 1,3-dipolar form.114  
Generally, steric bulk is reported to have little effect on the barrier to rotation about the N(2)-
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N(3) bond, but in the extreme case of 2,2-dimethyl- and 2,2,6,6-tetramethylpiperidine-based 
triazenes the barrier is reduced to ∼11 kcal mol−1 in CS2.115 
2.5.3. Examples of Selective Protection  
A general reaction protocol was established for this synthetic method. A series of primary 
and secondary diamines were treated with 1.1 equivalents of benzenediazonium tetrafluoroborate 
in methanol/water in the presence of powdered potassium or sodium carbonate followed by 
protection of the primary amines as the azides, benzyloxy carbamates or fluorenyl methyl 
carbamates. Workup and silica gel chromatography then gave the product in moderate to good 
yield. Yields were not improved by the use of excess benzenediazonium tetrafluoroborate as this 
leads to complications in isolation arising from the decomposition of the reagent. All these 
results are summarized in Table 1.  
 
 
 
  
34 
 
 
 
Table 1. Examples of selective protection of secondary amines as the N-phenyl 
triazenes 
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Consistent with expectations, the 1H NMR spectra of the azido triazenes are mostly sharp 
in CDCl3 and CD3OD at room temperature with the exception of those compounds containing 
multiple Cbz groups. The contrast between the 1H NMR spectra of phenyl triazene protected 
dissymmetric secondary amines and those of the corresponding carbamates is illustrated in 
(Figure 22). The room-temperature 1H NMR spectrum of 58, obtained by sequential treatment of 
spermidine with imidazole sulfonyl azide and benzyl chloroformate, displays significant 
broadening of all resonances in this pseudosymmetric secondary carbamate (Figure 22a). In 
contrast, the 1H NMR spectrum of the corresponding diazido triazene 51 is sharp (Figure 22b). 
 
 
 
Figure 22. Room-temperature 600 MHz 1H NMR spectra of (a) 58 and (b) 51 in CD3OD.  
2.5.4. Application to Aminoglycosides 
Having established the viability of the method, its application to the aminoglycosides was 
explored.  First, sisomicin 8 with its single secondary and four primary amino groups was 
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investigated.  Reaction with one equivalent of benzenediazonium tetrafluoroborate under the 
standard conditions was followed by treatment with either an excess of imidazole sulfonyl azide 
or benzyloxy carbonyl chloride resulting in the isolation of 59 and 60 respectively, in excellent 
yields (Scheme 10). 
 
Scheme 10. Application to sisomicin 
The method was also applied to the monosubstituted deoxystreptamine aminoglycoside 
apramycin 9, when the azido and carbamate-protected triazenes 61 and 62 were both obtained in 
moderate yield (Scheme 11). Triazenes can be easily deprotected using trifluoroacetic acid in 
essentially quantitative yield. 
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Scheme 11. Application to Apramycin 
2.5.5. Synthesis of Netilmicin derivatives 
The protected netilmicin 67 was prepared in three steps (Scheme 12). First, netilmicin 
was reacted with imidazole-1-sulfonyl azide hydrochloride (Stick’s reagent)116 in the presence of 
excess K2CO3 and catalytic CuSO4 to form the triazido derivative 65 through diazo transfer.
117-
118 The secondary amines were then protected as triazenes using benzenediazonium 
tetrafluoroborate to give derivative 66. Intermediate 66 was finally acetylated to give the 
diacetylated derivative 67. 
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Scheme 12. Synthesis of a protected netilmicin intermediate 
After the common intermediate 67 was obtained, iodination using N-iodosuccinimide119 
in the presence of silver nitrate installed iodine in the 4'-position. Attempted bromination of the 
4'-position using bromine120 was unsuccessful. However, the reaction proceeded using N-
bromosuccinimide and K2CO3 as a base in acetonitrile as a solvent in 29% yield. The yield 
increased to 50% when a catalytic amount of tetrabutylammonium nitrate was added (Scheme 
13). This can be explained either by the lipophilic tetrabutylammonium ion acting as phase 
transfer catalyst facilitating the deprotonation or by the effect of nitrate ion which traps the 
oxocarbenium ion and facilitates subsequent deprotonation (Scheme 14) as has been proposed in 
related processes.121  Chlorination was best achieved with iodobenzene dichloride122 (Scheme 
13). Intermediates 68, 69 and 70 were subjected to a stepwise sequential deprotection: 
deacetylation, reduction of the azide groups under Staudinger conditions,123 and removal of the 
triazene group with trifluoroacetic acid to give the final products 72, 73 and 74. 
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Scheme 13. Synthesis of 4'-iodo netilmicin, 4'-bromo netilmicin and 4'-chloro netilmicin 
 
 
  Scheme 14. A proposed mechanism for nitrate catalysis of bromination of glycals 
The 4'-phenyl derivative 75 was prepared from intermediate 69 via Suzuki coupling using 
Pd(dppf).CH2Cl2
124 as catalyst in 23% yield (Scheme 15). The 4'-butyl derivative 70 was 
achieved by B-alkyl Suzuki coupling of intermediate 69. This reaction was challenging as the 
major product was the debrominated derivative 67. Different large bite angle catalysts were tried 
in order to enforce the necessary reductive elimination in the catalytic cycle instead of the β-
hydride elimination that results in debromination.125 However, the best yield, 8%, was obtained 
with Pd(dppf).CH2Cl2 (Table 2). Nevertheless, this was deemed sufficient to obtain a sample for 
screening, with further reaction optimization deferred until required by good biological results. 
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Deprotection of intermediates 75 and 76 was done as described in (Scheme 13) to give the 
desired products 78 and 79. 
 
 
Scheme 15. Synthesis of 4'-phenyl netilmicin and 4'-butyl netilmicin 
Table 2. Catalysts used in the B-alkyl Suzuki reaction and their yields 
 
 
 
Entry  Catalyst Solvent % Yield 
of 76 
% Yield 
of 69 
1 Pd(dppf).CH2Cl2 dioxane:water (3:1) 0 - 
2 Pd(dppf).CH2Cl2 toluene:water (3:1) 8 32 
3 Pd(PPh3)4 toluene:water (4:1) traces - 
4 Pd(PCy3) Cl2 toluene:water (4:1) 5 14 
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Triazene protecting groups were found to be incompatible with the ethylsulfenyl chloride 
needed to prepare 4'-(ethylsulfanyl) netilmicin 83; therefore, all amines were protected as the 
2,2,2-trichloroethyl carbamate (Troc) group,126 followed by acetylation of the hydroxyl groups 
(Scheme 16). The resulting compound 81 was reacted with ethylsulfenyl chloride,127 formed in 
situ from diethyl disulfide and sulfuryl chloride, to give the desired intermediate 82. One step 
deprotection using 6 N NaOH afforded the desired product 83. 
 
Scheme 16. Synthesis of 4'-(ethylsulfanyl) netilmicin 
2.5.6. Synthesis of plazomicin 
As discussed in the introduction, plazomicin 16 is one of the recently developed AGAs 
and is currently in phase 3 clinical trials for complicated urinary tract infections.83-84 An 
authentic sample was needed to serve as a standard for the comparison of biological activity of 
the synthesized compounds. However, although the synthesis of plazomicin from sisomicin has 
been outlined in the patent84 and in the open literature,83 few details and characterization data 
were available.  Accordingly, the semisynthesis of plazomicin from sisomicin was undertaken by 
a novel synthetic route featuring the use of the phenyltriazenyl protecting group for secondary 
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amines in only 7 steps and 8.5% overall yield, which compares favorably to the published 0.16% 
yield.83 
The synthesis of plazomicin started by selective protection of the 6'-NH2 group of 
sisomicin 8 using 4-nitrobenzyl N-hydroxysuccinimidyl carbonate128 to give 6'-N-(4-
nitrobenzyloxycarbonyl) sisomicin 84 in 75% yield.  The amino substituents at positions 2' and 3 
were then selectively protected as the Boc derivatives by the temporary protection of the other 
amines in the form of zinc chelates, resulting in the formation of 85 in 52% yield.129  The 
reaction of 85 with a 10 mol% excess of phenyl diazonium tetrafluoroborate in acetonitrile in the 
presence of potassium carbonate gave an 88% yield of the desired triazene 86 (Scheme 17), 
whose sharp, well-resolved NMR spectra facilitated spectral elucidation in this and the following 
steps. Thus, the triazene moiety fulfills the expectation of a disymmetric secondary amine 
protecting group, free of the rotamer problems associated with the more common carbamates.  
Furthermore, as suggested by the model studies, it was selectively introduced onto a secondary 
amine in the presence of a primary amine without the need for an excess of the diazonium salt.   
The remaining amine at position N1 was then coupled to N-Boc-4-amino-2(S)-hydroxy-
butyric acid130 under standard carbodiimide conditions in the presence of hydroxy-5-norbornene-
2,3-dicarboximide131 and afforded the amide 87 in high yield.  The 4-nitrobenzyl carbamate 
group was then cleaved with aqueous sodium hydroxide in dioxane to yield 70% of the amine 
88, which was subjected to reductive amination with tert-butyldimethylsilyloxy acetaldehyde 
and sodium triacetoxyborohydride132 to give 89 in 52% yield.  The reductive amination was 
conducted in the presence of Hünig’s base133 so as to avoid premature cleavage of the triazene 
group.  Finally, removal of the Boc and triazene groups was achieved with 50% trifluoroacetic 
acid in dichloromethane to give plazomicin 16 in 77% yield after purification by 
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chromatography over Sephadex C-25.  A sample of the analog N1-(4-amino-2(S)-hydroxybutyryl 
sisomycin 88 was obtained in 54% by simple acid-mediated deprotection of 90. 
 
Scheme 17.  Synthesis of plazomicin. 
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2.6. Biological Evaluation 
The above synthesized samples were screened for ribosomal selectivity and antibacterial 
activity by the Böttger lab in Zurich. To assess the effect of the antibiotic on translation, IC50 
values of cell-free translation assays with purified 70S ribosomes of both wild-type and mutant 
M. smegmatis strains that carry the rRNA A sites of either eukaryotic cytoplasmic or 
mitochondrial ribosomes were determined. The IC50 value is the concentration required to inhibit 
protein synthesis by 50% (Table 3).134 In addition, the MIC values for Mycobacterium smegmatis 
(Sms), Methicillin-resistant Staphylococcus aureus (MRSA), E. coli and  P. aeruginosa were 
recorded.72  The minimal inhibitory concentration (MIC) is the lowest concentration of an 
antimicrobial agent (AGA) that inhibits 50% of the visible growth of a microorganism (Table 4).  
Table 3.  Inhibition of wild-type bacterial and hybrid ribosomes (IC50, M).  
IN VITRO (IC50, M) Sms (M) 
Mit (M) 
(selectivity) 
A1555G (M) 
(selectivity) 
Cyt (M) 
(selectivity) 
Sisomicin (8) 0.02 25.4 (1137) 1.4 (64) 93.8 (4196) 
Netilmicin (11) 0.02 31.3 (1490) 1.4 (66) 98.8 (4698) 
Apramycin (8) 0.17 124.8 (747) 51.5 (308) 108.7 (651) 
Gentamicin (7) 0.03 19 (594) 1.1 (34) 58 (1812) 
4'-Iodo netilmicin (72) 0.15 81.7 (545) 2.6 (17) 366.8 (2451) 
4'-Bromo netilmicin (73) 0.09 71.3 (791) 1.8 (20) 261.5 (2900) 
4'-Chloro netilmicin (74) 0.18 305.9 (1733) 84.8 (481) 980.3 (5555) 
4'-Phenyl netilmicin (78) 0.27 28.9 (106) 3.5 (13) 81.4 (299) 
4'-Butyl netilmicin (79) 0.58 407.6 (699) 21.9 (37) 940.4 (1612) 
4-(Ethylsulfanyl) netilmicin (83) 0.67 256.3 (381) 46.3 (69) 783.3 (1165) 
Plazomicin (16) 0.08 68.2 (808) 4.7 (56) 388.5 (4605) 
1-[4-Amino-2-hydroxy-butyryl] 
sisomicin (90) 
0.02 8.5 (467) 0.4 (24) 169.1 (9278) 
Sms: M. Smegmatis ribosome, Cyt: M. Smegmatis ribosome with human cytosolic A-site, Mit: M. Smegmatis 
ribosome with human mitochondrial A-site, A1490G: M. Smegmatis ribosome with human mitochondrial A-site 
with A1555G mutation. Selectivities are obtained by dividing the hybrid ribosomal activity by M. Smegmatis 
ribosomal activity 
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The addition of an iodo group at the 4’-position of apramycin results in a 7-fold reduction 
in ribosomal activity and reduction of overall selectivities. When compared to the parent 
netilmicin, 4'-bromo netilmicin 73 exhibits a 4 to 5-fold loss in activity and a smaller (2 to 3-
fold) reduction in activities against the mitochondrial wild-type, the A1555G mitochondrial 
mutant, and the cytosolic hybrid. On the other hand, 4'-chloro netilmicin 74 showed a 9-fold loss 
in activity against the bacterial ribosome, but an increase in selectivity overall, especially over 
the A1555G mitochondrial mutant hybrid that is considered to be the allele responsible for 
hyper-susceptibility to AGAs ototoxicity. A clear trend is visible in which the selectivities 
increase as the electronegativity of the halogen, introduced at the 4’-position, increases. The 
inclusion of phenyl, butyl and ethylsulfide groups at 4’-position of netilmicin is detrimental for 
activities against the wild-type bacterial ribosome, and also causes an overall reduction in 
ribosomal selectivities.  
1-L-HABA sisomicin 90 shows a similar bacterial ribomosal activity when compared to 
sisomicin and netilmicin. The L-HABA group decreases the selectivities in the mitochondrial 
and A1555G mutant hybrid ribosomes but increases the selectivity over the cytosolic hybrid. 
Plazomicin 16, on the other hand, showed a 4-fold reduction in the bacterial ribomosal activity 
and decreased selectivities over the mitochondrial and A1555G hybrid ribosomes but to a lesser 
extent than 1-L-HABA sisomicin 90. Therefore, the 6’-(2-hydroxyethyl) group results in 
decreased antibacterioribosomal activity probably due to moderation of the hydrogen bond 
between the 6’-amine and A1408, resulting in a weakened pseudobase pair interaction. Inclusion 
of the 6’-N-(2-hydroxyethyl) does however increase selectivity over the mitoribosomes when 
compared to L-HABA sisomicin 90. A similar effect of 6’-N-(2-hydroxyethyl) substituent on the 
selectivities of neomycin was recently reported by the Crich group.135 
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Table 4.  In vivo minimal inhibitory concentrations (MIC, μg/ml) of clinical isolates. 
IN VIVO 
 (MIC, μg/ml) 
Sms 
MRSA E coli P aeruginosa 
AG03
8 
AG039 
AG04
2 
AG04
4 
AG00
1 
AG05
5 
AG00
3 
AG03
1 
AG03
2 
AG03
3 
AG08
6 
Sisomicin 1 
0.25- 
0.5 
0.25-
0.5 
16- 
32 
4 1-2 1-2 32 16 0.5 >128 4 
Netilmicin 2 0.5 0.5 2 1 2 2 8 2 2 >128 >128 
4'-Iodo 
netilmicin 
(72) 
2 4-8 16 64 16 2 1-2 16 4-8 4-8 >128 >128 
4'-Bromo 
netilmicin 
(73) 
2 4 8-16 64 8-16 2 1-2 16 8 8 64 2 
4'-Chloro 
netilmicin 
(74) 
2 2-4 8 32 8 4 2-4 
16-
32 
4 64 >128 n.d. 
4'-Phenyl 
netilmicin 
(78) 
8 8 16 64 16 4 2 64 
16-
32 
16-
32 
>64 2 
4'-Butyl 
Netilmicin 
(79) 
32 16 16 64 32 8-16 5 8-16 64 64 >128 8-16 
4-
(Ethylsulfanyl
) netilmicin 
(83) 
64 32 32 128 
32-
64 
16 8-16 8-16 >128 128 >128 16 
Plazomicin 
(16) 
≤0.2
5 
2 2 2 2 2 2 2 4 4 16 32 
1-[4-amino-
2-hydroxy-
1-oxobutyl] 
sisomicin 
(90) 
≤0.2
5 
1 1-2 1 1 2 2 1 2 2 >128 16 
MIC (μg/ml) in vivo: minimal inhibitory concentrations of netilmicin derivatives to inhibit Sms (M smegmatis), 
MRSA (Methicillin-resistant S aureus), E coli and P aeruginosa. 
Consideration of the MIC values reveals that the 4’-iodo, bromo and chloro derivatives of 
netilmicin have almost the same activity against Sms and E. coli as netilmicin, but that they are 
less active against MRSA. On the other hand, the presence of phenyl, butyl and ethylsulfanyl 
groups in the 4'-position of netilmicin results in considerable loss of activity in most strains. All 
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4’-derivatives synthesized (except the 4’-iodo derivative) have good to moderate activity against 
the AG086 clinical strain of P. aeruginosa (Table 4). This is relevant as this strain is resistant to 
both netilmicin and sisomicin, and indicates that modification at the 4’-position gives some 
protection against the aminoglycoside modifying enzyme responsible for resistance to netilmicin 
and sisomicin in this strain. Overall it is apparent that 4’-modifications reduce activity in the 4,6-
series to a greater extent than in the 4,5-series. The same effect was encountered with 4’-
modifications of the 4,6-aminoglycoside kanamycin B.11  
As expected, plazomicin 16 has good activity with all strains tested including the strains 
that are resistant to netilmicin, suggesting that L-HABA and hydroxyethyl groups were 
successfully able to shield the drug from most AMEs. Compound 90, lacking the 6’-N-
hydroxyethyl group displayed slightly better activity in all strains than plazomicin, except for the 
P aeruginosa strain AG033, which was completely resistant to it.  
A mouse cochlear explant study, conducted by Professor Jochen Schacht at the Kresge 
hearing institute of the University of Michigan, was done to compare the ototoxicities of 
plazomicin 16, apramycin 9 and gentamicin 7. This study depends on extracting the cochleae of 
mice and soaking them in various concentrations of the drug.  The extent of the loss of outer hair 
cells (OHC) is examined and quantified (Figure 23). The results showed that plazomicin is more 
cochleotoxic than apramycin and comparable to gentamicin (Figure 24). The cochlear damage 
caused by plazomicin in comparison to apramycin and gentamicin is consistent with predictions 
from the A1555G hypersusceptibility mutant of the mitochondrial ribosome, albeit the 
differences are less apparent on the mitochondrial ribosomes themselves.  
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Figure 23. The outer hair cells (OHC) in different parts of the cochlea (apex, mid and base) 
at 3 M (OHC are still intact) and 30 M (considerable loss in OHC) of plazomicin. 
 
 
 
Figure 24. The effect of concentration of plazomicin (16) in comparison to gentamicin (7) 
and apramycin (9) in the percentage of outer hair cell (OHC) loss. 
2.7. Conclusion 
This chapter elaborated the use of phenyl triazenes as selective protecting groups for secondary 
amines in the presence of primary amines providing sharp 1H NMR spectra at room temperature. 
The protecting group enabled the synthesis of several 4’-netilmicin derivatives, which were 
examined for antibacterial activities as well as ribosomal selectivities. Unfortunately, the 4’-
netilmicin derivatives showed reduced antiribosomal and antibacterial activities compared to the 
parent and to a greater extent than in the 4,5-series.  The triazene protecting group also facilitated 
the synthesis of plazomicin, an aminoglycoside in the phase III clinical trials, in less steps and 
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higher yield than the published synthesis, and enabled the study of the ribosomal selectivity and 
ototoxicity of this compound. 
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CHAPTER 3. DEVELOPMENT OF APRAMYCIN DERIVATIVES WITH 
MODIFICATION AT THE 5-POSITION AND EXAMINATION OF THEIR 
ANTIRIBOSOMAL AND ANTIBACTERIAL ACTIVITY 
3.1. Mode of binding of apramycin to the bacterial ribosomal A-site 
Apramycin 9, which was previously called nebramycin factor 2, is produced by 
Streptomyces tenebrarius bacteria. Apramycin 9, with a unique bicyclic structural feature, is 
active against many Gram-positive and Gram-negative MDR infectious bacteria136-139 and 
overcomes all of the known AME except AAC(3).57 Although apramycin has not been used in 
humans yet, it has found wide application in veterinary medicine,140 as a consequence of which 
much pharmacological data is available.141  Recent reports showed that in animal models 
apramycin displays minimal ototoxicity, the main adverse effect of AGAs, and suggesting its re-
evaluation for human use.134, 142   
The X-ray crystal structure of apramycin in complex with the 30S ribosomal subunit of 
Thermus thermophilus bacteria showed that the bicyclic ring I of apramycin is bound in a similar 
way to ring I of the 4,5- and 4,6-AGAs. Ring I (bicyclic ring) interacts through CH-π interactions 
with G1491 in the ribosomal A-site. Thus, ring I forms a pseudo base-pair interaction with 
A1408, as presented for netilmicin in chapter 2. The importance of the 6’- and N7’-positions in 
the pseudo base-pair interaction was emphasized by the Crich group whose modifications at 
these positions negated activity of apramycin.143 This casts doubt on an alternative binding 
mode,  from an NMR structure of a short RNA oligonucleotide complex with apramycin, in 
which the 6’- and N7’-positions have minimal role in binding.144 
In the X-ray of apramycin with the actual 30S ribosomal subunit, ring III is oriented so as 
to allow the formation of direct hydrogen bonds with the highly flexible A1492 (Figure 25).134 
This interaction may stabilize a partially flipped-out A1492 conformation, that makes it difficult 
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for A1492 to contact with the minor groove of the codon-anticodon helix and cause misreading. 
This explains the failure of apramycin to induce misreading leaving the inhibition of 
translocation as the main cause of bacterial protein synthesis inhibition.79  This rationale for the 
absence of misreading by apramycin is supported by work on the cleavage of ring III to give 
aprosamine 91 (Figure 26), which, albeit with lower levels of activity, induces misreading.23 
 
  
 
 
 
 
 
 
Figure 25. a) X-Ray crystal structure of apramycin bound to the bacterial A site showing 
CH/π-stacking of ring I with G1491 base, pseudo base-pair interaction of ring I with A1408 
and interaction of ring III with A1492 (PDB code: 4AQY) and b) detailed interaction of 
apramycin with the bacterial A site.  
 
Figure 26. Structures of apramycin (9) and aprosamine (91) 
3.2. Modifications of apramycin 
Many modifications of apramycin have been done in order to increase its potency. Most 
are reported in patents and include modifications at the 5- and 6-positions,93, 145-146 modifications 
G1491 
A1408 
A1492 
A1493 
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at the N1, N2', N7', and N4''-positions,142-143, 147-150 modifications at the 6''-position,151 and 
modifications at the N7’-Me and 6’-position.143 These modifications are summarized in (Figure 
27) and show how apramycin has started to gain attention recently after having been neglected 
since the 1980s. This ensemble of studies reveals that enhanced bacterial activity might best be 
achieved through modifications to ring II (2-DOS), and most modifications to ring I (bicyclic 
ring) decreased the bacterial activity. The following sub-sections will discuss the art of selective 
modification at these positions.  
 
 
Figure 27. A schematic diagram showing known modifications of apramycin and the year 
modified; modifications in green showed increased bacterial activity, modifications in red 
showed a decreased bacterial activity, and modifications in black showed an unreported or 
comparable bacterial activity. 
3.2.1. Modifications at the 5- and 6-positions of apramycin 
A method of derivatizing apramycin at the 5- and/or 6-positions was reported that passes 
through a common intermediate 95, which requires only four steps to synthesize.  In this 
sequence, all amines were first protected as carbamates, which was followed by protection of the 
5- and 6-hydroxyl groups as a cyclohexylidene ketal. Subsequent protection of the remaining 
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hydroxyl groups as esters was followed by acid hydrolysis of the ketal to give the 5,6-diol 
compound 95, that is the key intermediate for modifications at these positions (Scheme 18).93, 145-
146 
 
Scheme 18. Preparation of the key intermediate 95 for modification at the 5,6-positions 
Reaction of 95 with dihydropyran was unselective and gave both the 5- and 6-protected 
alcohols 96 and 97. The alcohols 96 and 97 were separated, glycosylated and deprotected to 
achieve the 5-O-glycoside 98 and the 6-O-glycosides 99 (Scheme 19).93  
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Scheme 19. Synthesis of 5-O-glycosides 98 and 6-O-glycosides 99 
Additionally, the 5,6-diol intermediate 95 was selectively acetylated at the 6-position 
followed by chlorination at 5-position to afford the compound 100.  This was followed by radical 
de-chlorination to give the compound 101. Global deprotection by catalytic hydrogenolysis and 
basic hydrolysis afforded the 5-deoxyapramycin 102.145 Further, the key intermediate 95 was 
subjected to mesylation to give 103, which was reacted with sodium iodide and then zinc dust to 
give the 5,6-alkene 104. Finally, hydrolysis and catalytic hydrogenation gave 5,6-
dideoxyapramycin derivative 105 (Scheme 20).146 
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Scheme 20. Synthesis of 5-deoxyapramycin 102 and 5,6-dideoxyapramycin 105 
3.2.2. Modifications at the N1,N2',N7',N4''-positions of apramycin 
A novel method for regioselective derivatization at the N1, N3 or N2'-positions of 
apramycin was introduced by Kirst and co-workers.152 The method reported facilitates the 
synthesis of N1, N3 or N2'-derivatives of apramycin by transition metal-directed acylations of 
apramycin. The transition metals co-ordinate with all except the amine to be acylated and so act 
as transient protecting groups that save the conventional steps of protection and deprotection. 
Selectively among the different amines is achieved by changing the transition metal cations. Zinc 
salts are used to achieve regioselective acylation and alkylation of N1 of apramycin in a single 
reaction. Copper salts are used for the synthesis of N3-acyl derivatives of apramycin, while 
nickel salts are used to accomplished the regioselective acylation of N2' of apramycin (Scheme 
21). The so-formed acyl derivatives can be reduced subsequently by diborane or lithium 
aluminium hydride to give the corresponding N-alkyl derivatives.149-150, 152 
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Scheme 21. Transition metal directed derivatization  
The regioselective derivatization at the 4'' position of apramycin is reported in a US 
patent.147 The approach for the selective modification at 4'' position involves protection of all 
amines as their Cbz derivatives, then the 5,6- and 2'',3''- vicinal diols are both protected with an 
isopropylidine group. The 6''-hydroxyl group is next acylated prior to deprotection of the 
isopropylidine groups. The key step in this method involves releasing the free amines by 
hydrogenolysis so that migration of 6''-O-acyl group to the proximal 4’’-amine takes place and 
gives the 4''-derivatives of apramycin. The 4''-N-alkyl analogues are prepared by reduction of 
corresponding acyl derivatives with diborane or lithium aluminum hydride (Scheme 22).  
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Scheme 22. Synthetic scheme for the modification at the 4’-position  
The synthesis of 7'-N-alkylapramycin derivatives proceeded by the initial preparation of 
an apramycin-carbon dioxide complex that then was reacted with acetic anhydride to form 
1,3,2',4''-tetra-N-acetyl apramycin 113 (Scheme 23). This was followed by alkylation of the 
acetylated intermediate to provide the 7'-N-alkyl-1,3,2',4''-tetra-N-acetyl apramycin derivatives 
114. General deprotection strategies finally yielded the 7'-N-alkyl apramycins 115.148  
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Scheme 23. Synthetic scheme for the modification at the 7’-position 
3.2.3. Modifications at the 6''-position of apramycin 
Modification at the 6''-position of apramycin is achieved by a comparable approach to 
that used to modify the N4’’-position. In this chemistry, instead of 6’’-acylation of the derivative 
110, the 6’’-hydroxyl is converted to the corresponding mesylates, tosylates, chlorides, and 
amines or is deoxygenated. Unlike acyl groups, these groups were not to migrate after 
unmasking of the apramycin amines (Scheme 24).151  
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Scheme 24. Synthetic scheme for the modification at the 4’’-position 
3.2.4. Modifications at the N7’-Me and 6’-positions of apramycin 
Crich and co-workers reported modifications at N7’ and 6’-postions (Scheme 25).143 All 
amines and hydroxyl groups except at the N7’ and 6’-O-postions of apramycin were selectively 
protected in five steps. First, all the primary amines were protected as azides using triflyl azide. 
Subsequently, the secondary amine was protected as the benzyl carbamate, which upon 
cyclization using sodium hydride provided the 6’,7’-oxazolidinone ring. Benzylation of all the 
remaining hydroxyl groups and finally the cleavage of oxazolidinone ring afforded the key 
intermediate 122. This key intermediate allowed the subsequent modifications at the 6’-position, 
including the inversion of the hydroxyl group configuration or replacement of hydroxyl group 
with both inversion and retention of configuration by an amine group.  The introduction of CH3 
and CF3 groups geminal to the 6’-alcohol was also achieved in both configurations. 
Modifications can also be made at the 7’-position from intermediate 122, including the 
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preparation of analogues in which the methyl group is removed or replaced by longer alkyl 
chains.  
 Scheme 25. Synthetic scheme for the modification at the N7’-Me and 6’-positions 
3.3. Rationale  
Comparison of the antiribosomal and antibacterial activities of 4,5- or 4,6-disubstituted 2-
deoxystreptamine derivatives with the corresponding 4-monosubstituted 2-deoxystreptamine 
derivatives generally shows the higher activity of the disubstituted compounds. For example, 
AGAs like kanamycin B, neomycin and ribostamycin are more active than neamine (Figure 28 
and Table 5).153 Correspondingly, in apramycin, there was an enhancement of activity when it 
was glycosylated at the 6-position to give 6-O-(3-amino-deoxy-α-D-glucopyranosyl) apramycin 
99, and when it was glycosylated at the 5-position to give 5-O-(β-D-ribofuranosyl) apramycin 98 
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(Table 6).93  Thus, modification of apramycin at the 5- and/or 6-positions was considered to offer 
the most promise for the development of improved derivatives.  The knowledge that bacterial 
resistance arising from the presence of ribosomal methyltransferases (e.g., ArmA) renders most 
of the 4,6-disubstituted AGAs obsolete focused the project on substitution of apramycin at the 5-
position. Consequently, it was decided to re-evaluate the 5-O-β-D-ribofuranosyl apramycin (98, 
Scheme 19) previously prepared by a Japanese group,93 preferably by a shortened and improved 
route. Extrapolating further, the attachment of aminosugars such as the paromomycin CD ring to 
the 5-position was projected to give an apramycin-paromomycin hybrid; the goal being to 
combine paromomycin’s high activity with apramycin’s low ototoxicity (Figure 28). A 
simplified form of this hybrid, in which a 2-aminoethyl group replaces the D ring paromomycin, 
was also designed.  
 
Figure 28. Paramomycin structure showing rings A-D, its hybrid with apramycin and a 
simplified form of the hybrid. 
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Table 5. %Inhibition of in vitro R17 phage RNA-directed polypeptide synthesis by 
various aminoglycoside antibiotics at four concentrations. 
Antibiotic 
Drug concentration (g/ml) 
0.1 1 10 50 
Neamine 2 6 37 75 
Ribostamycin 5 45 65 92 
Kanamycin B 22 48 58 82 
Neomycin 28 55 80 96 
 
Table 6. In vivo minimal inhibitory concentrations (MIC, μg/ml) of clinical isolates. 
 
 
 
 
 
 While this work was underway, Fridman and coworkers described the ribosylation of the 
4,6-AGAs at the 5-position to give 4,5,6-trisubstitued AGAs (Figure 29).92 The resulting 
compounds were slightly less active than the parents, but apparently gave improved ribosomal 
selectivity in the 5-O-ribosylated kanamycin B (X = OH, Y = NH2, Z = H) and tobramycin (X = 
H, Y = NH2, Z = H) series, both of which contain 2′-amines. The 2′-amine in these AG structures 
forms a hydrogen bond with the ribofuranose sugar ring oxygen,154 which may assist in orienting 
the ribofuranose ring in the A-site. However, these compounds are still expected to have the 
ArmA resistance problem of 4,6 AGAs. 
IN VIVO (MIC, μg/ml) E coli  
NIHJ 
P. aeruginosa 
A9930 
K. pneumoniae 
D11 
Apramycin 3.1 3.1 0.8 
5-O-(β-D-ribofuranosyl) 
apramycin (98) 
1.6 0.8 0.8 
6-O-(3-amino-deoxy-α-D-
glucopyranosyl) apramycin (99) 
1.6 1.6 0.4 
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Figure 29. A Schematic diagram showing the 5-ribosylation of the 4,6 AGAs 
3.4. Synthesis of apramycin derivatives 
3.4.1. Synthesis of a key apramycin intermediate 
The synthesis of the apramycin derivatives started by preparing the key intermediate 124, 
which has all functionality blocked except for the crucial 5-hydroxyl group. The apramycin 
primary amines were protected as azides and both the N7’ amino and 6-hydroxyl groups were 
tied up in an oxazolidinone ring as described previously.82 Consistent with previous reports on 
the regioselective acetylation of neamine,155-156 treatment of 120 with a controlled amount of 
acetic anhydride in pyridine then gave the 6, 2’’,3’’-6’’-tetra-O-acetate 124 in 61% yield 
(Scheme 26).  This method, which gives access to a simple 5-hydroxy apramycin derivative in 4 
steps and 26% overall yield, is a considerable improvement over the earlier chemistry outlined in 
(Schemes 18 and 19). 
 
Scheme 26.  Synthesis of key apramycin intermediate 124. 
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3.4.2. Synthesis of 5-O--ribofuranosyl apramycin, 5-O--paromobiosyl apramycin and 5-
O--[3-O-(2-aminoethyl) ribofuranosyl] apramycin 
Glycosylation of 124 with 2,3,5-tri-O-acetyl-α,β-D-ribofuranosyl trichloroacetimidate157 
125 with promotion by BF3.OEt2 afforded the glycoside 126 in 95% yield as a separable 
anomeric mixture ( = 1:9).  Deprotection of the β-anomer by saponification then 
hydrogenolysis allowed the formation of 127 (Scheme 27).   
 
Scheme 27. Synthesis of 5-O--ribofuranosyl apramycin 127. 
Treatment of pentaazido per-O-acetylparomomycin158 with p-thiocresol and BF3.OEt2, as 
described for neomycin B,159-160 gave a 43% yield of the parombiosyl thioglycoside 128.  
Complications of anomer separation following glycosylations of 124 with 128 prompted its 
conversion to the 4-methoxybenzoate 130, after which oxidation with ozone gave the disaccharyl 
sulfoxide 131 (Scheme 28).  Triflic anhydride activation161-162 of 131 and exposure to 124 then 
afforded the anticipated saccharide 132 in 48% yield as a single β-anomer. Finally, 
saponification of the carbamate and ester groups followed by Staudinger reduction of the azides 
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gave the apramycin-paromomycin chimera 133 in 35% yield, which was isolated in the form of 
the peracetate salt (Scheme 28). 
 
Scheme 28.  Synthesis of 5-O--paromobiosyl apramycin 133. 
Preparation of the 3-O-(2-azidoethyl) ribofuranosyl donor 136 from 5-O-benzyl-1,2-O-
isopropylidene-α-D-ribofuranose 134 was achieved by alkylation with 2-azidoethyl tosylate163 to 
give 135.  Acidic hydrolysis of the acetonide, p-nitrobenzoylation gave the donor 136 in 45% 
yield. This is a considerable improvement over an earlier synthesis of the related 3-O-(2-
azidoethyl) ribofuranosyl groups reported by the Wong group.164  Activation of 136 with 
BF3.OEt2 in the presence of 124 gave a separable anomeric mixture ( = 1.15:1) of the 
glycosides 137 in 43% yield.  Deprotection of individual isomers resulted in the formation of 
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138 and 138, both of which were isolated as the peracetate salts in excellent yields (Scheme 
29).  
 
Scheme 29.  Synthesis of compounds 138 and 138. 
The synthesized compounds 127, 133, 138 and 138 were screened for the 
antiribosomal and antibacterial activities. Compared to apramycin, the 5-O-β-D-ribofuranosyl 
apramycin 127 showed moderately increased antiribosomal activity and especially selectivity 
over the mitoribosome (Table 7), but reduced antibacterial activity against all strains tested 
(Table 8). On the other hand, the 5-O-paromobiosyl apramycin 133 shows better antiribosomal 
activity and better antibacterial activity towards MRSA and E coli. Unfortunately, 133 has less 
mitoribosomal selectivity and less activity towards P aeruginosa. 5-O-[3-(2-Aminoethyl)-β-D-
ribofuranosyl] apramycin (138 shows an enhanced antiribosomal activity and mitoribosomal 
selectivity with comparable antibacterial activity towards MRSA and E coli but is less active 
towards P aeruginosa. In addition, both compounds 133 and 138 were active towards AAC(3) 
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containing bacteria, that inactivate apramycin by acetylation at the 3-position. Biological results 
will be discussed in detail in Section 3.5. In view of the increased activity of paromobiosyl and 
aminoethylribosyl apramycin compared to the parent compound, and their ability to overcome 
AAC(3) AME resistance, more derivatives were explored and evaluated. 
3.4.3 Synthesis of 5-O--[3-O-(2-hydroxyethyl) ribofuranosyl] apramycin 
Two hypotheses were prompted by the observation that 5-[3-(2-aminoethyl)-β-D-
ribofuranosyl] apramycin 138 shows activity towards AAC(3) containing bacteria: i) the 
aminoethyl group was bulky enough to block the AAC(3) enzyme’s active site or ii) the 
increased affinity for the ribosome resulting from the addition of the extra amine outweighs the 
reduction in activity due to N3 acetylation by the AME. To differentiate between these 
hypotheses, a similar compound was synthesized in which a hydroxyethyl side chain replaced the 
aminoethyl group of 138. The preparation of compound 142 started by alkylation of the 
reported intermediate 134165 with 2-(benzyloxy)ethyl tosylate166 to afford the compound 139 in 
83% yield (Scheme 30). Acetonide cleavage then p-nitrobenzoylation of intermediate 139 
enabled the preparation of the donor 140, which was glycosylated with 124 to allow the 
formation of the ribofuranoside product 141 in 25% yield as an anomeric mixture ( = 1:1). 
Finally, deprotection of the -isomer allowed the formation of the target compound 142. When 
this compound was screened for activity against AAC(3) containing bacteria (Table 9) it showed 
a loss in activity, which supports the hypothesis that the amino group of 138is essential and 
plays role in increasing the overall activity of the aminoglycoside. Biological results will be 
discussed in detail in Section 3.5. 
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Scheme 30.  Synthesis of compound 142. 
3.4.4. Modification of the 5’’-hydroxyl group of 5-O--ribofuranosyl apramycin and 5-O--
[3-O-(2-aminoethyl) ribofuranosyl] apramycin 
The presence of the ribosyl 5-hydroxyl group in compounds 127 and 138 renders them 
prone to antibacterial resistance due to the action of the APH(3’,5’’) AMEs. Previous 
modifications to the ribosyl 5-hydroxyl group in the 4,5-aminoglycoside series carried out with a 
view to circumventing this AME include deoxygenation accompanied with cyclization with the 
2’-amine167 or substitution by a halogen atom.168 However, these modifications were reported to 
reduce antibacterial activity substantially and so were not considered useful. Therefore, two 
alternative approaches to the solution of this problem were developed. Thus, it was decided i) to 
explore the effect of removing the offending CH2OH group from the ribosyl ring altogether, and 
ii) to substitute a formamido group for the 5-hydroxyl group in the ribose ring. Consequently, a 
compound analogous to the 5-O--ribofuranosyl apramycin 127 lacking the 5’’-hydroxymethyl 
group (-O--D-erythrofuranosyl apramycin) 152 was synthesized and screened. The -O-(5''-
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formamido-5''-deoxy--D-ribofuranosyl) and the 5-O-[3-O-(2-aminoethyl)-5-deoxy-5-
formamido-D-ribofuranosyl] apramycin derivatives 157 and 166, in both of which the primary 
hydroxyl group of the ribose ring was substituted with a formamido group, also were prepared 
and screened.  
To synthesize the erythrofuranose derivative, 2,3-O-isopropylidene--D-
erythrofuranose169 143 was treated with trichloroacetonitrile in basic conditions to give the 
trichloroacetimidate derivative 144, which was glycosylated with 124 to allow the formation of 
the ribofuranoside product 145 in 96% yield as a single  anomer.  Unfortunately, all attempts to 
cleave the acetonide from the furanose sugar, ended up cleaving the furanose ring altogether 
(Scheme 31)  
 
Scheme 31.  Synthesis of compound 145. 
Alternatively, erythrolactone170 147 was benzoylated followed by selective DIBAL 
reduction of the lactone to give 149. The product was treated with trichloroacetonitrile in basic 
conditions to give the trichloroacetimidate derivative 150 (Scheme 32). This donor was then 
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activated with BF3.OEt2 in the presence of the apramycin acceptor 124 to afford the 5-O-β-D-
erythrofuranoside 151 in 50% yield as a single  anomer. Deprotection of 151 gave 5-
eythrofuranosyl apramycin 152 in 71% yield as its peracetate salt. 
 
Scheme 32.  Synthesis of compound 152. 
The preparation of 5-O-(5-deoxy-5-formamido-β-D-ribofuranosyl) apramycin 157 started 
with the synthesis of 1,2,3-tri-O-acetyl-5-O-p-tolylsulfonyl-D-ribofuranose 153 following the 
reported procedure.171 Subsequent reaction with potassium phthalimide gave intermediate 154. 
Acidic treatment cleaved the anomeric acetate for conversion to trichloroacetimidate 155 using 
trichloroacetonitrile (Scheme 33). Glycosylation of 155 with 124 allowed the formation of the -
anomer of the 5-phthalimido ribofuranoside 156 in 76% yield. Partial deprotection using NaBH4 
freed the amino group from the phthalimide and also liberated the 7’-amino group from the 
oxazolidinone.  This was followed by selective formylation at the 5’’’-amine with N-
(diethylcarbamoyl)-N-methoxyformamide.172 Reduction of the remaining azides to amines 
enabled the preparation of the desired compound 157 as a pentaacetate salt in 42% yield.  
71 
 
 
 
Scheme 33.  Synthesis of compound 157. 
The synthesis of compound 166 began with the preparation of the reported compound 
158,173 which was alkylated with 2-(benzyloxy)ethyl tosylate to give 159 (Scheme 34). 
Subsequent hydrogenolysis converted the azide to an amine and the benzyl ether to a hydroxyl 
group, and was followed by Cbz protection of the amine to give compound 160. Conversion of 
the free hydroxyl group to an azide was done by tosylation then substitution with sodium azide to 
give the intermediate 161 in 84% yield.  
The NHCbz group was then converted to an imide 162 by introduction of a second Cbz 
group using CbzCl and KHMDS. This N,N-di-Cbz moiety is functionally analogous to the 
phthalimido group but affords greater versatility in deprotection.  Acidic hydrolysis of the 
acetonide followed by p-nitrobenzoylation then gave the donor 163 in quantitative yield, which 
was employed to glycosylate 124 giving 164 in 45% yield as a single -anomer. Partial 
deprotection of 164 under basic conditions freed the ribosyl amine as well as the 7’-apramycin 
secondary amine and was followed by selective formylation of the ribosyl amine. Reduction  of 
the azide using the Staudinger reaction in 1 N NaOH unfortunately cleaved the formamide and 
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provided 5-O-[5-amino-3-O-(2-aminoethyl)-5-deoxy--D-ribofuranosyl] apramycin 165. The 
cleavage of the formamide was avoided by conducting the Staudinger reaction under neutral 
conditions when the desired product 166 was obtained in 57% yield as the peracetate salt 
(Scheme 34). The 1H-NMR spectrum of compound 166 showed two rotamers about the 
formamide N-CHO bond in a ratio of 9:1. NMR analysis of the major rotamer showed a 3JH-
5’’,C=O = 3.1 and 
2JCHO,C=O = 197.1, which are in agreement with it being the expected trans-
rotamer.174-175 
  
Scheme 34.  Synthesis of the compounds 165 and 166 
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In an attempt to cleave the acetonide of 161 followed by p-nitrobenzoylation of the 
resulting diol, complications arose from the formation of a pyranose side product 170 due to ring 
closure of the 6-amino group with the aldose moiety of 168 (Scheme 35).176  This problem was 
solved by introduction of a second Cbz onto the amine to give the imide 162 as presented above 
in (Scheme 34). 
 
Scheme 35. The formation of the pyranose side product 170 
Compared to 5-O--ribofuranosyl apramycin 127, both the dehydroxmethyl analog, 5-O-
(β-D-erythrofuranosyl) apramycin 152, and its 5’’’-formamido analog, -O-(5-deoxy-5-
formamido--D-ribofuranosyl) apramycin 157, were more active towards MRSA and P 
aeruginosa, suggesting that the presence of an APH (3’,5’’) resistance determinant may at least 
in part be responsible for the poor activity of the simple ribofuranosyl derivative 127 (Tables 8 
and 9).  Similarly, when compared to 5-O-[3-O-(2-aminoethyl)--D-ribofuranosyl] apramycin 
138, the 5-amino-5-deoxy-ribosyl analog 165 and 5-deoxy-5-formamido ribosyl analog 166 
showed a higher activity in the presence of the APH(3’,5’’) AME (Table 9).  In addition, both of 
these compounds, but especially 165 showed i) potent antibacterial activity exceeding that of 
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apramycin in all strains and ii) better ribosomal selectivity. Biological results will be discussed in 
detail in Section 3.5. 
3.4.5. Synthesis of 6-O-propyl apramycin, 6-O-(2,3-dihydroxypropyl) apramycin and 6-O-
(2-hydroxyethyl) apramycin 
Introduction of some simpler modifications at the 5-position of apramycin was attempted. 
Thus, compound 124 was allylated using allyl bromide and a base, however the 6-O-allyl 
derivative 172 was obtained instead of the desired 5-O-allyl isomer. Clearly, under the basic 
conditions the 6-O-acetyl group migrated to the adjacent 5-hydroxyl group drive the allylation 
reaction toward the more reactive 6-hydroxy group following the Curtin-Hammett principle 
(Figure 30).177-178 Different bases were tried and but even under the mild silver oxide conditions 
the 6-O-allyl derivative 172 was separated in 59% yield. 
 
Figure 30. Reaction co-ordinate diagram showing the formation of 6-O-allyl apramycin 
derivative 172 under Curtin-Hammett control 
Nevertheless, compound 172 was deprotected to give the 6-O-propyl apramycin 
derivative 173 (Scheme 36). In addition, dihydroxylation of intermediate 172 by OsO4 gave the 
dihydroxylated intermediate 174 in 71% yield, which was either deprotected to give 6-O-(2,3-
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dihydroxypropyl) apramycin 175 or exposed to oxidative cleavage then reduction before 
deprotection to allow the formation of 6-O-(2-hydroxyethyl) apramycin 177. Biological 
screening of 173, 175 and 177 didn’t show any advantage over the parent apramycin (Tables 7 
and 8). 
 
Scheme 36.  Synthesis of compounds 173, 175 and 177. 
3.4.6. Synthesis of 5-epi-apramycin, 5-deoxy-5-fluoro apramycin, 5-deoxy-5-epi-fluoro- 
apramycin and 5-deoxy apramycin 
A previous report showed that the 5-hydroxyl group is not essential for activity, and that 
removing it even increases antibacterial activity,145 suggesting further exploration of this 
position. Thus, inversion of configuration at the 5-position and replacement of the 5-hydroxy 
group with fluoride in both configurations were explored. Moreover, 5-deoxyapramycin was also 
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synthesized as a comparator. To synthesize 5-epi-apramycin 179, compound 124 was triflated at 
the 5-position and the triflate displaced by potassium acetate to afford the inverted acetate 
intermediate 178 (Scheme 37). Basic hydrolysis followed by Staudinger reaction of the 
intermediate 178 enabled the preparation of compound 179 in 65% yield as the pentaacetate salt. 
Preparation of 5-deoxy-5-fluoro apramycin 182 started by triflation and was followed by 
substitution with sodium nitrite, which upon workup gave the inverted hydroxyl group 
intermediate 180.179 Subsequent treatment with diethylaminosulfur trifluoride (DAST) 
substituted the hydroxyl group with fluoride with inversion of configuration giving 181 in 81% 
yield. Deprotection of 181 by basic hydrolysis of the esters and subsequent Staudinger reaction 
enabled the preparation of 182 in 58% yield. The 5-deoxy-5-epi-fluoro apramycin derivative 183 
was accessed from 124 in 74% yield by displacement of the 5-hydroxyl group with fluoride 
using DAST. Global deprotection of 183 gave the 5-deoxy-5-epi-fluoro apramycin pentaacetate 
salt 184 in 59% yield. Finally, 5-deoxyapramycin was synthesized by the initial displacement of 
the 5-hydroxyl group of 124 with iodide via the triflate intermediate giving 185.  This was 
followed by deacetylation and parallel hydrogenolysis of the azides and of the C-I bond. Basic 
hydrolysis of the oxazolidinone ring gave 186, which was isolated as the peracetate salt in 47% 
yield. Biological screening (Table 7 and Table 8) of 5-deoxyapramycin was consistent with the 
previous report.145 All compounds tested in this series (5-epi-OH, 5-fluoro, 5-epi-fluoro and 5-
deoxy) showed better antiribosomal activity than apramycin. Derivatives 5-epi apramycin 179, 
5-fluoro-5-deoxy apramycin 182, 5-epifluoro apramycin 184 and 5-deoxy apramycin 186 had 
better antibacterial effect against MRSA and E. coli strains and comparable antibacterial effects 
toward P aeruginosa compared to the parent compound (Table 7 and Table 8). Biological results 
will be discussed in detail in Section 3.5. 
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Scheme 37.  Synthesis of compounds 179, 182, 184 and 186. 
3.4.7. Synthesis of 3-N-formyl apramycin and 3-N-acetyl apramycin 
The only known AME that affects apramycin is AAC(3)-IV that acetylates the 3-amino 
group of apramycin.57  As formamido groups are tolerated at other positions on aminoglycoside 
skeletons when acetamido groups are not,180 it was possible that installation of a formamide 
group at the 3-amino group of apramycin would block the action of AAC(3)-IV but not 
compromise the antibacterial activity. Consequently, 3-N-formyl apramycin was synthesized 
together with 3-N-acetyl apramycin that was needed as a comparison standard. The synthesis of 
these derivatives began with the preparation of the compound 187 using copper-based selective 
acylation as reported.152 Subsequently, the remaining primary amines were protected as azides 
and the 3-amino group was freed in basic conditions to afford the compound 188. Selective 
formylation at the 3-position was achieved with using N-(diethylcarbamoyl)-N-
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methoxyformamide.172 Reduction of the remaining azides to amines enabled the preparation of 
the desired compound 190. In a similar way, 3-amino group of 188 was acetylated using N-
(diethylcarbamoyl)-N-methoxyacetamide 189 and the azides were reduced to afford compound 
191 (Scheme 38). Interestingly, the 1H-NMR spectra of 3-N-formyl apramycin shows two 
rotamers in 4:3 ratio favoring the trans-rotamer, with the assignment-based on an nOe spectrum 
of 190, which showed clear enhancement of the resonances for H-3 and CHO in the cis-form but 
not of H-3 on irradiation of the formyl proton in the trans-rotomer (Scheme 39). The biological 
data for compounds 190 and 191 showed complete loss of antibacterial activity (Table 7 and 
Table 8) thereby negating the hypothesis that a formamido group might be tolerated at the 3-
position of apramycin. 
 
Scheme 38.  Synthesis of compounds 190 and 191. 
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Scheme 39.  Diagnostic nOe interactions in the cis and trans rotamers of 3-N-formyl 
apramycin  
3.5. Biological Evaluation 
All the synthesized compounds were submitted to the Böttger lab in Zurich, where they were 
screened for antiribosomal activity (Table 7) and antibacterial activity against strains of E. coli, 
MRSA and P aeruginosa (Table 8). The methods were identical to the ones applied in the 
netilmicin series (Chapter 2). In addition, the MIC of the compounds were obtained against 
engineered E. coli strains with known AME resistance mechanisms. 
Table 7.  Inhibition of wild-type bacterial and hybrid ribosomes (IC50, M).  
IN VITRO (IC50, M) Sms (M) Mit (M) A1555G (M) Cyt (M) 
Apramycin (9) 0.17 124.8 (747) 51.5 (308) 108.7 (651) 
Neomycin (2) 0.03 3.8 (127) 0.4 (14) 32.8 (1094) 
5-O-(β-D-Ribofuranosyl) 
apramycin (127) 
0.09 368.9 (4130) 272.8 (3054) 436.2 (4883) 
5-O-(β-Paramobiosyl) 
apramycin (133) 
0.13 2.1 (16) 0.5 (4) 29.7 (225) 
5-O-[3-(2-Aminoethyl)--
ribofuranosyl] apramycin 
(138 
0.07 77.4 (1106) 16.9 (241) 202.6 (2896) 
5-O-[3-(2-Aminoethyl)-α-
ribofuranosyl] apramycin 
(138 
0.35 192.4 (550) 284.8 (814) 257.2 (735) 
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5-O-[3-(2-Hydroxyethyl)-β-D-
ribofuranosyl] apramycin (142) 
0.31 904.0 (2945) 456.0 (1483) 1227.0 (3991) 
5-O-(β-D-Erythrofuranosyl) 
apramycin (152) 
0.12 312.2 (2504) 235.0 (1885) 448.6 (3598) 
5-O-β-(5'''-Formamido-5'''-
deoxy-D-ribofuranosyl) 
apramycin (157) 
0.33 571.5 (1744) 263.2 (803) > 
5-O-[5-Deoxy-5-amino-3-(2-
aminoethyl)-β-D-
ribofuranosyl] apramycin (165) 
0.04 48.0 (1143) 22 (524) 37.0 (881) 
5-O-[5-Deoxy-5-formamido-3-
(2- 
aminoethyl)-β-D-ribofuranosyl] 
apramycin (166) 
0.09 93.0 (1094) 11.0 (129) 142.0 (1671) 
6-O-Propyl apramycin (173) 2.49 448.7 (180) 828.5 (332) 646.0 (259) 
6-O-(2,3-Dihydroxypropyl) 
apramycin (175) 
0.57 403.1 (707) 565.3 (991) 462.4 (811) 
6-O-(2-Hydroxyethyl) 
apramycin (177) 
0.39 638.1 (1619) 388.6 (986) 425.34 (1079) 
5-Epi apramycin (179) 0.11 39.9 (359) 17.8 (160) 25.5 (229) 
5-Deoxy-5-fluoro-apramycin 
(182) 
0.12  113.7 (978) 125.2 (1076) 136.6 (1175) 
5-Deoxy-5-epifluoro-
apramycin (184) 
0.10  55.8 (559) 50.4 (506) 51.7 (519) 
5-Deoxy apramycin (186) 0.11  86.5 (824) 67.4 (642) 80.2 (764) 
3-N-Formyl apramycin (190) 69  > 2000 > 2000 > 2000 
3-N-Acetyl apramycin (191) n.d. n.d. n.d. n.d. 
Sms: M. Smegmatis ribosome, Cyt: M. Smegmatis ribosome with human cytosolic A-site, Mit: M. Smegmatis 
ribosome with human mitochondrial A-site, A1490G: M. Smegmatis ribosome with human mitochondrial A-site 
with A1555G mutation. Selectivities are obtained by dividing the hybrid ribosomal activity by M. Smegmatis 
ribosomal activity. 
The inhibitory activity of apramycin against the bacterial ribosome is less than that of 
neomycin but much greater selectivities is displayed toward the wild-type mitochondrial and the 
A1555G mutant mitochondrial ribosomes, which is reflected in lower cochleotoxicity of 
apramycin compared to neomycin75, 134 Compared to apramycin, the installation of a ribosyl 
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group at the 5-position, as in compound 127, resulted in moderately increased antiribosomal 
activity (2-fold) and greater selectivity over the wild-type mitoribosome hybrid (5- to 6-fold) and 
the A1555G mutant mitoribosome hybrid (10-fold). On the other hand, the 5-O-paromobiosyl 
group shifted the activities of apramycin to resemble more those of neomycin: like neomycin, 5-
O-paromobiosyl apramycin 133 exhibits strong antibacterioribosomal activity but very low 
mitoribosomal selectivity. 5-O-[3-(2-Aminoethyl)-β-D-ribofuranosyl] apramycin 138 shows an 
enhanced antiribosomal activity (2 to 3-fold) and mitoribosomal selectivity in wild-type but not 
in the A1555G mutant hybrid. Both changing the anomeric configuration of the ribose ring as in 
compound 138 or subtituting the 2-aminoethyl group with hydroxyethyl group 142 had a 
detrimental effect on the ribosomal activity. On the other hand, the 5’’’-amine analog 165 of 
compound 138 showed enhanced antibacterioribosomal activity (2-fold) and a comparable 
mitoribosomal selectivity when compared to the parent. Replacing the 5’’’-hydroxyl group of 
138  with a 5’’’-fomamido group as in compound 166 did not change much the ribosomal 
activity and selectivities Compared to 5-O--ribofuranosyl apramycin 127, both the 
dehydroxmethyl analog 152, and its 5’’’-formamido analog 157, exhibited reduced 
antibacterioribosomal activities and mitoribosomal selectivities.  
Derivatives 5-epi apramycin 179, 5-fluoro-5-deoxy apramycin 182, 5-epifluoro 
apramycin 184 and 5-deoxy apramycin 186 showed better antiribosomal activity than apramycin. 
Enhancement of selectivity over the wild-type and mutant mitoribosomal were also obtained in 
case of 5-fluoro-5-deoxy apramycin 182 and 5-deoxy apramycin 186. 
All the compounds synthesized with substitutions at the 6-position and the 3-position 
abolish the ribosomal activity. 
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Table 8.  Minimal inhibitory concentrations (MIC, μg/mL) of clinical isolates. 
 
(MIC, μg/ml) 
MRSA E coli P aeruginosa 
AG03
8 
AG03
9 
AG04
2 
AG04
4 
AG00
1 
AG05
5 
AG00
3 
AG03
1 
AG03
2 
AG03
3 
AG086 
Apramycin (9) 8 8 8 16 16 8 8-16 8 8 8 4 
Neomycin (2) 0.5-1 128 128 0.5-1 ---- 4 4 32 
32-
64 
≥128 ≥128 
5-O-(β-D-
Ribofuranosyl) 
apramycin (127) 
64 64 64 
32-
64 
16 
16-
32 
16 64 
32-
64 
128 >128 
5-O-(β-
Paramobiosyl) 
apramycin (133) 
2-4 2-4 2 2 4 8 4 64 64 64 ≥128 
5-O-[3-(2-
Aminoethyl)--
ribofuranosyl] 
apramycin (138 
8-16 8 8 8-16 8 8 4-8 32 32 128 >128 
5-O-[3-(2-
Aminoethyl)-α-
ribofuranosyl] 
apramycin (138 
16 16 16 16 32 
16-
32 
16-
32 
32-
64 
64 128 >128 
5-O-[3-(2-
Hydroxyethyl)-β-D-
ribofuranosyl] 
apramycin (142) 
32 32 32 n.d. 32 16 16 >32 >32 >32 n.d. 
5-O-(β-D-
Erythrofuranosyl) 
apramycin (152) 
16-
32 
16-
32 
16 16 16 16 16 32 32 
64-
128 
>128 
5-O-β-(5'''-
Formamido-5'''-
deoxy-D-
ribofuranosyl) 
apramycin (157) 
32 
16-
32 
32 n.d. 8 16 8 >32 >32 >32 n.d. 
5-O-[5-Deoxy-5-
amino-3-(2-
aminoethyl)-β-D-
ribofuranosyl] 
apramycin (165) 
1 1 1 n.d. 2 2 1-2 2 2 2 n.d. 
5-O-[5-Deoxy-5-
formamido-3-(2- 
aminoethyl)-β-D-
ribofuranosyl] 
apramycin (166) 
4 4-8 4-8 n.d. 2 4 2 16 32 64 n.d. 
6-O-Propyl 
apramycin (173) 
≥128 ≥128 
64-
128 
128 
64-
128 
64-
128 
64-
128 
>128 >128 >128 >128 
6-O-(2,3-
Dihydroxypropyl) 
apramycin (175) 
64 64 64 
64-
128 
32 32 32 64 64 ≥128 ≥128 
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6-O-(2-
Hydroxyethyl) 
apramycin (177) 
16-
32 
16-
32 
64 64 16 16 16 32 32 
64-
128 
4-8 
5-Epi apramycin 
(179) 
4 4 2-4 4 4 4 4 4 4 8 32 
5-Deoxy-5-fluoro-
apramycin (182) 
4-8 4-8 8 n.d. 8 4 8 8-16 16 32 n.d. 
5-Deoxy-5-
epifluoro-apramycin 
(184) 
2-4 2-4 4 n.d. 8 4 4 8-16 8-16 32 n.d. 
5-Deoxy apramycin 
(186) 
2-4 2 4 n.d. 4 4 4 8 8 16 n.d. 
3-N-Formyl 
apramycin (190) 
>64 n.d. n.d. n.d. >64 n.d. n.d. >64 n.d. n.d. n.d. 
3-N-Acetyl 
apramycin (191) 
>64 >32 >32 n.d. >32 >32 >32 >32 >32 >32 n.d. 
MIC (μg/mL) of apramycin derivatives to inhibit Sms (Mycobacterium smegmatis), MRSA (Methicillin-resistant 
Staphylococcus aureus), E coli and P aeruginosa. 
Compared to apramycin, the 5-O-β-D-ribofuranosyl apramycin 127 showed a reduced 
antibacterial activity against all strains tested (Table 8). On the other hand, the 5-O-paromobiosyl 
apramycin 133 shows an increase in antibacterial activity towards MRSA and E coli but a 
reduced activity towards P aeruginosa. 5-O-[3-(2-Aminoethyl)-β-D-ribofuranosyl] apramycin 
138 exhibits comparable antibacterial activity towards MRSA and E coli but is less active 
towards P aeruginosa. Both the dehydroxmethyl analog, 5-O-(β-D-erythrofuranosyl) apramycin 
152, and the 5’’-formamido analog, 5-O-(5'’'-deoxy-5’’’-formamido--D-ribofuranosyl) 
apramycin 157, were more active than their ribosyl congener towards MRSA and P aeruginosa, 
suggesting that the presence of an APH (3’,5’’) resistance determinant may at least in part be 
responsible for the poor activity of the simple ribofuranosyl derivative 127.  Similarly, when 
compared to 5-O-[3-O-(2-aminoethyl)--D-ribofuranosyl] apramycin 138, the 5-amino-5-
deoxy-ribosyl analog 165 and 5-deoxy-5-formamido ribosyl analog 166 showed a higher activity 
towards MRSA and E coli.  
Compared to apramycin, 5-epi apramycin 179, 5-fluoro-5-deoxy apramycin 182, 5-
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epifluoro apramycin 184 and 5-deoxy apramycin 186 had better antibacterial effects against 
MRSA and E. coli strains and comparable antibacterial effects toward P aeruginosa. This 
highlights the fact that a 5-hydroxy group is not necessary for activity and that its removal or 
substitution may be beneficial. 
All the compounds synthesized with the substitution at the 6-position (6-O-propyl 173, 6-
O-(2,3-dihydroxypropyl) 175 and 6-O-(2-hydroxyethyl) 177) were less active in all tested 
bacterial strains. Similarly, 3-N-formyl apramycin 190 and 3-N-acetyl apramycin 191 showed 
greatly reduced activity. 
Table 9.  Minimal inhibitory concentrations (MIC, μg/mL) of engineered E coli strains 
carrying known AMEs  
 
(MIC, μg/ml) 
E coli 
AG173 AG163 AG166 AG182 AG037 
AAC(3)-IV APH(3’)-Ia APH(3’)-IIa 
AAC(3)-IV 
APH(3’)-Ia 
APH(3’)-IIIa 
Apramycin (9) 256 4 4-8 >128 1 
Neomycin (2) n.d. >64 >64 n.d. >64 
5-O-(β-D-Ribofuranosyl) 
apramycin (127) 
16-32 8-16 8 64 4 
5-O-(β-Paramobiosyl) apramycin 
(133) 
1-2 8 2 64 1 
5-O-[3-(2-Aminoethyl)--
ribofuranosyl] apramycin (138 
4 4-8 2 16 0.5 
5-O-[3-(2-Aminoethyl)-α-
ribofuranosyl] apramycin (138 
n.d. n.d. n.d. n.d. n.d. 
5-O-[3-(2-Hydroxyethyl)-β-D-
ribofuranosyl] apramycin (142) 
32-64 8 8 n.d. n.d. 
5-O-(β-D-Erythrofuranosyl) 
apramycin (152) 
128 8 8 >128 1-2 
5-O-β-(5'''-Formamido-5'''-deoxy-
D-ribofuranosyl) apramycin (157) 
>64 8 8-16 n.d. n.d. 
5-O-[5-Deoxy-5-amino-3-(2-
aminoethyl)-β-D-ribofuranosyl] 
apramycin (165) 
4 2 2 8 0.25 
5-O-[5-Deoxy-5-formamido-3-(2- 
aminoethyl)-β-D-ribofuranosyl] 
apramycin (166) 
32 2 4 32-64 0.25 
6-O-Propyl apramycin (173) n.d. n.d. n.d. n.d. n.d. 
6-O-(2,3-Dihydroxypropyl) 
apramycin (175) 
n.d. n.d. n.d. n.d. n.d. 
6-O-(2-Hydroxyethyl) apramycin 
(177) 
>128 8-16 8-16 >128 2 
85 
 
 
 
5-Epi apramycin (179) 64 n.d. n.d. >128 n.d. 
5-Deoxy-5-fluoro-apramycin (182) 64 n.d. n.d. >128 n.d. 
5-Deoxy-5-epifluoro-apramycin 
(184) 
128 n.d. n.d. >128 n.d. 
5-Deoxy apramycin (186) 32 n.d. n.d. 128 n.d. 
3-N-Formyl apramycin (190) n.d. n.d. n.d. n.d. n.d. 
3-N-Acetyl apramycin (191) n.d. n.d. n.d. n.d. n.d. 
 
AAC(3)‐IV AME is the only resistance determinant currently effective in the abrogation 
of apramycin activity,57 consequently it was important to examine the synthesized compounds 
against bacteria known to carry this and other enzymes. Interestingly, adding the β-D-
ribofuranosyl group 127 at the 5-position protects the compound from the action of AAC(3)-IV. 
This protection is increased at least 4-fold by further incorporation of a 2-aminoethyl group at 
the 3’’’-position of compound 138 and 8-fold if a diaminoidose sugar is incorporated instead as 
in 5-O-(β-paramobiosyl) apramycin 133. Compared to 5-O-(β-D-ribofuranosyl) apramycin 127, 
removal of the 5’’’-CH2OH 152 or substituting the 5’’’-OH with a formamido group 157 made 
the compounds more prone to AAC(3)-IV. Similarly, when compared to 5-O-(2-aminoethyl)--
ribofuranosyl] apramycin 138, its 5’’’ formamide analog 166 or substituting the 3’’’-
aminoethyl group with a hydroxyethyl group 142 reduced the activity at least 8-fold against 
AAC(3)-IV containing bacteria. On the other hand, activity was not reduced in the 5’’’ amine 
analog 165 of 5-O-[3-(2-aminoethyl)--ribofuranosyl] apramycin 138. 
Compared to apramycin, the 5-epi apramycin 179, 5-fluoro-5-deoxy apramycin 182, and 
5-epifluoro apramycin 184 showed moderately increased activity (2- to 4-fold) against AAC(3)-
IV containing E coli , whereas 5-deoxy apramycin 186 showed a more substantial increase in 
activity (8-fold).  
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Apramycin is inheritably not susceptible to APH(3’) due to the absence of a hydroxy 
group at the 3’-position, thus all synthesized compounds tested showed results with APH(3’)-Ia 
and APH(3’)-IIa containing bacteria comparable to the wild type. However, APH(3’)-IIIa 
enzymes are also known to phosphorylate the 5-hydroxyl of the ribose ring in 4,5-AGAs.38 Thus, 
the presence of APH (3’)-IIIa results in a 4-fold reduction activity in antibacterial activity when a 
ribofuranosyl group is attached at the 5-position as in compound 127. Removal of the ribosyl 5-
OH as in the erythrofuranose restores activity in the presence of the APH(3’)-IIIa.  Similarly, the 
replacement of the ribosyl 5-OH by a formamido or amino group overcomes the presence of 
APH(3’)-IIIa as is clear from the comparison of 5-O-[3-(2-aminoethyl)--ribofuranosyl] 
apramycin 138, with its formamido 166 and amino 165 analogs. 
3.6. Conclusion 
An easy and efficient method has been developed for derivatization of apramycin at the 
5-position. Compounds 5-O-[3-(2-aminoethyl)--ribofuranosyl] apramycin 138, 5-O-(β-
paramobiosyl) apramycin 133, 5-O-[5-deoxy-5-formamido-3-(2-aminoethyl)-β-D-ribofuranosyl] 
apramycin 166 and 5-Deoxy apramycin 186 showed improved antibacterial activity against 
MRSA and E. coli strains and reduced antibacterial activity toward P aeruginosa in comparison to 
the parent apramycin. 5-Epi apramycin 179 exhibits higher activity against all bacterial strains, 
albeit with less mitoribosomal selectivity. The apramycin-paromomycin hybrid 133and its 
simplified form 138were active in the presence of the AAC(3)-IV class of AME that is the only 
resistance determinant currently effective in the abrogation of apramycin activity The 5-O-[5-
deoxy-5-amino-3-(2-aminoethyl)-β-D-ribofuranosyl] apramycin 165 is considered a 
breakthrough in so far as it satisfies all the project needs with improved antibacterial activity 
compared to apramycin against all bacterial strains screened including P aeruginosa, and strains 
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carrying the AAC(3) and APH(3’,5’’) AMEs. In addition, compound 165 showed improved ribosomal 
selectivity. Moreover, this study showed that a hydroxy group at the 5-position of apramycin is 
not essential, in fact its removal, inversion of configuration, or replacement by a fluoro group as 
in compounds 179, 182, 184 and 186 increases activity. Overall, new apramycin derivatives were 
developed which are more active than the parent drug. Moreover, aminoglycosides with better 
mitoribosomal selectivity and the ability to overcome the AAC(3)resistance determinant were 
developed for potential treatment of multidrug resistant bacterial infections. 
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CHAPTER 4. CONCLUSIONS 
In order to investigate the effect of 4’-modifications of the 4,6-AGA netilmicin on the 
reduction of ototoxicity but not antibiotic activity several netilmicin derivatives have been 
prepared. These derivatives were screened for antiribosomal activity in cell-free translation 
assays as well as antibacterial activity against clinical isolates of methicillin-resistant 
Staphylococcus aureus, Escherichia coli (E coli) and Pseudomonas aeruginosa. Unfortunately, 
all modifications of netilmicin at the 4’-position showed similar or reduced antibacterial 
activities to the parent. All derivatives except 4'-chloro netilmicin showed less selectivity than 
netilmicin for inhibition of the bacterial ribosome as compared to the eurkaryotic ribosomes. 
Overall, the 4’-modifications reduce activity in 4,6-series to a greater extent than in the 4,5-
series. This conclusion is consistent with the results observed in a series of  4’-modifications of 
the 4,6-aminoglycoside kanamycin B.11 
This work made use of phenyl triazenes as selective protecting groups for secondary 
amines in the presence of primary amines. A number of polyamine substrates were used in the 
study including aliphatic and heterocyclic polyamines, amino acids and aminoglycosides. The 
secondary amines in these substrates were selectively protected as phenyl triazenes, and the 
primary amines were subsequently protected as the azides, benzyloxy carbamates or 
fluorenylmethyl carbamates. Phenyl triazenes also gave the advantage over carbamates of 
showing sharp 1H NMR spectra at room temperature. This protecting group enabled the synthesis 
of plazomicin, an aminoglycoside in the 3rd phase of clinical trials, in fewer steps and higher 
yield than previously reported. 
A series of novel apramycin derivatives were designed by focusing on derivatization and 
modifications at the 5-position. An apramycin-paromomycin hybrid, in which the paromobiosyl 
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group (rings III and IV) of paromomycin was attached to the 5-postion of apramycin, was 
synthesized with the aim of combining paromomycin’s high activity with apramycin’s low 
ototoxicity. The hybrid 133 showed better antibacterial activity against MRSA and E coli strains 
compared to the parent apramycin, but unfortunately with reduced antibacterial activity toward P 
aeruginosa and reduced ribosomal selectivity. Further truncation and modifications of this hybrid 
led to the development of 5-O-[5-amino-3-O-(2-aminoethyl)-5-deoxy-β-D-ribofuranosyl] 
apramycin 165, 5-O-[3-O-(2-aminoethyl)-5-deoxy-5-formamido-β-D-ribofuranosyl] apramycin 
166, 5-epi apramycin 179 and 5-deoxy apramycin 186 that showed an overall better antibacterial 
effect with better ribosomal selectivity than the parent. Compound 165 is considered the best of 
all derivatives synthesized as it was more active against all bacterial strains than apramycin 
including P aeruginosa and AAC(3) and APH(3’)-IIIa- containing bacteria, and also showed a 
better ribosomal selectivity. Overall, apramycin-class aminoglycoside derivatives with better 
antibacterial activities and ribosomal selectivities, and the ability to overcome the AAC(3) and 
APH(3’)-IIIa resistance determinants were developed with for the treatment of multidrug 
resistant bacterial infections. 
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CHAPTER 5. EXPERIMENTAL SECTION 
General Information 
All reagents and solvents were purchased from commercial suppliers and were used 
without further purification unless otherwise specified. Chromatographic purifications were 
carried out over silica gel. Analytical thin-layer chromatography was performed with pre-coated 
glass backed plates (w/UV 254) and visualized by UV irradiation (254 nm) or by staining with 
25% H2SO4 in EtOH or ceric ammonium molybdate (ceric sulfate: (4.0 g); ammonium 
molybdate (10 g); H2SO4: 40 mL, H2O: 360 mL) solution. Specific rotations were obtained using 
a digital polarimeter in the solvent specified at 589 nm and 23 ºC on an Autopol III polarimeter 
(Rudolph Research Analytical, Hackettstown, NJ) with a path length of 10 cm. Infrared spectra 
were recorded on a FT/IR instrument. High resolution mass spectra were recorded with an 
electrospray source coupled to a time-of-flight mass analyzer (Waters). 1H, 13C and 2D NMR 
spectra were recorded on 400 MHz, 500 MHz or 600 MHz instruments as specified. 
Assignments in 1H and 13C NMR were done by the assistance of H−H COSY, HSQC and/or 
HMBC experiments 
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General procedure A.  Selective protection of secondary amines as phenyl triazenes 
with subsequent protection of primary amines as azides: An ice cooled solution of the amine 
(1 equiv) in a water/methanol mixture (3:7, 0.1 M) was treated with Na2CO3 (8 equiv), and then 
dropwise over 0.5 h with a solution of phenyldiazonium tetrafluoroborate (1.1 equiv) in water 
(0.1 M). After completion of the addition, Stick's reagent (imidazole-1-sulfonyl azide 
hydrochloride, 0.3 mmol per primary amine) and a catalytic amount of CuSO4 were added. The 
reaction mixture was allowed to warm to rt and stirred overnight before it was diluted with ethyl 
acetate and washed with water and brine. The organic layer was dried and concentrated. The 
residue was purified by chromatography over silica gel. 
General procedure B: Selective protection of secondary amines as phenyl triazenes 
with subsequent protection of primary amines as azides: The substrate (1 equiv) was 
dissolved in acetonitrile:H2O (1:1, 0.1 M). K2CO3 (8 equiv) was added and the reaction mixture 
was cooled to 0 oC using an ice bath. A solution of phenyldiazonium tetrafluoroborate (1.1 
equiv) in acetonitrile (0.1 M) was added using a syringe pump over 0.5 h. After completion of 
the addition, 0.22 mmol per amine of imidazole-1-sulfonyl azide hydrochloride and a catalytic 
amount of CuSO4 were added. The reaction mixture was allowed to warm to rt and stirred 
overnight. The reaction mixture was diluted with ethyl acetate and washed with water and brine. 
The organic layer was dried and concentrated. The residue was purified by chromatography over 
silica gel. 
General procedure C:  Selective protection of secondary amines as phenyl triazenes 
with subsequent protection of primary amines as benzyl carbamates: An ice cooled solution 
of the amine (1 equiv) in a water/methanol mixture (3:7, 0.1 M) was treated with Na2CO3 (8 
equiv), and then dropwise over 0.5 h with a solution of phenyldiazonium tetrafluoroborate (1.1 
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equiv) in water (0.1 M). After completion of the addition, 0.24 mmol per amine of benzyl 
chloroformate was added. The reaction mixture was allowed to warm to rt and stirred overnight. 
The reaction mixture was diluted with ethyl acetate and washed with water and brine. The 
organic layer was dried and concentrated. The residue was purified by chromatography over 
silica gel. 
General procedure D:  Deprotection by deacetylation, Staudinger and acid cleavage 
of phenyl triazenes: A stirred solution of substrate (0.04 mmol, 1 equiv) in dioxane (1.5 mL) 
was treated with 1N NaOH (0.5 mL) and heated with stirring at 60 °C for 1.5 h. The reaction 
mixture was cooled to rt before 1M P(CH3)3 in THF (4.5 equiv) was added and the reaction 
mixture stirred at rt for 6h. The reaction mixture was then concentrated and purified by column 
chromatography (eluent: 5% to 12% ammonical MeOH in DCM). The product-containing 
fractions were concentrated, dissolved in ethanol (0.9 mL) and treated with sodium 
hypophosphite (2 equiv) and trifluoroacetic acid (12 equiv), and stirred at rt for 8 h. The reaction 
mixture was neutralized using Amberlite® IRA400 hydroxide form, filtered and dried. The crude 
product was dissolved in D.I. water (1 mL), acidified by glacial acetic acid till pH = 3-4 and 
loaded to a Sephadex column (CM Sephadex C-25) from which it was flushed with D.I. water 
(20 mL), then by gradient elution of 0.1% - 1.0% NH4OH in D.I. water. The fractions containing 
the product were combined, acidified with glacial acetic acid and lyophilized to give a white 
solid. 
Methyl 2-azido-6-(1-methyl-3-phenyltriaz-2-en-1-yl) hexanoate (50). This compound 
was prepared according to the general procedure A using compound 42 (38 mg, 0.22 mmol) to 
afford the desired product 7 (38 mg, 58 %) as a yellow oil; Rf = 0.8 (40% EtOAc in hexanes); 
[α]D25= -26.1 (c 0.025, MeOH); IR (film) (cm-1): 2105, 1745, 1594 (w); 1H NMR (400 MHz, 
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CD3OD) δ 7.36 (dd, J = 8.5, 1.2 Hz, 2H), 7.33 – 7.24 (m, 2H), 7.09 (t, J = 7.3 Hz, 1H), 4.00 (dd, 
J = 8.2, 5.3 Hz, 1H), 3.77 (t, J = 7.0 Hz, 2H), 3.71 (s, 3H), 3.19 (s, 3H), 1.91 – 1.81 (m, 1H), 
1.79-1.66 (m, 3H), 1.47 – 1.36 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 171.2, 151.0, 128.3, 
124.9, 120.0, 61.6, 51.6, 30.5, 27.2, 22.4; ESI-HRMS: m/z calcd. for C14H20N6NaO2 [M+Na]
+ 
327.1545; found, 327.1561. 
3-(4-Azidobutyl)-3-(3-azidopropyl)-1-phenyltriaz-1-ene (51). This compound was 
prepared according to the general procedure A using compound 43 (50 mg, 0.20 mmol) to afford 
the desired product 51 (36 mg, 61 %) as a yellow oil; Rf = 0.5 (20% EtOAc in hexanes); IR 
(film) (cm-1): 2093, 1593 (w); 1H NMR (600 MHz, CD3OD) δ 7.35 (d, J = 7.4 Hz, 2H), 7.28 (t, J 
= 7.9 Hz, 2H), 7.09 (t, J = 7.3 Hz, 1H), 3.77 (t, J = 7.0 Hz, 2H), 3.73 (t, J = 7.2 Hz, 2H), 3.35 (t, 
J = 6.6 Hz, 2H), 3.32 (t, J = 6.8 Hz, 2H), 1.93 (p, J = 6.7 Hz, 2H), 1.74 (p, J = 7.3 Hz, 2H), 1.60 
(p, J = 7.1 Hz, 2H); 13C NMR (151 MHz, CD3OD) δ 150.8, 128.3, 125.0, 120.1, 50.7, 48.7, 27.7, 
25.9, 23.8; ESI-HRMS: m/z calcd. for C13H20N9 [M+H]
+, 302.1842; found, 302.1845. 
3-(3-Azidobenzyl)-3-methyl-1-phenyltriaz-1-ene (52). This compound was prepared 
according to the general procedure A using compound 44 (100 mg, 0.74 mmol) to afford the 
desired product 52 (135 mg, 69 %) as a yellow oil; Rf= 0.7 (20% EtOAc in hexanes); IR (film) 
(cm-1): 2109, 1590 (w); 1H NMR (400 MHz, CD2Cl2) δ 7.53 (d, J = 8.2 Hz, 2H), 7.42-7.31 (m, 
3H), 7.23 (t, J = 7.3 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 7.05 – 6.92 (m, 2H), 4.97 (s, 2H), 3.21 (br 
s, 3H); 13C NMR (101 MHz, CD2Cl2) δ 150.6, 140.5, 139.0, 130.1, 128.9, 125.8, 124.4, 120.8, 
118.5, 118.3, 59.0, 34.9; ESI-HRMS: m/z calcd. for C14H15N6 [M+H]
+, 267.1358; found, 
267.1363.  
4-Azido-1-(phenyldiazenyl)piperidine (53). This compound was prepared according to 
the general procedure A using compound 45 (100 mg, 1 mmol) to afford the desired product 53 
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(160 mg, 70 %) as a yellow oil; Rf= 0.65 (20% EtOAc in hexanes); IR (film) (cm-1): 2092, 1593 
(w); 1H NMR (400 MHz, CDCl3) δ 7.46 (dd, J = 8.4, 1.4 Hz, 2H), 7.40 – 7.33 (m, 2H), 7.21 (t, J 
= 7.3 Hz, 1H), 4.16 (ddd, J = 13.6, 6.4, 4.3 Hz, 2H), 3.74 (tt, J = 8.3, 3.7 Hz, 1H), 3.56 (ddd, J = 
13.6, 8.8, 3.9 Hz, 2H), 2.06 – 1.96 (m, 2H), 1.77 (dtd, J = 13.1, 8.7, 4.2 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 150.3, 128.9, 126.3, 120.7, 57.3, 44.2, 29.9; ESI-HRMS: m/z calcd. for C11H15N6 
[M+H]+, 231.1358; found, 231.1367. 
3-(3-Azidopropyl)-3-cyclohexyl-1-phenyltriaz-1-ene (54). This compound was 
prepared according to the general procedure A using compound 46 (100 mg, 0.64 mmol) to 
afford the desired product 54 (110 mg, 60 %) as a yellow oil; Rf= 0.75 (20% EtOAc in hexanes); 
IR (film) (cm-1): 2094, 1594 (w);  1H NMR (600 MHz, CD2Cl2) δ 7.43 (dd, J = 8.5, 1.2 Hz, 2H), 
7.37 – 7.32 (m, 2H), 7.14 (t, J = 7.3 Hz, 1H), 3.77 – 3.72 (m, 2H), 3.66 (br s, 1H), 3.37 (t, J = 6.7 
Hz, 2H), 2.05-1.94 (m, 4H), 1.90 (d, J = 13.6 Hz, 2H), 1.76 – 1.61 (m, 3H), 1.42 (qt, J = 13.1, 
3.3 Hz, 2H), 1.24 (qt, J = 13.0, 3.7 Hz, 1H); 13C NMR (151 MHz, CD2Cl2) δ 151.2, 128.7, 125.0, 
120.4, 64.4, 49.6, 43.6, 32.4, 26.6, 25.8, 25.5; ESI-HRMS: m/z calcd. for C15H23N6 [M+H]
+, 
287.1984; found, 287.1979. 
3-(2-Azidoethyl)-1,3-diphenyltriaz-1-ene (55). This compound was prepared according 
to the general procedure A using compound 47 (100 mg, 0.74 mmol) to afford the desired 
product 55 (81 mg, 41 %) as a red oil; Rf= 0.7 (20% EtOAc in hexanes); IR (film) (cm-1): 2098, 
1601;  1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.2 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.47-
7.37 (m, 4H), 7.28 (t, J = 7.3 Hz, 1H), 7.17 (t, J = 7.3 Hz, 1H), 4.46 (t, J = 6.4 Hz, 2H), 3.69 (t, J 
= 6.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 149.8, 144.6, 129.3, 129.0, 127.2, 123.9, 121.5, 
117.4, 47.4, 44.7; ESI-HRMS: m/z calcd. for C14H15N6 [M+H]
+, 267.1358; found, 267.1350. 
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4-Fluorenylmethyloxycarbonylamino-1-(phenyldiazenyl)piperidine (56). An ice 
cooled solution of 45 (100 mg, 1 mmol) in a water/methanol mixture (3:7, 4 mL) was treated 
with Na2CO3 (5 mmol), and then dropwise over 0.5 h with a solution of phenyldiazonium 
tetrafluoroborate (1.1 mmol) in water (4 mL). After completion of the addition, Fmoc-Cl (1.1 
mmol) was added. The reaction mixture was allowed to warm to rt and stirred 7 h before it was 
diluted with brine and extracted with DCM thrice. The organic layer was dried and concentrated. 
The residue was purified by column chromatography (15% EtOAc in hexanes) over silica gel to 
give the desired product 56 (329 mg, 77 %) as a yellow solid. Rf= 0.25 (20% EtOAc in hexanes); 
IR (film) (cm-1): 1687, 1538; 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 
7.4 Hz, 2H), 7.47 – 7.30 (m, 8H), 7.19 (t, J = 7.3 Hz, 1H), 4.71 (br d, J = 6.1 Hz, 1H), 4.45 (d, J 
= 6.0 Hz, 4H), 4.22 (t, J = 6.3 Hz, 1H), 3.90 – 3.75 (br s, 1H), 3.32 – 3.14 (m, 2H), 2.16 – 2.04 
(m, 2H), 1.59 – 1.34 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 155.5, 150.3, 143.9, 141.4, 128.9, 
127.7, 127.1, 126.2, 124.9, 120.7, 120.0, 66.5, 48.3, 47.3, 45.7, 31.5; ESI-HRMS: m/z calcd. for 
C26H26N4NaO2 [M+H]
+, 449.1953; found, 449.1939.  
Benzyl N-(4-(1-(3-(benzyloxycarbonylamino)propyl)-3-phenyltriaz-2-en-1-yl)butyl) 
carbamate (57). This compound was prepared according to the general procedure C using 
compound 43 (50 mg, 0.2 mmol) to afford the desired product 57 (55 mg, 54 %) as a yellow oil; 
Rf= 0.5 (60% EtOAc in hexanes); IR (film) (cm-1): 1700, 1591 (w);  1H NMR (600 MHz, 
CD2Cl2) δ 7.42 (d, J = 7.6 Hz, 2H), 7.33 (m, 12H), 7.14 (t, J = 7.3 Hz, 1H), 5.09 (m, 4H), 3.76 (t, 
J = 6.5 Hz, 2H), 3.74 – 3.68 (m, 2H), 3.25 – 3.20 (m, 2H), 3.19 (br s, 2H), 1.84 (br s, 2H), 1.72 
(br s, 2H), 1.59 – 1.47 (m, 2H); 13C NMR (101 MHz, CD2Cl2) δ 156.3, 150.7, 137.1, 137.0, 
128.8, 127.92, 127.88, 127.85, 127.8, 125.3, 120.3, 66.3, 40.5, 38.4, 27.9, 27.2, 24.7; ESI-
HRMS: m/z calcd. for C29H36N5O4 [M+H]
+, 518.2767; found, 518.2770. 
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Benzyl (4-azidobutyl)(3-azidopropyl)carbamate (58). A solution of 43 (100 mg, 0.39 
mmol) in a water/methanol mixture (1:1, 4 mL) was treated with Na2CO3 (3.9 mmol), imidazole-
1-sulfonyl azide hydrochloride (3 equiv) and a catalytic amount of CuSO4. The mixture was 
stirred for 3 h, after which 5 equiv of benzyl chloroformate was added. The reaction mixture was 
stirred for another hour before it was diluted with brine and extracted with DCM thrice. The 
organic layer was dried using Na2SO4 and concentrated. The residue was purified by column 
chromatography to give the desired product 58 (77 mg, 59 %) as a colorless oil; Rf= 0.4 (25% 
EtOAc in hexanes); 1H NMR (600 MHz, CD3OD) δ 7.43 – 7.20 (m, 5H), 5.11 (s, 2H), 3.40 – 
3.17 (m, 11H), 1.87 – 1.71 (m, 2H), 1.66 – 1.57 (m, 2H), 1.57 – 1.45 (m, 2H); 13C NMR (151 
MHz, CD3OD) δ 156.5, 136.3, 128.1, 127.7, 127.6, 66.9, 50.7, 48.63, 48.59, 46.7, 46.4, 44.7, 
44.2, 27.6, 27.0, 25.7, 25.4, 24.8. (151 MHz, CD3OD); ESI-HRMS: m/z calcd. for 
C15H21N7NaO2 [M+Na]
+, 354.1654; found, 154.1666. 
1,3,2’,6’-Tetra-deamino-1,3,2',6'-tetraazido-3''-N-(phenylazo)sisomicin (59). This 
compound was prepared according to the general procedure A using compound 8 (100 mg, 0.14 
mmol) to afford the desired product 59 (83 mg, 88 %) as a yellow solid; Rf= 0.4 (5% MeOH in 
CH2Cl2); [α]D25= +143.4 (c 0.037, MeOH); IR (film) (cm-1):3442, 2102, 1594 (w);   1H NMR 
(400 MHz, CD3OD) δ 7.40 (d, J = 7.4 Hz, 2H), 7.29 (t, J = 7.9 Hz, 2H), 7.11 (t, J = 7.3 Hz, 1H), 
5.89 (d, J = 2.3 Hz, 1H), 5.48 (d, J = 4.2 Hz, 1H), 4.98 (dd, J = 5.2, 2.2 Hz, 1H), 4.40 (dd, J = 
11.4, 3.8 Hz, 1H), 4.30 (d, J = 12.1, 1H), 4.29 (d, J = 11.2, 1H) 3.83 – 3.60 (m, 6H), 3.43 (m, 
3H), 3.34 (s, 3H), 2.45 (dd, J = 15.5, 11.5 Hz, 1H), 2.28 (m, 2H), 1.42 (q, J = 12.6 Hz, 1H), 1.11 
(s, 3H); 13C NMR (101 MHz, CD3OD) δ 151.1, 145.7, 128.4, 125.0, 120.3, 98.9, 98.0, 97.0, 
80.1, 79.7, 74.6, 73.2, 68.8, 68.5, 65.3, 60.7, 60.2, 55.1, 54.6, 51.9, 32.6, 21.1, 20.8; ESI-HRMS: 
m/z calcd. for C25H34N15O7 [M+H]
+, 656.2766; found, 656.2747. 
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1,3,2',6'-Tetra-N-(benzyloxycarbonyl)-3''-N-(phenylazo)sisomicin (60). This 
compound was prepared according to the general procedure C using compound 8 (100 mg, 0.14 
mmol) to afford the desired product 60 (125 mg, 79 %) as a yellow solid; Rf= 0.33 (5% MeOH 
in CH2Cl2); [α]D25= +9.8 (c 5.7, CH2Cl2); IR (film) (cm-1): 3416, 1702, 1592 (w);  1H NMR (600 
MHz, CD2Cl2 + CD3OD) δ 7.42 – 7.22 (m, 24H), 7.16 (t, J = 7.0 Hz, 1H), 5.41 (br s, 1H), 5.18 – 
4.94 (m, 9H), 4.56 (br s, 1H), 4.37 – 4.30 (m, 1H), 3.99 – 3.88 (m, 2H), 3.86 – 3.79 (m, 1H), 
3.72 – 3.59 (m, 3H), 3.59 – 3.45 (m, 3H), 3.43 – 3.28 (m, 5H), 2.31 (br s, 1H), 2.11 (s, 1H), 2.00 
(br s, 1H), 1.30 (br s, 1H), 1.08 (br s, 3H); 13C NMR (151 MHz, CD2Cl2 + CD3OD) δ 156.8, 
156.2, 150.7, 146.2, 136.7, 136.5, 128.9, 128.5, 128.4, 128.3, 128.03, 127.95, 127.9, 127.7, 
125.7, 120.5, 100.8, 97.3, 96.3, 85.6, 79.7, 75.8, 73.1, 69.1, 68.9, 67.3, 66.7, 66.5, 50.3, 49.6, 
47.3, 42.5, 36.4, 33.8, 22.7, 22.2; ESI-HRMS: m/z calcd. for C57H65N7NaO15 [M+Na]
+ 
1110.4436; found, 1110.4463.  
1,3,2’,4’’-Tetra-deamino-1,3,2',4''-tetraazido-7'-N-(phenylazo) apramycin (61). This 
compound was prepared according to the general procedure B using compound 9 (free base, 100 
mg, 0.19 mmol) to afford the desired product 61 (83 mg, 60 %) as a buff solid; Rf= 0.5 (40% 
EtOAc in hexanes); [α]D25= +52.3 (c 0.7, MeOH); IR (film) (cm-1): 3410, 2105, 1595 (w);    1H 
NMR (600 MHz, CD3OD) δ 7.35 (d, J = 7.5 Hz, 2H), 7.30 (t, J = 7.7 Hz, 2H), 7.13 (d, J = 7.2 
Hz, 1H), 5.60 (d, J = 3.2 Hz, 1H), 5.53 (d, J = 8.4 Hz, 1H), 5.26 (d, J = 3.7 Hz, 1H), 4.35 (s, 1H), 
4.03 – 3.98 (m, 1H), 3.95 (dd, J = 10.8, 4.3 Hz, 1H), 3.92 (t, J = 6.3 Hz, 1H), 3.56 (t, J = 9.6 Hz, 
1H), 3.53 – 3.46 (m, 3H), 3.45 – 3.36 (m, 3H), 3.33 (s, 1H), 3.32 – 3.30 (m, 4H), 3.29 – 3.19 (m, 
4H), 3.19 – 3.10 (m, 2H), 2.28 – 2.19 (m, 2H), 2.08 (q, J = 11.3 Hz, 1H), 1.47 – 1.36 (m, 1H); 
13C NMR (151 MHz, CD3OD) δ 150.8, 128.4, 125.3, 120.6, 97.7, 95.3, 93.9, 79.4, 76.6, 76.5, 
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72.0, 71.4, 71.0, 70.1, 68.8, 67.8, 66.5, 61.2, 60.3, 60.1, 59.7, 56.4, 35.2, 31.8, 28.0; ESI-HRMS: 
m/z calcd. for C27H37N15NaO11 [M+Na]
+, 770.2695; found, 770.2660. 
1,3,2',4''-Tetra-N-(benzyloxycarbonyl)-7'-N-(phenylazo)apramycin (62).This 
compound was prepared according to the general procedure C using compound 9 (free base, 100 
mg, 0.19 mmol) to afford the desired product 62 (162 mg, 74 %) as a buff solid; Rf= 0.6 (10% 
MeOH in CH2Cl2); [α]D25= +19.8 (c 2.6, MeOH); IR (film) (cm-1): 3396, 1691, 1532 (w); 1H 
NMR (600 MHz, CD3OD) δ 7.35 – 7.16 (m, 24H), 7.04 (t, J = 7.3 Hz, 1H), 5.53 (d, J = 8.4 Hz, 
1H), 5.33 – 5.25 (m, 3H), 5.09 – 5.02 (m, 5H), 4.97 (d, J = 12.5 Hz, 1H), 4.87 (d, J = 12.9 Hz, 
1H), 4.39 (s, 1H), 3.97 (d, J = 7.7 Hz, 1H), 3.95 – 3.88 (m, 1H), 3.80 – 3.70 (m, 2H), 3.66 – 3.37 
(m, 9H), 3.35 – 3.30 (m, 1H), 3.27 – 3.13 (m, 4H), 2.09 – 1.96 (m, 2H), 1.82 - 1.71 (m, 1H), 1.50 
– 1.39 (m, 1H); 13C NMR (151 MHz, CD3OD) δ 157.7, 157.2, 156.9, 156.7, 150.6, 136.8, 128.5, 
128.1, 128.0, 127.6, 127.5, 127.4, 125.3, 120.5, 98.2, 95.5, 93.9, 81.4, 77.1, 75.1, 72.2, 72.0, 
70.4, 70.2, 69.3, 67.5, 66.5, 66.3, 66.2, 66.1, 60.8, 52.8, 51.4, 50.3, 49.9, 35.0, 34.0, 30.0; ESI-
HRMS: m/z calcd. for C59H69N7NaO19 [M+Na]
+, 1202.4546; found, 1202.4500. 
1,3,2’,4’’-Tetra-deamino-1,3,2',4''-tetraazidoapramycin (63). Compound 61 (10 mg, 
0.015 mmol)) was dissolved in a CH2Cl2/ethanol mixture (1:1, 0.3 mL) and cooled in an ice bath 
before trifluoroacteic acid (0.05 mL) was added. The reaction mixture was allowed to warm to rt 
and was stirred for 0.5 h. After completion the solution was concentrated, toluene (1 mL) was 
added and the solution concentrated again.  The crude product was purified using column 
chromatography (10% methanol/CH2Cl2) to afford 63 (8.5 mg, 98 %) as a buff solid with 
spectral data identical to the literature.181  
1,3,2',4''-Tetra-N-(benzyloxycarbonyl)apramycin (64). Compound 62 (40 mg, 0.034 
mmol)) was dissolved in a CH2Cl2/ethanol mixture (1:1, 0.5 mL) and cooled in an ice bath before 
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trifluoroacteic acid (0.1 mL) was added. The reaction mixture was allowed to warm to rt and was 
stirred for 0.5 h. After completion the solution was concentrated, toluene (1 mL) was added and 
the solution concentrated again.  The crude product was purified using column chromatography 
(10% methanol/CH2Cl2) to afford 64 (35 mg, 96 %) as a buff solid; Rf= 0.2 (10% MeOH in 
CH2Cl2);  [α]D25= +12.5 (c 0.002, MeOH);  13C NMR (101 MHz, CD3OD) δ 157.3, 156.9, 156.7, 
136.8, 128.3, 128.1, 128.1, 127.7, 127.6, 127.6, 127.5, 127.4, 127.3, 97.6, 94.3, 92.1, 80.4, 77.2, 
75.1, 71.7, 69.6, 69.1, 66.8, 66.4, 66.3, 66.1, 63.0, 61.5, 60.7, 53.7, 51.5, 50.2, 49.7, 33.9, 29.7, 
29.5, 29.3; ESI-HRMS: m/z calcd. for C53H66N5O19 [M+H]
+, 1076.4352; found, 1076.4324.  1H-
NMR spectral data are not listed for this compound owing to complications owing to the 
presence of multiple rotamers arising from the presence of the four Cbz groups.  
3,2',6'-Triazido netilmicin (65). K2CO3 (8.06 g, 58.3 mmol) was added slowly to a 
stirred solution of netilmicin sulfate (5.00 g, 6.94 mmol) in 1:1 dioxane:water (150 mL). A 
catalytic amount of copper sulfate (110.7 mg, 0.69 mmol) was added before the solution was ice 
cooled. Stick’s reagent (5.27 g, 25.0 mmol) was added and the reaction mixture was stirred for 4 
h at rt. After completion, the reaction mixture was concentrated in vacuo and purified by gradient 
chromatography over silica gel (eluent: 5% to 12% ammonical MeOH in DCM) to give 65 (2.2 
g, 57%) as a white solid; [α]D25= +94.1 (c 2.8, DCM); 1H NMR (600 MHz, CDCl3): δ 5.89 (s, 
1H, H-1’), 4.93 (d, J = 5.1 Hz, 1H, H-4’), 4.85 (d, J = 3.3 Hz, 1H, H-1’’), 3.78 – 3.68 (m, 3H, H-
4, H-6’, H-5’’), 3.63 (m, 2H, H-5, H-6’), 3.58 – 3.52 (m, 2H, H-2’’, H-5’’), 3.37 (ddd, J = 11.0, 
6.1, 2.0 Hz, 1H, H-2’), 3.33 – 3.26 (m, 1H, H-3), 3.05 (t, J = 9.5 Hz, 1H, H-6), 2.86 – 2.78 (m, 
1H, NCH2), 2.62 – 2.49 (m, 5H, H-1, NCH2, NCH3), 2.48 – 2.42 (m, 1H, H-3’), 2.41 (d, J = 10.2 
Hz, 1H, H-3’’), 2.33 (m, 1H, H-2), 2.27 (dt, J = 16.2, 5.8 Hz, 1H, H-3’), 1.13 (s, 3H, 4’’CH3), 
1.12 – 1.06 (m, 3H, NCH2CH3, H-2); 13C NMR (151 MHz, CDCl3): δ 145.4 (C-5’), 102.7 (C-
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1’’), 98.3 (C-4’), 96.4 (C-1’), 88.3 (C-6), 79.4 (C-4), 76.6 (C-5), 71.1 (C-4’’), 69.7 (C-2’’), 67.4 
(C-5’’), 65.7 (C-3’’), 60.6 (C-3), 56.0 (C-1), 54.6 (C-2’), 52.3 (C-6’), 41.5 (NCH2), 39.0 (NCH3), 
33.3 (2), 24.3 (4’’CH3), 21.1 (C-3’), 15.0 (NCH2CH3); ESI-HRMS: m/z calcd. for C21H36N11O7 
[M+H]+ 554.2799; found, 554.2789. 
Triazido-1,3''-bis(phenyltriaz-2-en-1-yl) netilmicin (66). A stirred solution of 65 (2.26 
g, 4.07 mmol) in 2:1 acetonitrile:water (50 mL) was treated with K2CO3 (5.61 g, 40.7 mmol) and 
cooled to 0 °C. Benzenediazonium tetrafluoroborate (2.34 g, 12.2 mmol) was added slowly and 
the reaction mixture was stirred for 2 h. The reaction mixture was diluted with EtOAc and 
washed with aqueous NaHCO3 and brine, then dried with sodium sulfate, filtered and 
concentrated. The crude product was purified by gradient chromatography over silica gel (eluent: 
20% to 40% EtOAc/hexanes) to yield 66 (2.5 g, 82%) as a buff solid; [α]D25= +33.0 (c 0.3, 
DCM); 1H NMR (600 MHz, CD2Cl2): δ 7.42 – 7.37 (m, 2H, ArH), 7.35 – 7.28 (m, 6H, ArH), 
7.19 – 7.12 (m, 2H, ArH), 5.93 (d, J = 2.4 Hz, 1H, H-1’), 5.32 (t, J = 1.1 Hz, 1H, OH), 5.08 (d, J 
= 3.9 Hz, 1H, H-1’’), 4.99 (dd, J = 5.5, 2.3 Hz, 1H, H-4’), 4.66 (s, 1H, OH), 4.26 (td, J = 10.9, 
3.8 Hz, 1H, H-2’’), 4.00 – 3.93 (m, 2H, H-6, H-5’’), 3.93 – 3.86 (m, 2H, H-5, NCH2), 3.82 (t, J = 
9.4 Hz, 1H, H-4), 3.78 (d, J = 14.0 Hz, 1H, H-6), 3.71 (d, J = 14.0 Hz, 1H, H-6), 3.66 – 3.55 (m, 
3H, H-3’’, H-5’’, NCH2), 3.52 (ddd, J = 12.5, 9.7, 4.5 Hz, 1H, H-3), 3.46 (ddd, J = 11.1, 6.2, 2.4 
Hz, 1H, H-2’), 3.09 (s, 3H, NCH3), 2.58 – 2.45 (m, 1H, H-3’), 2.37 – 2.26 (m, 2H, H-2, H-3’), 
1.82 (q, J = 13.0 Hz, 1H, H-2), 1.68 (d, J = 11.0 Hz, 1H, OH), 1.26 (t, J = 7.2 Hz, 3H, 
NCH2CH3), 1.14 (s, 3H, 4’’CH3); 13C NMR (151 MHz, CD2Cl2): δ 150.6 (ArC), 150.3 (ArC), 
145.5 (ArC), 128.8 (ArC), 126.1(ArC), 125.8 (ArC), 120.6 (ArC), 120.5 (ArC), 101.0 (C-1’’), 
98.3 (C-4’), 96.9 (C-1’), 84.5 (C-6), 79.9 (C-4), 76.5 (C-5), 73.3 (C-4’’), 69.2 (C-5’’, C-3’’), 
67.7 (C-2’’), 60.5 (C-3), 54.9 (C-2’), 52.4 (C-6’), 42.4 (NCH2), 37.0 (NCH3), 32.8 (C-2), 22.5 
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(4’’CH3), 21.3 (C-3’), 12.5 (NCH2CH3); ESI-HRMS: m/z calcd. for C33H43N15NaO7 [M+Na]+ 
784.3368; found:784.3348. 
5,2'''-Di-O-acetyl-3,2',6'-triazido-1,3''-bis(phenyltriaz-2-en-1-yl) netilmicin (67). 4-
Dimethylaminopyridine (7.95 g, 65.1 mmol) and 66 (2.48 g, 3.2 mmol) were dissolved in dry 
DCM and the resulting solution was stirred and ice cooled before acetic anhydride (1.2 mL, 13.0 
mmol) was added dropwise. The reaction mixture was stirred overnight at rt under argon, then it 
was diluted with DCM and the organic layer was washed with aqueous NaHCO3 followed by 
brine, dried with Na2SO4, and concentrated in vacuo. The crude product was purified via silica 
gel chromatography eluting with 15% to 40 % EtOAc in hexanes to give 67 (2.10 g, 75%) as a 
white foam; [α]D25= -19.7 (c 1.0, DCM); 1H NMR (600 MHz, CD2Cl2): δ 7.39 – 7.28 (m, 8H, 
ArH), 7.19 – 7.13 (m, 2H, ArH), 5.43 (d, J = 10.4 Hz, 1H, H-2’’), 5.34 (t, J = 9.7 Hz, 1H, H-5), 
5.32 (s, 1H, H-1’), 5.08 (d, J = 2.8 Hz, 1H, H-1’’), 5.03 (dd, J = 5.5, 1.8 Hz, 1H, H-4’), 4.10 (s, 
3H, H-6, H-3’’, NCH2), 3.88 – 3.80 (m, 2H, H-1, H-5’’), 3.79 (d, J = 14.0 Hz, 2H, H-6’, H-1), 
3.73 (d, J = 14.0 Hz, 1H, H-6’), 3.68 – 3.60 (m, 1H, NCH2), 3.60 – 3.53 (m, 1H, H-3), 3.42 (ddd, 
J = 11.3, 6.1, 2.4 Hz, 1H, H-2’), 3.35 (d, J = 12.3 Hz, 1H, H-5’’), 3.15 (s, 3H, NCH3), 2.54 – 
2.46 (m, 1H, H-3’), 2.33 (dt, J = 15.4, 5.5 Hz, 1H, H-3’), 2.31 – 2.25 (m, 1H, H-2), 2.20 (s, 3H, 
COCH3), 2.08 – 1.95 (m, 1H, H-2), 1.69 (s, 3H, COCH3), 1.27 (s, 3H, NCH2CH3), 1.14 (s, 3H, 
4’’CH3); 13C NMR (151 MHz, CD2Cl2): δ 170.1 (C=O), 169.8 (C=O), 150.5 (ArC), 150.4 (ArC), 
145.3 (C-5’), 128.8 (ArC), 128.8 (ArC), 125.9 (ArC), 125.8 (ArC), 120.6 (ArC), 120.5 (ArC), 
98.6 (C-1’’), 98.3 (C-4’), 97.1 (C-1’), 81.4 (C-6), 77.8 (C-4), 74.9 (C-5), 73.6 (C-4’’), 68.9 (C-
2’’, C-5’’), 65.9 (C-3’’), 61.6 (C-1), 60.7 (C-3), 54.4 (C-2’), 52.2 (C-6’), 43.9 (NCH2), 38.2 
(NCH3), 34.2 (C-2), 22.4 (4’’CH3), 21.5 (COCH3), 20.6 (COCH3), 20.1 (C-3’); ESI-HRMS: m/z 
calcd. for C37H48N15O9 [M+H]
+ 846.3759; found, 846.3747. 
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5,2'''-Di-O-acetyl-3,2',6'-triazido-4'-iodo-1,3''-bis(phenyltriaz-2-en-1-yl) netilmicin 
(68). To a stirred solution of compound 67 (100 mg, 0.11 mmol) in dry acetonitrile (1 mL), N-
iodosuccinimide (37 mg, 0.16 mmol) and silver nitrate (500 mg, 0.59 mmol) were added.  The 
reaction mixture was stirred at 80 °C for 2.5 h then cooled to rt and filtered through Celite®. The 
filtrate was diluted with EtOAc and washed with saturated aqueous Na2S2O3 and brine, dried and 
concentrated. The residue was purified by silica gel column chromatography eluting with 12% 
acetone/hexanes to give 68 (52 mg, 45%) as white solid; [α]D25= +33.5 (c 0.4, DCM); 1H NMR 
(600 MHz, CD2Cl2): δ 7.38 – 7.28 (m, 8H, ArH), 7.20 – 7.12 (m, 2H, ArH), 5.48 – 5.39 (m, 2H, 
H-1’, H-2’’), 5.35 (t, J = 9.6 Hz, 1H, H-5), 5.12 – 5.05 (s, 1H, H-1’’), 4.24 (d, J = 13.8 Hz, 1H, 
H-6’), 4.17 – 4.06 (m, 2H, H-6, NCH2), 4.04 (d, J = 13.8 Hz, 1H, H-6’), 3.90 – 3.74 (m, 3H, H-4, 
H-3’’, H-5’’), 3.69 – 3.58 (m, 2H, H-3, NCH2), 3.55 (ddd, J = 11.1, 6.2, 2.5 Hz, 1H, H-2’), 3.35 
(d, J = 12.3 Hz, 1H, H-5’’), 3.15 (s, 3H, NCH3), 2.95 (dd, J = 16.1, 11.5 Hz, 1H, H-3’), 2.80 (dd, 
J = 16.3, 6.2 Hz, 1H, H-3’), 2.33 – 2.25 (m, 1H, H-2), 2.19 (s, 3H, COCH3), 2.09 – 2.00 (m, 1H, 
H-2), 1.69 (s, 3H, COCH3), 1.27 (s, 3H, NCH2CH3), 1.14 (s, 3H, 4’’CH3); 13C NMR (151 MHz, 
CD2Cl2): δ 170.0 (C=O), 169.8 (C=O), 150.5 (ArC), 150.4 (ArC), 145.3 (C-5’), 128.8 (ArC), 
128.8 (ArC), 125.9 (ArC), 125.8 (ArC), 120.6 (ArC), 120.5 (ArC), 98.6 (C-1’’), 97.1 (C-1’), 
81.4 (C-6), 78.3 (C-4), 74.8 (C-5), 73.6 (C-4’’), 68.9 (C-2’’, 5’’), 66.1 (C-4’), 65.9 (C-3’’), 61.5 
(C-1), 60.7 (C-3), 55.0 (C-2’), 54.5 (C-6’), 43.9 (NCH2), 34.0 (C-3’), 22.4 (4’’CH3), 21.4 
(COCH3), 20.6 (COCH3), 11.9 (NCH2CH3); ESI-HRMS: m/z calcd. for C37H47IN15O9 [M+H]
+ 
972.2726; found, 972.2701. 
5,2'''-Di-O-acetyl-3,2',6'-triazido-4'-bromo-1,3''-bis(phenyltriaz-2-en-1-yl) 
netilmicin (69). In a round bottom flask, protected netilmicin 67 (500 mg, 0.59 mmol), K2CO3 
(408 mg, 2.95 mmol), tetrabutylammonium nitrate (5 mol%) and BHT (5 mol%) were dissolved 
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with stirring in dry acetonitrile (5 mL) and the flask was wrapped with aluminum foil before N-
bromosuccinimide (126 mg, 0.71 mmol) was added. The reaction mixture was stirred for 1.5 h 
for completion, then was diluted with EtOAc and washed with saturated aqueous Na2S2O3 and 
brine, dried and concentrated. The resulting crude product was purified using silica gel 
chromatography (eluent: 25% to 50% EtOAc/hexanes) to yield 69 (270 mg, 50%) as an orange 
solid; [α]D25= +14.03 (c 0.5, DCM); 1H NMR (499 MHz, CD2Cl2): δ 7.36 (p, J = 10.7, 9.4 Hz, 
8H, ArH), 7.21 – 7.15 (m, 2H, ArH), 5.46 (dd, J = 11.0, 3.0 Hz, 1H, H-2’’), 5.41 (d, J = 2.5 Hz, 
1H, H-1’), 5.38 (t, J = 11.9 Hz, 1H, H-5), 5.10 (d, J = 3.1 Hz, 1H, H-1’’), 4.24 (d, J = 13.8 Hz, 
1H, H-6’), 4.19 – 4.03 (m, 2H, H-6, NCH2), 4.01 – 3.93 (m, 2H, H-6’, H-3’’), 3.85 (t, J = 9.9 Hz, 
1H, H-4), 3.89 – 3.83 (m, 1H, H-1), 3.81 (d, J = 13.6 Hz, 1H, H-5’’), 3.71 – 3.62 (m, 2H, H-3, 
NCH2), 3.59 (ddd, J = 11.2, 6.3, 2.6 Hz, 1H, H-2’), 3.37 (d, J = 12.4 Hz, 1H, H-5’’), 3.17 (s, 3H, 
NCH3), 2.95 (dd, J = 16.6, 11.1 Hz, 1H, H-3’), 2.75 (dd, J = 16.2, 6.4 Hz, 1H, H-3’), 2.36 – 2.26 
(m, 1H, H-2), 2.22 (s, 3H, COCH3), 2.11 – 2.01 (m, 1H, H-2), 1.72 (s, 3H, COCH3), 1.29 (t, J = 
5.7 Hz, 3H, NCH2CH3), 1.16 (s, 3H, 4’’CH3); 13C NMR (126 MHz, CD2Cl2): δ 170.1 (C=O), 
169.8 (C=O), 150.5 (ArC), 143.3 (C-5’), 128.9 (ArC), 128.8 (ArC), 126.0 (ArC), 125.8 (ArC), 
120.6 (ArC), 120.5 (ArC), 98.7 (C-1’’), 97.0 (C-4’), 96.2 (C-1’), 81.5 (C-6), 78.5 (C-4), 74.8 (C-
5), 73.6 (C-4’’), 68.9 (C-2’’), 66.0 (C-3’’), 61.6 (C-1), 60.6 (C-3), 54.7 (C-2’), 50.9 (C-6’), 41.9 
(NCH2), 33.9 (C-2), 30.4 (C-3’), 22.4 (4’’CH3), 21.5 (COCH3), 20.6 (COCH3); ESI-HRMS: m/z 
calcd. for C37H47BrN15O9[M+H]
+ 924.2865; found, 924.2836. 
5,2'''-Di-O-acetyl-3,2',6'-triazido-4'-chloro-1,3''-bis(phenyltriaz-2-en-1-yl) netilmicin 
(70). A mixture of K2CO3 (123 mg, 0.89 mmol) and compound 67 (150 mg, 0.18 mmol) in dry 
acetonitrile (2 mL) was dried over 3Å molecular sieves for 1 h, then  cooled to 0 °C and the flask 
wrapped with aluminium foil before iodobenzene dichloride122 (58.5 mg, 0.21 mmol) was added. 
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The reaction mixture was stirred for 45 min for complete consumption of the starting material, 
then was diluted with EtOAc and washed with saturated aqueous Na2S2O3 and brine, dried and 
concentrated. The crude product was purified by gradient chromatography over silica gel (eluent: 
15% to 30% EtOAc/hexanes) to yield 70 (45 mg, 30%) as a foam; [α]D25= +17.25 (c 0.1, DCM); 
1H NMR (600 MHz, CD2Cl2): δ 7.41 – 7.27 (m, 8H, ArH), 7.19 – 7.13 (m, 2H, ArH), 5.43 (d, J 
= 11.7 Hz, 1H, H-2’’) 5.39 – 5.31 (m, 2H, H-1’, H-5), 5.08 (d, J = 2.9 Hz, 1H, H-1’’), 4.19 (d, J 
= 13.9 Hz, 1H, H-6’), 4.16 – 3.97 (m, 2H, H-6, NCH2), 3.92 (d, J = 13.9 Hz, 1H, H-6’), 3.89 – 
3.75 (m, 3H, H-4, H-3’’, H-5’’), 3.64 – 3.59 (m, 2H, H-3, NCH2), 3.56 (ddd, J = 11.3, 6.3, 2.5 
Hz, 1H, H-2’), 3.34 (d, J = 12.4 Hz, 1H, H-5’’), 3.15 (s, 3H, NCH3), 2.84 (dd, J = 16.0, 11.4 Hz, 
1H, H-3’), 2.61 (dd, J = 16.1, 6.3 Hz, 1H, H-3’), 2.33 – 2.24 (m, 1H, H-2), 2.19 (s, 3H, COCH3), 
2.08 – 1.99 (m, 1H, H-2), 1.69 (s, 3H, COCH3), 1.31 – 1.23 (m, 3H, NCH2CH3), 1.14 (s, 3H, 
4’’CH3); 13C NMR (151 MHz, CD2Cl2): δ 170.1 (C=O), 169.8 (C=O), 150.5 (ArC), 150.4 (ArC), 
142.3 (C-5’), 128.8 (ArC), 128.8 (ArC), 126.0 (ArC), 125.8 (ArC), 120.5 (ArC), 120.5 (ArC), 
107.9 (C-4’), 98.7 (C-1’’), 96.9 (C-1’), 81.6 (C-6), 78.5 (C-4), 74.8 (C-5), 73.6 (C-4’’), 69.3 (C-
2’’), 68.9 (C-5’’), 65.9 (C-3’’), 61.5 (C-1), 60.6 (C-3), 54.3 (C-2’), 48.8 (C-6’), 44.0 (NCH2), 
34.0 (C-2), 28.5 (C-3’), 22.4 (4’’CH3), 21.5 (COCH3), 20.6 (COCH3), 11.8 (NCH2CH3); ESI-
HRMS: m/z calcd. for C37H46ClN15NaO9 [M+Na]
+ 902.3189; found, 902.3177.  
4'-Iodonetilmicin pentaacetate salt (72). Substrate 68 (30 mg, 0.03 mmol) was 
deprotected using the general procedure D to yield 72 (13 mg, 57%) as a white solid; [α]D25= 
+87.3 (c 0.3, H2O);
 1H NMR (600 MHz, D2O): δ 5.63 (s, 1H, H-1’), 4.91 (s, 1H, H-1’’), 4.09 (d, 
J = 10.8 Hz, 1H, H-2’’), 3.95 (d, J = 14.6 Hz, 1H, H-6’), 3.81 (d, J = 13.4 Hz, 1H, H-5’’), 3.79 – 
3.68 (m, 3H, H-4, H-2’, H-6’), 3.64 – 3.55 (m, 2H, H-5, H-6), 3.37 – 3.28 (m, 3H, H-1, H-3’’, H-
5’’), 3.23 (t, J = 10.0 Hz, 1H, H-3), 3.12 (dq, J = 13.1, 7.2 Hz, 1H, NCH2), 2.97 (dd, J = 18.3, 5.3 
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Hz, 1H, H-3’), 2.92 (dt, J = 13.4, 7.3 Hz, 1H, NCH2), 2.76 (s, 3H, NCH3), 2.67 (dd, J = 18.2, 4.1 
Hz, 1H, H-3’), 2.44 – 2.35 (m, 1H, H-2), 1.66 (q, J = 13.0 Hz, 1H, H-2), 1.18 (s, 3H, 4’’CH3), 
1.14 (t, J = 6.6 Hz, 3H, NCH2CH3);
 13C NMR (151 MHz, D2O): δ 180.9 (C=O), 142.6 (C-5’), 
101.6 (C-1’’), 96.7 (C-1’), 83.2 (C-6), 79.6 (C-4), 73.6 (C-5), 69.8 (C-4’’), 68.3 (C-4’), 67.6 (C-
5’’), 66.4 (C-2’’), 63.6 (C-3’’), 56.1 (C-1), 48.0 (C-3), 47.9 (C-2’), 43.1  (NCH2), 40.8 (C-6’), 
36.2 (C-3’), 34.6 (NCH3), 26.2 (C-2), 23.0 (COCH3), 20.7 (4’’CH3), 10.9 (NCH2CH3); ESI-
HRMS: m/z calcd. for C21H41IN5O7 [M+H]
+ 602.2051; found, 602.2043. 
4'-Bromonetilmicin pentaacetate salt (73). Substrate 69 (40 mg, 0.04 mmol) was 
deprotected using the general procedure D to yield 73 (16.2 mg, 58%) as a white solid; [α]D25= 
+50.0 (c 1.1, H2O);
 1H NMR (600 MHz, D2O): δ 5.56 (s, 1H, H-1’), 4.89 (s, 1H, H-1’’), 4.07 (dt, 
J = 10.8, 3.0 Hz, 1H, H-2’’), 3.91 (d, J = 14.5 Hz, 1H, H-6’), 3.82 (d, J = 12.9 Hz, 1H, H-5’’), 
3.70 – 3.64 (m, 2H, H-6’, H-2’), 3.64 – 3.59 (m, 1H, H-4), 3.59 – 3.51 (m, 2H, H-5, H-6), 3.36 – 
3.23 (m, 3H, H-1, H-3’’, H-5’’), 3.12 – 3.01 (m, 2H, H-3, NCH2), 2.92 – 2.81 (m, 2H, H-3’, 
NCH2), 2.75 (s, 3H, NCH3), 2.63 – 2.54 (m, 1H, H-3’), 2.33 – 2.25 (m, 1H, H-2), 1.49 (q, J = 
12.7, 12.3 Hz, 1H, H-2), 1.17 (s, 3H, 4’’CH3), 1.11 (t, J = 7.2 Hz, 3H, NCH2CH3); 13C NMR 
(151 MHz, D2O): δ 181.2 (C=O), 140.3 (C-5’), 101.5 (C-1’’), 98.1 (C-4’), 96.8 (C-1’), 83.8 (C-
6), 80.8 (C-4), 73.9 (C-5), 69.8 (C-4’’), 67.6 (C-5’’), 66.5 (C-2’’), 63.6 (C-3’’), 56.4 (C-1), 48.1 
(C-3), 47.3 (C-2’), 40.7 (NCH2), 39.5 (C-6’), 34.6 (NCH3), 32.6 (C-3’), 27.4 (C-2), 23.1 
(COCH3), 20.8 (4’’CH3), 11.1 (NCH2CH3); ESI-HRMS: m/z calcd. for C21H41BrN5O7 [M+H]+ 
554.2189; found, 554.2200. 
4'-Chloronetilmicin pentaacetate salt (74). Substrate 70 (37 mg, 0.04 mmol) was 
deprotected using the general procedure D to yield 74 (19.6 mg, 59%) as a white solid; [α]D25= 
+41.8 (c 1.2, H2O);
 1H NMR (600 MHz, D2O): δ 5.56 (s, 1H, H-1’), 4.91 (d, J = 3.7 Hz, 1H, H-
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1’’), 4.09 (dd, J = 10.8, 3.7 Hz, 1H, H-2’’), 3.93 (d, J = 14.5 Hz, 1H, H-6’), 3.82 (d, J = 12.9 Hz, 
1H, H-5’’), 3.79 (t, J = 5.9 Hz, 1H, H-2’), 3.77 – 3.73 (m, 1H, H-4), 3.65 (d, J = 14.5 Hz, 1H, H-
6’), 3.63 – 3.55 (m, 2H, H-5, H-6), 3.36 –3.28 (m, 3H, H-1, H-3’’, H-5’’), 3.20 (td, J = 11.4, 
10.7, 3.9 Hz, 1H, H-3), 3.11 (dq, J = 14.2, 7.1 Hz, 1H, NCH2), 2.91 (dq, J = 14.4, 7.2 Hz, 1H, 
NCH2), 2.84 (dd, J = 18.1, 6.1 Hz, 1H, H-3’), 2.76 (s, 3H, NCH3), 2.52 (dd, J = 18.0, 4.8 Hz, 1H, 
H-3’), 2.38 (dt, J = 12.4, 4.1 Hz, 1H, H-2), 1.63 (q, J = 12.5 Hz, 1H, H-2), 1.18 (s, 3H, 4’’CH3), 
1.13 (t, J = 7.2 Hz, 3H, NCH2CH3);
 13C NMR (151 MHz, D2O): δ 181.1 (C=O), 139.7 (C-5’), 
110.0 (C-4’), 101.5 (C-1’’), 96.8 (C-1’), 83.3 (C-6), 80.0 (C-4), 73.6 (C-5), 69.8 (C-4’’), 67.6 (C-
5’’), 66.4 (C-2’’), 63.6 (C-3’’), 56.2 (C-1), 48.0 (C-3), 46.9 (C-2), 40.8 (NCH2), 37.4 (C-6’), 
34.6 (NCH3), 30.7 (C-3’), 26.4 (C-2), 23.0 (COCH3), 20.8 (4’’CH3), 10.9 (NCH2CH3); ESI-
HRMS: m/z calcd. for C21H41ClN5O7 [M+H]
+ 510.2695; found, 510.2687. 
5,2'''-Di-O-acetyl-3,2',6'-triazido-4'-phenyl-1,3''-bis(phenyltriaz-2-en-1-yl) 
netilmicin (75). A round bottom flask was charged with compound 69 (146 mg, 0.16 mmol), 
K2CO3 (66 mg, 0.47 mmol), phenylboronic acid (29 mg, 0.24 mmol) and Pd(dppf)Cl2 (10 mol%) 
then evacuated and and flushed with argon three times. Dry dioxane (3 mL), dried over 5 Å MS, 
was added and the reaction mixture was heated at 80 °C with stirring for 36 h. The reaction 
mixture was concentrated and purified by gradient chromatography over silica gel (eluent: 3% to 
5% IPA in hexanes) to give 75 in 23% yield; [α]D25= +54.6 (c 0.3, DCM); 1H NMR (500 MHz, 
CD2Cl2): δ 7.45 – 7.23 (m, 13H, ArH), 7.22 – 7.13 (m, 2H, ArH), 5.47 (dd, J = 11.7, 2.3 Hz, 1H, 
H-2’’), 5.44 (d, J = 2.5 Hz, 1H, H-1’), 5.40 (t, J = 9.3 Hz, 1H, H-5), 5.12 (d, J = 3.0 Hz, 1H, H-
1’’), 4.21 – 3.99 (m, 3H, H-6, H-3’’, NCH2), 3.96 (t, J = 9.9 Hz, 1H, H-4), 3.88 (d, J = 13.5 Hz, 
1H, H-6’), 3.84 (d, J = 12.1 Hz, 1H, H-5’’), 3.78 (d, J = 13.4 Hz, 1H, H-6’), 3.72 – 3.64 (m, 2H, 
H-3, NCH2), 3.63 (ddd, J = 11.4, 6.0, 2.6 Hz, 1H, H-2’), 3.38 (d, J = 12.4 Hz, 1H, H-5’’), 3.18 
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(s, 3H, NCH3), 2.90 (dd, J = 15.9, 11.7 Hz, 1H, H-3’), 2.60 (dd, J = 16.1, 6.0 Hz, 1H, H-3’), 2.40 
– 2.29 (m, 1H, H-2), 2.25 (s, 3H, COCH3), 2.18 – 2.08 (m, 1H, H-2), 1.73 (s, 3H, COCH3), 1.37 
– 1.25 (m, 3H, NCH2CH3), 1.17 (s, 3H, 4’’CH3); 13C NMR (126 MHz, CD2Cl2): δ 170.1 (C=O), 
169.9 (C=O), 150.5 (ArC), 142.4 (C-5’), 138.4 (ArC), 128.9 (ArC), 128.8 (ArC), 128.6 (ArC), 
128.4 (ArC), 127.4 (ArC), 126.0 (ArC), 125.8 (ArC), 120.6 (ArC), 113.0 (C-4’), 98.6 (C-1’’), 
96.9 (C-1’), 81.6 (C-6), 78.2 (C-4), 75.0 (C-5), 73.6 (C-4’’), 68.9 (C-5’’), 66.0 (C-3’’), 61.7 (C-
1), 60.6 (C-3), 54.6 (C-2’), 49.9 (C-6’), 33.9 (NCH2), 26.3 (C-3’), 22.4 (4’’CH3), 21.5 (COCH3), 
20.7 (COCH3), 11.9 (NCH2CH3);
 ESI-HRMS: m/z calcd. for C43H52N15O9 [M+H]
+ 922.4072; 
found, 922.4070. 
5,2'''-Di-O-acetyl-3,2',6'-triazido-4'-butyl-1,3''-bis(phenyltriaz-2-en-1-yl) netilmicin 
(76). A round bottom flask was charged with compound 69 (300 mg, 0.32 mmol), cesium 
carbonate (527 mg, 1.62 mmol), potassium butyltrifluoroborate (106 mg, 0.64 mmol) and 
Pd(dppf)Cl2 (10 mol%) then evacuated and flushed with argon three times. Degassed toluene (2 
mL) and degassed water (1 mL) were added and the reaction mixture was heated at 90 °C for 12 
h under argon. On completion, the reaction mixture was cooled and directly loaded in a silica gel 
column and eluted with 15% acetone in hexanes to give 76 in 8% yield as white solid; [α]D25= 
+23.14 (c 0.5, DCM); 1H NMR (600 MHz, CD2Cl2): δ 7.41 – 7.24 (m, 8H, ArH), 7.21 – 7.11 (m, 
2H, ArH), 5.43 (d, J = 11.6 Hz, 1H, H-2’’), 5.32 – 5.29 (m, 1H, H-5), 5.27 (d, J = 2.4 Hz, 1H, H-
1’), 5.07 (d, J = 2.8 Hz, 1H, H-1’’), 4.23 – 4.00 (m, 3H, H-6, H-3’’, NCH2), 3.96 (d, J = 13.7 Hz, 
1H, H-6’), 3.87 – 3.79 (m, 2H, H-4, H-5’’), 3.77 (d, J = 13.6 Hz, 1H, H-6’), 3.68 – 3.60 (m, 1H, 
NCH2), 3.60 – 3.54 (m, 1H, H-3), 3.40 (dq, J = 8.7, 2.8, 2.3 Hz, 1H, H-2’), 3.34 (d, J = 12.3 Hz, 
1H, H-5’’), 3.14 (s, 3H, NCH3), 2.45 (dd, J = 16.0, 11.8 Hz, 1H, H-3’), 2.27 (m, 2H, H-2, H-3’), 
2.19 (s, 3H, COCH3), 2.11 (m, 1H, CH2CH2CH2CH3), 2.07 – 1.99 (m, 1H, H-2), 1.95 (M, 1H, 
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CH2CH2CH2CH3), 1.69 (s, 3H, COCH3), 1.46 – 1.23 (m, 7H, CH2CH2CH2CH3, 
CH2CH2CH2CH3, NCH2CH3), 1.13 (s, 3H, 4’’CH3), 0.91 (t, J = 5.7 Hz, 3H, CH2CH2CH2CH3); 
13C NMR (151 MHz, CD2Cl2): δ 169.9 (C=O), 150.4 (ArC), 139.5 (C-5), 128.8 (ArC), 128.8 
(ArC), 125.9 (ArC), 125.8 (ArC), 120.5 (ArC), 111.3 (C-4’), 98.5 (C-1’’), 96.6 (C-1’), 81.53 (C-
6), 77.9 (C-4), 74.9 (C-5), 73.6 (C-4’’), 68.9 (C-5’’), 65.9 (C-3’’), 61.6 (C-1), 60.6 (C-3), 54.7 
(C-2’), 48.6 (C-6’), 43.9 (NCH2), 34.1 (C-2), 31.3 (CH2CH2CH2CH3), 30.9 (CH2CH2CH2CH3), 
23.9 (C-3’), 22.5 (CH2CH2CH2CH3), 22.4 (4’’CH3), 21.5 (COCH3), 20.6 (COCH3), 13.7 
(CH2CH2CH2CH3), 11.8 (NCH2CH3);
 ESI-HRMS: m/z calcd. for C41H56N15O9 [M+H]
+ 
902.4385; found, 902.4344.  
4'-Phenylnetilmicin pentaacetate salt (78). Substrate 75 (29 mg, 0.03 mmol) was 
deprotected using the general procedure D to yield 78 (14 mg, 54%) as a white solid; [α]D25= 
+64.09 (c 0.5, H2O);
 1H NMR (600 MHz, D2O): δ 7.36 – 7.26 (m, J = 26.9, 7.3 Hz, 3H, ArH), 
7.14 (d, J = 7.5 Hz, 2H, ArH), 5.66 (s, 1H, H-1’), 4.95 (d, J = 3.7 Hz, 1H, H-1’’), 4.12 (dd, J = 
10.7, 3.7 Hz, 1H, H-2’’), 3.92 – 3.83 (m, 2H, H-2’, H-5’’), 3.83 – 3.77 (m, 1H, H-4), 3.69 – 3.63 
(m, 2H, H-5, H-6), 3.61 (d, J = 14.4 Hz, 1H, H-6’), 3.53 (d, J = 14.3 Hz, 1H, H-6’), 3.41 – 3.32 
(m, 3H, H-1, H-3’’, H-5’’), 3.22 (td, J = 11.9, 4.2 Hz, 1H, H-3), 3.15 (dq, J = 14.5, 7.2 Hz, 1H, 
NCH2), 2.95 (dq, J = 14.7, 7.3 Hz, 1H, NCH2), 2.86 (dd, J = 18.2, 5.8 Hz, 1H, H-3’), 2.79 (s, 3H, 
NCH3), 2.55 (dd, J = 18.3, 5.2 Hz, 1H, H-3’), 2.41 (dt, J = 12.3, 4.0 Hz, 1H, H-2), 1.70 – 1.61 
(m, 1H, H-2), 1.21 (s, 3H, 4’’CH3), 1.17 (t, J = 7.2 Hz, 3H, NCH2CH3); 13C NMR (151 MHz, 
D2O): δ 180.9 (C=O), 139.1 (C-5’), 136.5 (ArC), 129.0 (ArC), 128.5 (ArC), 128.3 (ArC), 114.7 
(C-4’), 101.6 (C-1’’), 96.3 (C-1’), 83.5 (C-6), 80.1 (C-4), 73.9 (C-5), 69.9 (C-4’’), 67.7 (C-5’’), 
66.5 (C-2’’), 63.6 (C-3’’), 56.4 (C-1), 48.2 (C-3), 46.7 (C-2’), 40.8 (NCH2), 37.9 (C-6’), 34.6 
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(NCH3), 29.2 (C-3’), 26.8 (C-2), 23.0 (COCH3), 20.8 (4’’CH3), 11.0 (NCH2CH3); ESI-HRMS: 
m/z calcd. for C27H46N5O7 [M+H]
+ 552.3397; found, 552.3391. 
4'-Butylnetilmicin pentaacetate salt (79). Substrate 76 (27 mg, 0.03 mmol) was 
deprotected using the general procedure D to yield 79 (7 mg, 27%) as a white solid;; [α]D25= 
+38.02 (c 0.3, H2O);
 1H NMR (600 MHz, D2O): δ 5.32 (s, 1H, H-1’), 4.86 (d, J = 3.7 Hz, 1H, H-
1’’), 3.93 (dd, J = 10.7, 3.6 Hz, 1H, H-2’’), 3.86 (d, J = 12.8 Hz, 1H, H-5’’), 3.69 (d, J = 14.2 
Hz, 1H, H-6’’), 3.49 (t, J = 9.1 Hz, 1H, H-6), 3.44 (d, J = 14.4 Hz, 1H, H-6’’), 3.41 – 3.37 (m, 
1H, H-4), 3.35 (t, J = 9.6 Hz, 1H, H-5), 3.30 – 3.22 (m, 2H, H-5’’, H-2’), 3.01 (d, J = 10.9 Hz, 
1H, H-3’’), 2.98 – 2.90 (m, 1H, H-1), 2.89 – 2.80 (m, 1H, NCH2), 2.80 – 2.71 (m, 1H, H-3), 2.69 
– 2.57 (m, 4H, NCH3, NCH2), 2.19 (dd, J = 17.1, 5.9 Hz, 1H, H-3’), 2.11 (dt, J = 12.9, 3.9 Hz, 
1H, H-2), 2.06 (dd, J = 17.6, 9.3 Hz, 1H, H-3’), 1.96 (dt, J = 14.4, 7.4 Hz, 1H, 
CH2CH2CH2CH3), 1.91 – 1.85 (m, 1H, CH2CH2CH2CH3), 1.28 – 1.15 (m, 3H, CH2CH2CH2CH3, 
H-2), 1.14 (s, 3H, 4’’CH3), 1.10 (dq, J = 14.8, 7.6 Hz, 2H, CH2CH2CH2CH3), 1.03 (t, J = 7.1 Hz, 
3H, NCH2CH3), 0.71 (t, J = 7.3 Hz, 3H, CH2CH2CH2CH3);
 13C NMR (151 MHz, D2O): δ 181.4 
(C=O), 135.9 (C-5’), 113.4 (C-4’), 101.3 (C-1’’), 96.8 (C-1’), 84.9 (C-5), 81.4 (C-4), 74.4 (C-6), 
70.5 (C-4’’), 67.5 (C-5’’), 67.4 (C-2’’), 63.7 (C-3’’), 56.9 (C-1), 48.7 (C-3), 46.5 (C-2’), 40.5 
(NCH2), 37.0 (C-6’), 35.2 (NCH3), 30.0 (CH2CH2CH2CH3), 29.8 (CH2CH2CH2CH3), 29.7 (C-2), 
27.5 (C-3’), 23.1 (COCH3), 21.6 (CH2CH2CH2CH3), 20.9 (4’’CH3), 13.0 (CH2CH2CH2CH3), 
12.1 (NCH2CH3);
 ESI-HRMS: m/z calcd. for C25H50N5O7 [M+H]
+ 532.3710; found, 532.3694. 
1,3,2',6',3''-Penta(trichloroethyloxycarbonyl) netilmicin (80). A stirred solution of 
netilmicin sulfate (400 mg, 0.55 mmol) in 1:1 dioxane:water (10 mL) was ice-cooled and treated 
with Na2CO3 (883 mg, 8.33 mmol) and 2,2,2-trichloroethyl chloroformate (0.46 mL, 3.33 
mmol). The reaction mixture was stirred at rt for 4 h. After completion, the reaction mixture was 
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concentrated in vacuo then diluted with EtOAc and washed with brine, dried and concentrated. 
The crude product was purified by silica gel column chromatography eluting with 4% 
methanol/DCM to give 80 (722 mg, 96%) as a white solid; ESI-HRMS: m/z calcd. for 
C36H46Cl15N5NaO17 [M+Na]
+ 1367.8114; found, 1367.8109. 
5,2'''-Di-O-acetyl-1,3,2',6',3''-penta(trichloroethyloxycarbonyl) netilmicin (81). A 
stirred solution of compound 80 (1.06 g, 0.78 mmol) in pyridine (10 mL) was cooled to 0 °C and 
treated with acetic anhydride (1 mL). The resulting solution was stirred at rt for 12 h after which 
it was diluted with EtOAc and the organic layer was washed with aqueous NaHCO3 followed by 
brine, dried with Na2SO4, and concentrated. The crude product was purified via silica gel 
chromatography eluting with 20% to 35 % EtOAc in hexanes to give 81 (880 mg, 78%) as a 
white solid; ESI-HRMS: m/z calcd. for C40H50Cl15N5NaO19 [M+Na]
+ 1367.8114; found, 
1367.8109. 
5,2'''-Di-O-acetyl-1,3,2',6',3''-penta(trichloroethyloxycarbonyl)-4'-(ethylsulfanyl)-
netilmicin (82). Ethanesulfanyl chloride was freshly prepared for the reaction as described. 
Diethyl disulfide (1.22 mL, 10 mmol) was dissolved in dry DCM (20 mL) and cooled to -30 °C 
before sulfuryl chloride (0.80 mL, 10 mmol) was added dropwise. The resulting ethanesulfanyl 
chloride solution (0.52 mL, 0.52 mmol) was added to a stirred solution of 81 (500 mg, 0.35 
mmol) previously cooled to -50 °C. The reaction mixture was stirred for 1 h before DBU (78 L, 
0.52 mmol) was added, then it was stirred for an additional 4 h. After completion, the reaction 
mixture was diluted with DCM and washed with aqueous NaHCO3 followed by brine, dried, and 
concentrated. The crude product was purified via silica gel chromatography eluting with 20% to 
30 % EtOAc in hexanes to give 82 (225 mg, 43%) as a white foam; ESI-HRMS: m/z calcd. for 
C42H54Cl15N5NaO19S [M+Na]
+ 1511.8359; found, 1511.8390. 
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4'-(Ethylsulfanyl) netilmicin pentaacetate salt (83). Compound 82 (100 mg, 0.066 
mmol) was suspended in 6N NaOH (4 mL) in a closed vial and heated to 120 °C for 4 h during 
which the reaction mixture become clear. Upon completion, the reaction mixture was neutralized 
by 12 N H2SO4 till pH = 9 before it was lyophilized. The resulting solid residue was extracted 
with isopropyl alcohol (10 mL) and concentrated. The crude product was desalted and purified 
using Sephadex column (elution: D.I. water (20 mL), then gradient elution of 0.1% - 1.0% 
NH4OH in D.I. water). The fractions containing the product were combined, acidified with 
glacial acetic acid and lyophilized to afford 83 (8 mg, 15%) as the pentaacetate salt in the form 
of white solid; [α]D25= +87.4 (c 0.3, H2O); 1H NMR (600 MHz, D2O): δ 5.54 (s, 1H, H-1’), 4.89 
(d, J = 3.5 Hz, 1H, H-1’’), 4.15 (d, J = 14.3 Hz, 1H, H-6’), 4.07 (dd, J = 10.8, 3.6 Hz, 1H, H-
2’’), 3.81 (d, J = 12.9 Hz, 1H, H-5’’), 3.75 (t, J = 5.7 Hz, 1H, H-2’), 3.73 – 3.65 (m, 2H, H-6’, 
H-4), 3.60 – 3.54 (m, 2H, H-5, H-6), 3.37 – 3.25 (m, 3H, H-1, H-3’’, H-5’’), 3.16 – 3.05 (m, 2H, 
H-3, NCH2), 2.94 – 2.84 (m, 1H, NCH2), 2.74 (s, 4H, H-3’, NCH3), 2.51 (hept, J = 6.5, 5.9 Hz, 
2H, SCH2CH3), 2.42 (dd, J = 18.0, 5.5 Hz, 1H, H-3’), 2.34 (dt, J = 14.1, 4.3 Hz, 1H, H-2), 1.62 – 
1.51 (m, 1H, H-2), 1.16 (s, 3H, 4’’CH3), 1.11 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.00 (t, J = 7.4 Hz, 
3H, SCH2CH3);
 13C NMR (151 MHz, D2O): δ 181.1(C=O), 145.2 (C-5’’), 106.1 (C-4’’), 101.5 
(C-1’’), 96.5 (C-1’), 83.4 (C-6), 80.2 (C-4), 73.7 (C-5), 69.8 (C-4’’), 67.6 (C-5’’), 66.4 (C-2’’), 
63.5 (C-3’’), 56.3 (C-1), 48.0 (C-3), 46.8 (C-2’), 40.7 (NCH2), 38.2 (C-6’), 34.5 (NCH3), 28.4 
(C-3’), 26.7 (C-2), 26.0 (SCH2CH3), 23.0 (COCH3), 20.7 (4’’CH3), 14.0 (SCH2CH3), 10.9 
(NCH2CH3); ESI-HRMS: m/z calcd. for C23H46N5O7S [M+H]
+ 536.3118; found, 536.3099. 
6'-N-(p-Nitrobenzyloxycarbonyl) sisomicin (84). Sisomicin sulfate 8 (2.00 g, 2.88 
mmol) was added to a stirred suspension of Amberlite IRA-400 (OH form) (20 g) in methanol 
(15 mL) and stirred overnight. The suspension was filtered from the resin and the filtrate was 
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concentrated to give sisomicin free base (1.54 g). A solution of sisomicin free base (1.29 g) in 
methanol (30 mL) was treated with Zn(AcO)2.2H2O (1.90 g, 8.67 mmol) and stirred for 1 h. A 
solution of N-(4-nitrobenzyloxycarbonyloxy) succinimide128, 182 (0.85 g, 2.88 mmol) in DCM 
(10 mL) was added using syringe pump over 3h and the reaction mixture was left to stir 
overnight. The reaction mixture was concentrated to dryness then dissolved in 10% aqueous 
NH4OH solution (8 mL). The aqueous layer was washed with DCM (3 mL) four times and 
extracted with 30% IPA in DCM which was washed with a 10% NH4OH:brine (7:3) mixture. 
The organic layer was dried over Na2SO4, filtered and dried to give 84 (1.35 g, 75%) as a foam; 
Rf = 0.55 (DCM:MeOH:NH4OH = 3:2:1); [α]D25 = +101.1 (c = 0.90, MeOH); 1H NMR (600 
MHz, CDCl3): δ 8.19 (d, J = 8.4 Hz, 2H, PNZ-mHs), 7.49 (d, J = 8.4 Hz, 2H, PNZ-oHs), 5.44 (s, 
1H, H-1'), 5.21-5.15 (m, 2H, CH2-4-NO2C6H4), 4.90 (d, J = 2.6 Hz, 1H, H-1''), 4.80 (d, J = 2.9 
Hz, 1H, H-4'), 3.89 (dd, J = 13.9 Hz, 5.9 Hz, 1H, H-6'), 3.79 (d, J = 12.1 Hz, 1H, H-5''), 3.57-
3.44 (m, 5H, H-2'', H-4, H-5, H-5'', H-6'), 3.07-3.04 (m, 1H, H-2'), 3.01 (t, J = 9.4 Hz, 1H, H-6), 
2.82-2.77 (m, 2H, H-1, H-3), 2.57 (s, 3H, NCH3), 2.45 (d, J = 9.9 Hz, 1H, H-3''), 2.16-2.12 (m, 
1H, H-3'), 2.00-1.91 (m, 2H, H-2, H-3'), 1.23-1.15 (m, 1H, H-2), 1.13 (s, 3H, 4''-CH3); 
13C NMR 
(151 MHz, CDCl3): δ 156.2 (s, C=O), 147.4 (s, C-5'), 145.8, 144.5, 128.0, 123.7 (s, arom.), 101.2 
(s, C-1''), 99.1 (s, C-1'), 98.3 (s, C-4'), 89.5 (s, C-6), 82.6 (s, C-4), 75.6 (s, C-5), 71.1 (s, C-4''), 
69.4 (s, C-2''), 67.3 (s, C-5''), 65.2 (s, C-3''), 64.8 (s, CH2-4-NO2C6H4), 50.6 (s, C-1), 49.7 (s, C-
3), 47.0 (s, C-2'), 43.5 (s, C-6'), 39.3 (s, C-2), 38.7 (s, C- NCH3), 25.9 (s, C-3'), 24.2 (s, C-4''-
CH3); ESI-HRMS: m/z calcd. for C27H43N6O11 [M+H]
+ 627.2990, found: 627.2971.  
6'-N-(p-Nitrobenzyloxycarbonyl)-2',3-di-N-(tert-butyloxycarbonyl) sisomicin (85). A 
solution of 84 (1.00 g, 1.60 mmol) and Zn(AcO)2.2H2O (1.05 g, 8.67 mmol) in methanol (20 
mL) was stirred for 1 h before a solution of N-(tert-butoxycarbonyloxy)succinimide (0.65 g, 3.02 
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mmol) in THF (10 mL) was added using a syringe pump over 4 h.  After stirring overnight (TEA 
0.17 mL) was added, followed by N-(tert-butoxycarbonyloxy)succinimide (0.18 g, 0.81 mmol) in 
THF (2 mL) and the resulting solution was stirred for 24 h.  The reaction mixture was quenched 
by addition of glycine (0.48 g, 6.4 mmol) and evaporated to dryness.  The crude product was 
dissolved in DCM (50 mL) and washed with 30% aqueous NH4OH and dried over Na2SO4 and 
concentrated. The residue was purified by chromatography over silica gel (eluent: gradient of 6% 
to 8% of ammonical methanol in dichloromethane) to give 85 (0.69 g, 52%) as a white solid Rf= 
0.5 (25% ammonical MeOH in DCM); [α]D2 5= +131.7 (c = 0.25, MeOH); 1H NMR (600 MHz, 
CD3OD): δ 8.21 (d, J = 8.4 Hz, 2H, PNZ-mHs), 7.58 (d, J = 8.4 Hz, 2H, PNZ-oHs), 5.40 (s, 1H, 
H-1'), 5.26-5.17 (m, 2H, CH2-4-NO2C6H4), 4.95 (d, J = 3.7 Hz, 1H, H-1''), 4.73 (br s, 1H, H-4'), 
3.97 (d, J = 12.1 Hz, 1H, H-5''), 3.87 (d, J =15.4, 1H, H-6'), 3.75 (dd, J = 10.5 Hz, 3.5 Hz, 1H, 
H-2''), 3.69 (t, J = 7.9, 1H, H-5), 3.65 (d, J = 15.4, 1H, H-6'), 3.50 (t, J = 8.1, 1H, H-5), 3.45 (m, 
2H, H-3, H-4), 3.32 (d, J = 12.1 Hz, 1H, H-5''), 3.08 (t, J = 9.4, 1H, H-6), 2.82 (t, J = 8.4, 1H, H-
1), 2.57 (s, 3H, NCH3), 2.53 (d, J = 10.3, 1H, H-3''), 2.08-2.03 (m, 2H, H-3'), 1.99 (br d, J =11.4, 
1H, H-2), 1.42 (s, 9H, C(CH3)3), 1.40 (s, 9H, C(CH3)3), 1.26(m, 1H, H-2), (, J =, H, H-'), 1.16 (s, 
3H, 4''-CH3); 
13C NMR (151 MHz, CD3OD): δ 157.0, 156.5, 156.3(s, C=O), 147.4 (s, arom.), 
146.4 (s, C-5'), 144.7 (s, arom.) 127.6, 123.2 (s, arom.), 101.0 (s, C-1''), 97.0 (s, C-1'), 95.9 (s, C-
4'), 88.6 (s, C-6), 80.2 (s, C-4), 78.8 (s, C(CH3)3), 75.6 (s, C-5), 71.4 (s, C-4''), 69.2 (s, C-2''), 
68.0 (s, C-5''), 64.7 (s, CH2-4-NO2C6H4), 64.0 (s, C-3''), 50.3 (s, C-1), 49.3 (s, C-3), 46.9 (s, C-
2'), 42.6 (s, C-6'), 36.9 (s, NCH3), 35.4 (s, C-2), 27.4 (s, C(CH3)3), 27.3 (s, C(CH3)3), 22.1 (s, C-
3'), 22.0 (s, C-4''-CH3); ESI-HRMS: m/z calcd. for C37H59N6O15 [M+H]
+ 827.4038, found: 
827.4023. 
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6'-N-(p-Nitrobenzyloxycarbonyl)-3''-N-phenylazo-2',3-di-N-(tert-butyloxycarbonyl) 
sisomicin (86). A stirred solution of 85 (675 mg, 0.82 mmol) in acetonitrile:H2O (1:1, 14 mL) 
was treated with K2CO3 (1.13 g, 8.17 mmol) and cooled to 0 
oC in an ice bath. A solution of 
phenyldiazonium tetrafluoroborate (173 mg, 0.90 mmol) in acetonitrile (7 mL) was added using 
a syringe pump over 1 h at 0 oC, after which the reaction was complete. The reaction mixture 
was diluted with ethyl acetate and washed with water, and brine. The organic layer was dried 
over Na2SO4 and concentrated. The residue was purified by chromatography over silica gel 
(eluent: gradient of 6% to 10% of methanol in dichloromethane) to give 86 (0.67 g, 88%) as a 
buff gum; Rf = 0.3 (10% MeOH in DCM); [α]D25 = +127.6 (c = 2.7, MeOH); 1H NMR (600 
MHz, CD3OD): δ 8.22 (d, J = 8.4 Hz, 2H, PNZ-mHs), 7.58 (d, J = 8.1 Hz, 2H, PNZ-oHs), 7.38 
(d, J = 7.7 Hz, 2H, Ph-oHs), 7.28 (t, J = 7.7 Hz, 2H, Ph-mHs),  7.10 (t, J = 7.2 Hz, 1H, Ph-pH),  
5.41 (s, 1H, H-1'), 5.26-5.17 (m, 2H, CH2-4-NO2C6H4), 5.16 (d, J = 3.7 Hz, 1H, H-1''), 4.73 (br 
s, 1H, H-4'), 4.44 (dd, J = 11 Hz, 3.7 Hz, 1H, H-2''), 4.21 (d, J = 11 Hz, 1H, H-3''), 4.13 (d, J 
=11.7, 1H, H-5''), 3.88 (d,  J = 15.4, 1H, H-6'), 3.71 (t,  J = 8.1, 1H, H-2'), 3.65 (d, J = 15.4, 1H, 
H-6'), 3.56 (m, 1H, H-5), 3.46 (m, 2H, H-3, H-4), 3.38 (d, J =11.7, 1H, H-5''), 3.31(s, 3H, 
NCH3), 3.17 (t, J = 9.4, 1H, H-6), 2.88 (t, J = 8.4, 1H, H-1), 2.10-2.06 (m, 2H, H-3'), 1.99 (br d, 
J =13.2, 1H, H-2), 1.42 (s, 9H, C(CH3)3), 1.41 (s, 9H, C(CH3)3), 1.31-1.25(m, 1H, H-2), 1.09 (s, 
3H, 4''-CH3);
 13C NMR (151 MHz, CD3OD): δ 157.1, 156.5, 156.4(s, C=O), 151.0, 147.4 (s, 
arom.), 146.5 (s, C-5'), 144.7, 128.5, 128.3, 127.7, 127.6, 124.9, 123.2, 120.2 (s, arom.), 101.5 (s, 
C-1''), 97.1 (s, C-1'), 95.9 (s, C-4'), 88.4 (s, C-6), 80.2 (s, C-4), 78.9 (s, C(CH3)3), 75.6 (s, C-5), 
72.9 (s, C-4''), 69.1 (s, C-5''), 68.0 (s, C-3''), 65.6 (s, C-2''), 64.7 (s, CH2-4-NO2C6H4), 50.4 (s, C-
1), 49.3 (s, C-3), 46.9 (s, C-2'), 42.6 (s, C-6'), 35.4 (s, C-2), 32.6 (s, NCH3), 27.4 (s, C(CH3)3), 
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27.2 (s, C(CH3)3), 22.1 (s, C-3'), 21.2 (s, C-4''-CH3); ESI-HRMS: m/z calcd. for C43H63N8O15 
[M+H]+ 931.4413, found: 931.4388. 
1-N-(N-tert-butyloxycarbonyl-4-amino-2(S)-hydroxybutyryl)-6'-N-(p-
nitrobenzyloxycarbonyl)-3''-N-phenylazo-2',3-di-N-(tert-butyloxycarbonyl) sisomicin (87). 
A solution of N-Boc-4-amino-2(S)-hydroxy-butyric acid (15.3 mg, 0.069 mmol), HONB183 (12.5 
mg, 0.069 mmol), DIPEA (18.0 mg, 0.14 mmol) and EDCI (13.4 mg, 0.069 mmol) in DMF (0.2 
mL) was stirred for 0.5 h before 86 (50 mg, 0.053 mmol) in DMF (2 mL) was added.  Stirring 
was continued for 24 h at room temperature before the reaction mixture was cooled to 0°C, 
quenched with saturated aqueous NaHCO3 (0.5 mL), and extracted with ethyl acetate. The 
organic layer was washed with saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered 
and concentrated to dryness. The residue was purified via silica gel chromatography eluting with 
25% to 40% acetone in hexanes to give 87 (54 mg, 89%) as a white foam; Rf = 0.3 (50% 
Acetone in hexanes); [α]D25 = +83.0 (c = 1.4, MeOH); 1H NMR (600 MHz, CD3OD): δ 8.23 (d, J 
= 8.4 Hz, 2H, PNZ-mHs), 7.59 (d, J = 8.4 Hz, 2H, PNZ-oHs), 7.38 (d, J = 7.7 Hz, 2H, Ph-oHs), 
7.28 (t, J = 7.9 Hz, 2H, Ph-mHs), 7.09 (t, J = 7.2 Hz, 1H, Ph-pH),  5.40 (s, 1H, H-1'), 5.27-5.18 
(m, 3H, CH2-4-NO2C6H4, H-1''), 4.74 (br s, 1H, H-4'), 4.34 (dd, J = 11.2 Hz, 3.5 Hz, 1H, H-2''), 
4.19 (m, 2H, H-3'', H-5''), 3.96 (dd, J = 8.4 Hz, 3.7 Hz, 1H, CH(OH)CH2CH2), 3.88 (m, 2H, H-1, 
H-6'), 3.71 (t,  J = 8.1, 1H, H-2'), 3.68-3.60 (m, 3H, H-5, H-6, H-6'), 3.51-3.47 (m, 2H, H-3, H-
4), 3.33 (d, J = 12.1, 1H, H-5''), 3.29(s, 3H, NCH3), 3.13-3.00 (m, 2H, CH(OH)CH2CH2), 2.11-
2.00 (m, 3H, H-3', H-2), 1.85-1.82 (m, 1H, CH(OH)CH2CH2), 1.73-1.67 (m, 1H, 
CH(OH)CH2CH2), 1.54-1.51 (m, 1H, H-2),  1.42- 1.40 (m, 27H, C(CH3)3), 1.08 (s, 3H, 4''-CH3);
 
13C NMR (151 MHz, CD3OD): δ 175.7, 157.2, 157.1, 156.4 (s, C=O), 151.0, 147.5 (s, arom.), 
146.5 (s, C-5'), 144.7, 128.3, 127.6,  124.9, 123.2, 120.2 (s, arom.), 95.6 (s, C-1''), 97.2 (s, C-1'), 
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96.0 (s, C-4'), 81.5 (s, C-6), 79.8 (s, C-4), 79.0, 78.6 (s, C(CH3)3), 75.9 (s, C-5), 73.0 (s, C-4''), 
69.4 (s, CH(OH)CH2CH2), 69.1 (s, C-5''), 68.6 (s, C-3''), 65.4 (s, C-2''), 64.7 (s, CH2-4-
NO2C6H4), 49.2 (s, C-3), 49.0 (s, C-1), 47.0 (s, C-2'), 42.6 (s, C-6'), 36.3 (s, CH(OH)CH2CH2), 
33.9 (s, CH(OH)CH2CH2), 33.7 (s, C-2), 32.8 (s, NCH3), 27.4 (s, C(CH3)3), 27.2 (s, C(CH3)3), 
22.1 (s, C-3'), 21.2 (s, C-4''-CH3); ESI-HRMS: m/z calcd. for C52H77N9NaO19 [M+Na]
+ 
1154.5233, found: 1154.5212. 
1-N-(N-tert-Butyloxycarbonyl-4-amino-2(S)-hydroxybutyryl)-3''-N-phenylazo-2',3-
di-N-(tert-butyloxycarbonyl) sisomicin (88). A stirred solution of 87 (50 mg, 0.08 mmol) in 
1,4-dioxane (1 mL) was treated with 1 N aqueous NaOH (1 mL) and heated to 40 oC for 14 h. 
The reaction mixture was diluted with H2O (2 mL) and extracted with ethyl acetate twice. The 
combined organic layers were washed with H2O and brine, dried over Na2SO4, filtered and 
concentrated. The residue was purified by column chromatography over silica gel (eluent: 
gradient of 6% to 15% of ammonical methanol in dichloromethane) to give 88 (38 mg, 70%) as a 
white solid; Rf = 0.5 (20% ammonical MeOH in DCM); [α]D25 = +116.5 (c = 0.086, MeOH); 1H 
NMR (600 MHz, CD3OD): δ 7.38 (d, J = 7.7 Hz, 2H, Ph-oHs), 7.28 (t, J = 7.9 Hz, 2H, Ph-mHs),  
7.10 (t, J = 7.2 Hz, 1H, Ph-pH),  5.44 (s, 1H, H-1'), 5.20 (d, J = 3.3, H-1''), 4.72 (br s, 1H, H-4'), 
4.35 (dd, J = 11.4 Hz, 3.7 Hz, 1H, H-2''), 4.23-4.19 (m, 2H, H-3'', H-5''), 3.96 (dd, J = 8.4 Hz, 3.7 
Hz, 1H, CH(OH)CH2CH2),  3.90 (m, 1H, H-1), 3.75-3.69 (m, 2H, H-6, H-2'), 3.65-3.60 (m, 1H,  
H-5), 3.55 (t, 1H, J = 9.4, H-4), 3.51-3.45 (m, 1H, H-3), 3.33 (d, J =12.1, 1H, H-5''), 3.29(s, 3H, 
NCH3), 3.23-3.15 (m, 2H, H-6'), 3.13-3.02 (m, 2H, CH(OH)CH2CH2), 2.14-2.00 (m, 3H, H-3', 
H-2), 1.88-1.82 (m, 1H, CH(OH)CH2CH2), 1.73-1.67 (m, 1H, CH(OH)CH2CH2), 1.57-1.51 (m, 
1H, H-2), 1.42- 1.40 (m, 27H, C(CH3)3), 1.08 (s, 3H, 4''-CH3);
 13C NMR (151 MHz, CD3OD): δ 
175.7, 157.1, 156.4, 156.3 (s, C=O), 151.0 (s, arom.),  149.4 (s, C-5'), 128.3, 124.9, 120.2 (s, 
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arom.), 95.6 (s, C-1''), 97.3 (s, C-1'), 95.2 (s, C-4'), 81.5 (s, C-6), 80.1 (s, C-4), 78.9, 78.6 (s, 
C(CH3)3), 75.9 (s, C-5), 73.0 (s, C-4''), 69.4 (s, CH(OH)CH2CH2), 69.1 (s, C-5''), 68.6 (s, C-3''), 
65.4 (s, C-2''), 49.2 (s, C-3), 49.0 (s, C-1), 47.0 (s, C-2'), 43.4 (s, C-6'), 36.4 (s, 
CH(OH)CH2CH2), 33.9 (s, CH(OH)CH2CH2), 33.7 (s, C-2), 32.7 (s, NCH3), 27.43 (s, C(CH3)3), 
27.42 (s, C(CH3)3), 22.1 (s, C-3'), 21.2 (s, C-4''-CH3); ESI-HRMS: m/z calcd. for C44H72N8NaO15 
[M+Na]+ 975.5015, found: 975.4996. 
6'-N-(2-tert-Butyldimethylsiloxyethyl)-1-N-(N-tert-butyloxycarbonyl-4-amino-2(S)-
hydroxybutyryl)-3''-N-phenylazo-2',3-di-N-(tert-butyloxycarbonyl) sisomicin (89). tert-
Butyldimethylsilyloxy acetaldehyde (Sigma-Aldrich, 20 μL, 0.11 mmol) and DIPEA (27.1 mg, 
0.21 mmol) were added to a stirred solution of 88 (100 mg, 0.11 mmol) in dry THF (2.5 mL). 
The reaction mixture was stirred for 10 min before sodium triacetoxyborohydride (26.7 mg, 0.13 
mmol) was added, after which stirring was continued for 24 h at room temperature. The solvent 
was evaporated under vacuum and the residue was purified by column chromatography on silica 
gel eluting with gradient of 4% to 15% ammonical methanol in dichloromethane to give 89 
(59mg, 51%) as a white foam; Rf = 0.5 (10% ammonical MeOH in DCM); [α]D25 = +95.3 (c = 
0.01, MeOH); 1H NMR (600 MHz, CD3OD): δ 7.38 (d, J = 7.7 Hz, 2H, Ph-oHs), 7.28 (t, J = 7.7 
Hz, 2H, Ph-mHs),  7.10 (t, J = 7.3 Hz, 1H, Ph-pH),  5.43 (s, 1H, H-1'), 5.20 (d, J = 3.3, H-1''), 
4.76 (br s, 1H, H-4'), 4.34 (dd, J = 11.4 Hz, 3.3 Hz, 1H, H-2''), 4.22-4.19 (m, 2H, H-3'', H-5''), 
3.96 (dd, J = 8.4 Hz, 3.7 Hz, 1H, CH(OH)CH2CH2),  3.88 (m, 1H, H-1), 3.77-3.67 (m, 4H, 
NHCH2CH2O, H-6, H-2'), 3.65-3.60 (m, 1H,  H-5), 3.57 (t, 1H, J = 8.4, H-4), 3.51-3.46 (m, 1H, 
H-3), 3.33 (d, J =12.1, 1H, H-5''), 3.30(m, 1H, H-6'), 3.29(s, 3H, NCH3), 3.16 (d,  J =13.6, 1H, 
H-6'), 3.12-3.02 (m, 2H, CH(OH)CH2CH2), 2.80-2.64 (m, 2H, NHCH2CH2O),   2.14-2.00 (m, 
3H, H-3', H-2), 1.88-1.82 (m, 1H, CH(OH)CH2CH2), 1.73-1.67 (m, 1H, CH(OH)CH2CH2), 1.59-
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1.51 (m, 1H, H-2), 1.42-1.40 (m, 27H, C(CH3)3), 1.08 (s, 3H, 4''-CH3), 0.91 (s, 9H, SiC(CH3)3), 
0.09 (s, 6H, Si(CH3)2);
 13C NMR (151 MHz, CD3OD): δ 175.7, 157.1, 156.5, 156.4 (s, C=O), 
151.0 (s, arom.),  146.5 (s, C-5'), 128.3, 124.9, 120.2 (s, arom.), 99.6 (s, C-1''), 97.6 (s, C-4'), 
97.2 (s, C-1'), 81.5 (s, C-6), 79.8 (s, C-4), 78.9, 78.8, 78.6 (s, C(CH3)3), 75.9 (s, C-5), 73.0 (s, C-
4''), 69.4 (s, CH(OH)CH2CH2), 69.2 (s, C-5''), 68.6 (s, C-3''), 65.4 (s, C-2''), 61.6 (s, 
NHCH2CH2O), 50.7 (s, C-6'), 49.9 (s, NHCH2CH2O), 49.3 (s, C-3), 49.0 (s, C-1), 47.1 (s, C-2'), 
36.4 (s, CH(OH)CH2CH2), 33.93 (s, CH(OH)CH2CH2), 33.87 (s, C-2), 32.7 (s, NCH3), 27.5 (s, 
C(CH3)3), 27.4 (s, C(CH3)3), 25.0(s, SiC(CH3)3), 22.2 (s, C-3'), 21.2 (s, C-4''-CH3), 17.8 (s, 
SiC(CH3)3), -6.6(s, Si(CH3)2); ESI-HRMS: m/z calcd. for C52H91N8O16Si [M+H]
+ 1111.6322, 
found: 1111.6307. 
6'-N-(2-Hydroxyethyl)-1-N-(4-amino-2(S)-hydroxybutyryl)sisomicin pentaacetate 
salt [Plazomicin.5AcOH] (16). Compound 89 (59 mg, 0.054 mmol) was dissolved in DCM (1 
mL) and cooled to 0 °C before trifluoroacetic acid (1 mL) was added. The reaction mixture was 
stirred for 6 h. Upon completion of the reaction, the reaction mixture was diluted with dry DCM 
(10 mL) and toluene (10 mL) and concentrated. The crude product was diluted with dry DCM 
(10 mL) and concentrated twice and the residue was purified by Sephadex C-25 chromatography 
eluting with a gradient of 0.1% to 3% ammonia in deionized H2O. Fractions containing the 
product were combined, acidified with glacial acetic acid and lyophilized to give 16 (19 mg, 
40%) as a white solid; [α]D25 = +46.5 (c = 0.67, H2O); 1H NMR (600 MHz, D2O): δ 5.51 ( s, 1H, 
H-1'), 5.16 (t, J = 3.5 Hz, H, H-4'), 4.99 (d, J = 4.0 Hz, 1H, H-1''), 4.11(dd, J =9.4 Hz, 3.9 Hz, 
1H, CH(OH)CH2CH2), 4.00 (d, J = 12.8 Hz, 1H, H-5''), 3.95 (m, 1H, H-1), 3.84 (dd,  J = 11.0 
Hz, 4.0 Hz, 1H, H-2''), 3.81 (t, J = 9.9 Hz, 1H, H-4), 3.77 (t, J = 5.3 Hz, 1H, H-2'), 3.71(t, J = 5.1 
Hz, 2H, NHCH2CH2O), 3.69-3.65 (m, 2H, H-6, H-6'), 3.64-3.94 (m, 2H, H-5, H-6'), 3.31 (m, 1H, 
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H-3), 3.24 (d, J = 12.8 Hz, 1H, H-5''), 3.15 (d, J = 11.0 Hz, 1H, H-3''), 3.07 (q, J = 4.9, 2H, 
NHCH2CH2O) 3.01 (t, J =7.2 Hz, 2H, CH(OH)CH2CH2), 2.74 (s, 3H, NCH3), 2.58-2.52 (m, 1H, 
H-3'), 2.29-2.24 (m, 1H, H-3'), 2.07(dt, J = 13.2 Hz, 4.4 Hz, 1H, H-2), 2.04-1.98 (m, 1H, 
CH(OH)CH2CH2), 1.84-1.79 (m, 1H, CH(OH)CH2CH2), 1.63-1.57 (q, 1H,  J = 12.5 Hz, H-2), 
1.17 (s, 3H, 4''-CH3);
 13C NMR (151 MHz, D2O): δ 181.2 (s, CH3COOH), 175.4 (s, NHCO), 
141.7 (s, C-5'), 102.5 (s, C-4'), 98.0 (s, C-1''), 96.9 (s, C-1'), 79.8 (s, C-4), 78.8 (s, C-6), 73.8 (s, 
C-5), 69.8 (s, C-4''), 69.4 (s, CH(OH)CH2CH2), 66.8 (s, C-5''), 65.9 (s, C-2''), 64.2 (s, C-3''), 56.4 
(s, NHCH2CH2O), 48.8 (s, C-1), 48.31 (s, NHCH2CH2O), 48.26 (s, C-3), 47.9 (s, C-6'), 45.9 (s, 
C-2'), 36.8 (s, CH(OH)CH2CH2), 34.9 (s, NCH3), 30.7 (s, CH(OH)CH2CH2), 30.4 (s, C-2), 23.1 
(s, CH3COOH), 23.0 (s, C-3'), 20.8 (s, 4''-CH3); ESI-HRMS: m/z calcd. for C25H49N6O10 [M+H]
+ 
593.3510, found: 593.3481. 
1-N-(4-Amino-2(S)-hydroxy-butyryl) sisomicin pentaacetate salt (90). Compound 88 
(50 mg, 0.052 mmol) was dissolved in DCM (1 mL) and cooled to 0 °C before trifluoroacetic 
acid (1 mL) was added. The reaction mixture was stirred for 45 min. Upon completion of the 
reaction, the reaction was diluted with dry DCM (10 mL) and toluene (10 ml) and concentrated. 
The crude product was diluted with dry DCM (10 mL) and concentrated twice and the residue 
was purified by a Sephadex column eluting with gradient of 0.1% to 3% ammonia in deionized 
H2O. Fractions containing the product were combined, acidified with glacial acetic acid and 
lyophilized to give 90 (24 mg, 54%) as a white solid; [α]D25= +34.5 (c=0.07, H2O); 1H NMR 
(600 MHz, D2O): δ 5.43 ( s, 1H, H-1'), 5.02 (t, J = 3.5 Hz, H, H-4'), 4.96(d, J = 4.0 Hz, 1H, H-
1''), 4.08(dd, J =9.2 Hz, 3.7 Hz, 1H, CH(OH)CH2CH2), 3.98 (d, J = 12.8 Hz, 1H, H-5''), 3.92 (m, 
1H, H-1), 3.84(dd, J = 11.0 Hz, 3.9 Hz, 1H, H-2''), 3.74 (t, J = 9.7 Hz, 1H, H-4), 3.70 (t, J = 5.1 
Hz, 1H, H-2'), 3.64 (m, 1H, H-6), 3.57 (m, 1H, H-5), 3.49 (s, 2H, H-6'), 3.25 (m, 1H, H-3), 3.21 
120 
 
 
 
(d, J = 12.8 Hz, 1H, H-5''), 3.11(d, J = 11.0 Hz, 1H, H-3''), 2.98 (t, J =7.3 Hz, 2H, 
CH(OH)CH2CH2), 2.71 (s, 3H, NCH3), 2.52-2.46 (m, 1H, H-3'), 2.23-2.17 (m, 1H, H-3'), 2.03-
1.95 (m, 2H, H-2, CH(OH)CH2CH2), 1.82-1.75 (m, 1H, CH(OH)CH2CH2), 1.63-1.57 (m, 1H, H-
2), 1.14 (s, 3H, 4''-CH3);
 13C NMR (151 MHz, D2O): δ 181.2 (s, CH3COOH), 175.4 (s, NHCO), 
143.3 (s, C-5'), 100.3 (s, C-4'), 98.1 (s, C-1''), 97.0 (s, C-1'), 80.0 (s, C-4), 78.8 (s, C-6), 73.8 (s, 
C-5), 69.8 (s, C-4''), 69.5 (s, CH(OH)CH2CH2), 66.8 (s, C-5''), 66.0 (s, C-2''), 64.2 (s, C-3''), 48.8 
(s, C-1), 48.4 (s, C-3), 46.0 (s, C-2'), 40.5 (s, C-6'), 36.8 (s, CH(OH)CH2CH2), 34.9 (s, NCH3), 
30.7 (s, CH(OH)CH2CH2), 30.4 (s, C-2), 23.2 (s, CH3COOH), 23.0 (s, C-3'), 20.8 (s, 4''-CH3); 
ESI-HRMS: m/z calcd. for C23H45N6O9 [M+H]
+ 549.3248, found: 549.3234. 
6,2’’,3’’,6’’-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-6′,7′-oxazolidino-apramycin (124). A 
stirred solution of 1,3,2′,4′′-tetraazido-6′,7′-oxazolidino-apramycin82 120 (100 mg, 0.15 mmol) in 
dry pyridine (0.3 mL) was cooled to 0 °C and treated with acetic anhydride (60 L, 0.62 mmol). 
The reaction mixture was allowed to warm up to rt and stirred overnight. The reaction progress 
was monitored by TLC and additional acetic anhydride (0.5-1 equiv) was added as needed. After 
completion, the reaction mixture was diluted with EtOAc and the organic layer was washed with 
aqueous NaHCO3 followed by brine, dried with Na2SO4, and concentrated. The crude product 
was purified via silica gel chromatography eluting with 0.6% to 0.8 % methanol in DCM to give 
124 (76 mg, 61%) as a white solid; [α]D25= +101.6 (c 3.1, DCM); 1H NMR (600 MHz, CDCl3): δ 
5.35 (t, J = 9.9 Hz, 1H, H-3''), 5.30 (d, J = 3.7 Hz, 1H, H-1''), 5.15 (d, J = 3.5 Hz, 1H, H-1'), 4.93 
(d, J = 2.9 Hz, 1H, H-8'), 4.93 – 4.87 (m, 2H, H-6, H-2''), 4.81 (dd, J = 8.6, 3.2 Hz, 1H, H-6'), 
4.61 (dd, J = 10.5, 3.2 Hz, 1H, H-5'), 4.31 (dd, J = 12.3, 2.2 Hz, 1H, H-6''), 4.20 (dd, J = 12.3, 
5.1 Hz, 1H, H-6''), 3.84 (dd, J = 8.7, 3.0 Hz, 1H, H-7'), 3.80 (dt, J = 10.9, 5.5 Hz, 1H, H-4'), 3.72 
(ddd, J = 10.7, 5.1, 2.3 Hz, 1H, H-5''), 3.66 (ddd, J = 12.3, 9.9, 4.7 Hz, 1H, H-3), 3.62 – 3.53 (m, 
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3H, H-2', H-4'', H-5), 3.49 (ddd, J = 12.5, 10.0, 4.5 Hz, 1H, H-1), 3.45 (t, J = 9.5 Hz, 1H, H-4), 
2.89 (s, 3H, NCH3), 2.41 (dt, J = 13.3, 4.6 Hz, 1H, H-2), 2.29 (dt, J = 10.9, 4.5 Hz, 1H, H-3'), 
2.13 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 1.89 (q, 
J = 11.7 Hz, 1H, H-3'), 1.60 (q, J = 12.7 Hz, 1H, H-2); 13C NMR (151 MHz, CDCl3): δ 170.37 
(C=O), 170.34 (C=O), 169.91 (C=O), 169.88 (C=O), 157.0 (NC=O), 98.8 (C-1'), 94.9 (C-8'), 
94.5 (C-1''), 83.8 (C-4), 74.9 (C-6), 74.3 (C-5), 70.7 (C-3''), 70.1 (C-2''), 69.8 (C-6'), 68.8 (C-5''), 
65.5 (C-5'), 65.1 (C-4'), 62.8 (C-6''), 60.1 (C-2'), 59.9 (C-7'), 58.4 (C-3), 58.0 (C-1), 57.6 (C-4''), 
32.0 (C-2), 30.6 (C-3'), 29.8 (C- NCH3), 20.9 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. 
for C30H39N13NaO16 [M+Na]
+ 860.2535; found, 860.2522.  
-O--2’’’,3’’’,5’’’-Tri-O-acetyl-D-ribofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-
1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin (126). A suspension of 2’’’,3’’’,5’’’-tri-O-
acetyl-D-ribofuranosyl trichloroacetimidate157 125 (150 mg, 0.36 mmol), acceptor 124 (100 mg, 
0.12 mmol) and activated 4 Å MS in dry DCM was stirred at rt for 1 h before cooling to 0 °C and 
addition of BF3.OEt2 (132 L, 0.54 mmol). After 4 h of stirring at 0 °C, the reaction was 
quenched with triethylamine (0.5 mL) and filtered through Celite®. The reaction mixture was 
diluted with EtOAc and washed with aqueous NaHCO3 and brine then concentrated. The crude 
product was purified using silica gel column chromatography (eluent: 20% - 40% 
EtOAc/hexanes) to give 126  = 1:9 (126 mg, 95%), further purification was done to give 126 
(47 mg) as the -anomer in the form of a white solid while the rest remained as a mixture. 
[α]D25= +47.2 (c 2.7, DCM); 1H NMR (600 MHz, CDCl3): δ 5.67 (d, J = 3.5 Hz, 1H, H-1'), 5.43 
(d, J = 10.1 Hz, 1H, H-3''), 5.40 (d, J = 2.3 Hz, 1H, H-1'''), 5.37 (d, J = 3.8 Hz, 1H, H-1''), 5.11 (t, 
J = 5.0 Hz, 1H, H-3'''), 5.07 (dd, J = 4.9, 3.3 Hz, 1H, H-2'''), 4.92 (t, J = 9.9 Hz, 1H, H-6), 4.85 
(dd, J = 10.4, 3.9 Hz, 1H, H-2''), 4.82 (d, J = 4.6 Hz, 1H, H-8'), 4.76 (dd, J = 7.4, 3.3 Hz, 1H, H-
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6'), 4.41 (dd, J = 10.3, 3.3 Hz, 1H, H-5'), 4.32 (m, 2H, H-6'', H-5'''), 4.24 (q, J = 4.0 Hz, 1H, H-
4'''), 4.21 (dd, J = 12.2, 5.4 Hz, 1H, H-6''), 4.09 (dd, J = 12.1, 4.1 Hz, 1H, H-5'''), 3.79 (d, J = 9.2 
Hz, 1H, H-5), 3.77 – 3.64 (m, 4H, H-4, H-7', H-4', H-5''), 3.60 – 3.53 (m, 2H, H-4'', H-3), 3.46 – 
3.38 (m, 1H, H-1), 3.22 (dt, J = 12.9, 4.1 Hz, 1H, H-2'), 2.93 (s, 3H, NCH3), 2.41 (dt, J = 13.0, 
4.5 Hz, 1H, H-2), 2.26 – 2.21 (m, 1H, H-3'), 2.20 (s, 3H, COCH3), 2.14 – 2.02 (m, 18H, 
6*COCH3), 1.93 (q, J = 11.7 Hz, 1H, H-3'), 1.58 (q, J = 12.6 Hz, 1H, H-2);
 13C NMR (151 MHz, 
CDCl3): δ 170.8 (C=O), 170.4 (C=O), 170.2 (C=O), 169.8 (C=O), 169.6 (C=O), 169.5 (C=O), 
169.5 (C=O), 157.0 (C=O), 106.1 (C-1'''), 97.4 (C-8'), 96.4 (C-1'), 94.0 (C-1''), 80.4 (C-5), 79.5 
(C-4'''), 77.5 (C-4), 74.5 (C-6), 74.1 (C-2'''), 71.0 (C-6'), 70.9 (C-3'''), 70.3 (C-3''), 69.9 (C-2''), 
69.1 (C-5''), 66.0 (C-5'), 65.7 (C-4'), 63.4 (C-5'''), 62.9 (C-6''), 60.2 (C-7'), 60.1 (C-4''), 59.1 (C-
3), 58.1 (C-1), 56.6 (C-2'), 31.5 (C-2), 30.1 (NCH3), 29.9 (C-3'), 20.8 (COCH3), 20.8 (COCH3), 
20.7 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 20.4 (COCH3), 20.4 (COCH3); ESI-HRMS: m/z 
calcd. for C41H54N13O23 [M+H]
+ 1118.3275; found, 1118.3234. 
-O-(-D-Ribofuranosyl) apramycin pentaacetate salt (127). A stirred solution of 
substrate 129 (47 mg, 0.04 mmol) in dioxane (0.5 mL) was treated with 3 N NaOH (0.25 mL) 
and heated at 100 °C for 12 h. The reaction mixture was cooled to rt and neutralized with glacial 
acetic acid before it was concentrated in vacuo. The crude product was purified through a silica 
gel column (eluent: 10-20% methanol/DCM). The product-containing fractions were 
concentrated, dissolved in dioxane:water:glacial acetic acid = 1:2:0.2 (0.3 mL) and Pd/C (0.5 
equiv) was added. The reaction mixture was stirred at room temperature under 1 atm of hydrogen 
(balloon) for 1 h. After completion, the reaction mixture was filtered over Celite® and the filtrate 
concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was 
charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water 
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(20 mL), then eluted with a gradient of 0.1% - 1.0% NH4OH in D.I. water. The fractions 
containing the product were combined, acidified with glacial acetic acid and lyophilized to afford 
127 (29 mg, 69%) as pentaacetate salt in the form of a white solid [α]D25= +66.25 (c 0.8, H2O); 
1H NMR (600 MHz, D2O): δ 5.66 (d, J = 4.0 Hz, 1H, H-1'), 5.29 (d, J = 3.8 Hz, 1H, H-1''), 5.14 
(s, 1H, H-1'''), 5.01 (d, J = 8.5 Hz, 1H, H-8'), 4.38 (s, 1H, H-6'), 4.00 (d, J = 4.7 Hz, 1H, H-2'''), 
3.98 – 3.93 (m, 1H, H-3'''), 3.86 – 3.74 (m, 3H, H-4''', H-4, H-3''), 3.74 – 3.63 (m, 5H, H-4', H-5, 
H-5'', H-5''', H-6''), 3.58 (dd, J = 12.4, 4.4 Hz, 1H, H-6''), 3.53 – 3.41 (m, 5H, H-5', H-2', H-2'', 
H-6, H-5'''), 3.29 – 3.21 (m, 1H, H-3), 3.19 (dd, J = 8.5, 2.4 Hz, 1H, H-7'), 3.12 (td, J = 11.6, 4.3 
Hz, 1H, H-1), 3.06 (t, J = 10.4 Hz, 1H, H-4''), 2.58 (s, 3H, NCH3), 2.24 (dt, J = 11.3, 3.1 Hz, 1H, 
H-2), 2.21 – 2.10 (m, 1H, H-3'), 1.92 – 1.81 (m, 1H, H-3'), 1.66 – 1.57 (m, 1H, H-2); 13C NMR 
(151 MHz, D2O): δ 110.3 (C-1'''), 94.5 (C-1'), 94.3 (C-1''), 92.8 (C-8'), 84.9 (C-5), 82.3 (C-4'''), 
75.9 (C-4), 75.1 (C-2''') 72.5 (C-6), 70.2 (C-5''), 69.6 (C-2''), 69.6 (C-4'), 68.9 (C-3''), 68.4 (C-
3'''), 66.0 (C-5'), 62.6 (C-6'), 60.8 (C-5'''), 60.2 (C-6''), 59.3 (C-7'), 52.0 (C-4''), 49.8 (C-3), 48.3 
(C-1), 47.8 (C-2'), 30.0 (NCH3), 28.6 (C-2), 26.7 (C-3'); ESI-HRMS: m/z calcd. for 
C26H49N5NaO15 [M+Na]
+ 694.3123; found, 694.3122. 
p-Cresyl-2’,6’-diazido-2,5,3’4’-tetra(4-methoxybenzoyl)-1-thio--paromobioside 
(130). p-Cresyl-2’,6’-diazido-2,5,3’4’-tetra-O-acetyl--thioparomobioside159-160 128 (375 mg, 
0.59 mmol) was dissolved in dry methanol, then NaOMe (4.7 mg, 0.12 mmol) was added and the 
reaction mixture was stirred for 1.5 h. The reaction was quenched with glacial acetic acid and 
concentrated till dryness. The crude product was dissolved in pyridine (5 mL) and p-
methoxybenzoyl chloride (802 mg, 4.72 mmol) was added followed by stirring for 48 h then 
diluting with EtOAc. The organic layer was washed with aqueous NaHCO3 followed by brine, 
dried with Na2SO4, and concentrated. The crude product was purified via silica gel 
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chromatography eluting with 10% to 40 % EtOAc in hexanes to give 130 (398 mg, 76%) as a 
white solid; [α]D25= -14.2 (c 13.2, DCM); 1H NMR (600 MHz, CDCl3): δ 8.08 (d, J = 8.8 Hz, 
2H, ArH), 8.04 (d, J = 8.8 Hz, 2H, ArH), 7.95 (d, J = 8.8 Hz, 2H, ArH), 7.85 (d, J = 8.9 Hz, 2H, 
ArH), 7.40 (d, J = 8.0 Hz, 2H, ArH), 7.02 (d, J = 7.8 Hz, 2H, ArH), 6.97 – 6.88 (m, 6H, ArH), 
6.78 (d, J = 8.9 Hz, 2H, ArH), 5.51 (d, J = 4.5 Hz, 1H, H-1), 5.43 (t, J = 4.9 Hz, 1H, H-2), 5.23 
(t, J = 2.8 Hz, 1H, H-3'), 5.16 (d, J = 1.8 Hz, 1H, H-1'), 5.04 (d, J = 1.8 Hz, 1H, H-4'), 4.78 (t, J 
= 5.6 Hz, 1H, H-3), 4.68 (dd, J = 12.0, 2.7 Hz, 1H, H-5), 4.56 (td, J = 5.8, 5.2, 2.7 Hz, 1H, H-4), 
4.50 (dd, J = 12.1, 4.6 Hz, 1H, H-5), 4.24 (ddd, J = 8.5, 4.1, 1.9 Hz, 1H, H-5'), 3.87 (s, 3H, 
OCH3), 3.85 – 3.73 (m, 9H, 3 OCH3), 3.57 (dd, J = 13.1, 8.4 Hz, 1H, H-6'), 3.41 (t, J = 2.2 Hz, 
1H, H-2'), 3.27 (dd, J = 13.1, 4.0 Hz, 1H, H-6'), 2.22 (s, 3H, CH3); 13C NMR (151 MHz, 
CDCl3): δ 166.0 (C=O), 165.4 (C=O), 165.0 (C=O), 164.03 (C=O), 163.97 (Ar-C), 163.9 (Ar-C), 
163.7 (Ar-C), 163.4 (Ar-C), 138.6 (Ar-C), 133.9 (Ar-C), 132.3 (Ar-C), 132.0 (Ar-C), 131.9 (Ar-
C), 131.8 (Ar-C), 129.8 (Ar-C), 127.7 (Ar-C), 122.3 (Ar-C), 121.1 (Ar-C), 120.9 (Ar-C), 120.8 
(Ar-C), 99.3 (C-1'), 88.2 (C-1), 81.2 (C-4), 76.7 (C-3), 74.5 (C-2), 74.2 (C-5'), 69.1 (C-3'), 65.7 
(C-4'), 63.8 (C-5), 56.9 (C-2'), 55.52 (OCH3), 55.46 (OCH3), 55.4 (2 OCH3), 50.8 (C-6'), 21.1 
(CH3); ESI-HRMS: m/z calcd. for C50H48N6NaO15S [M+Na]
+ 1027.2796; found, 1027.2749. 
p-Cresyl-2’,6’-diazido-2,5,3’4’-tetra(4-methoxybenzoyl)--thio-paromobiosyl S-
oxide (131). A solution of compound 130 (198 mg, 0.2 mmol) in dry DCM (15 mL) was cooled 
to -78 °C before ozone gas was bubbled in for 5 min till the solution turned blue. The solution 
was then warmed to rt, concentrated and the crude product purified by gradient chromatography 
over silica gel (eluent: 40% EtOAc/hexanes) to give 131 (162 mg, 80%) as a white solid; [α]D25= 
+60.0 (c 0.5, DCM); 1H NMR (400 MHz, CDCl3): δ 8.16 (d, J = 9.0 Hz, 2H, ArH), 8.12 – 8.03 
(m, 4H, ArH), 7.68 (d, J = 9.0 Hz, 2H, ArH), 7.51 (d, J = 8.2 Hz, 2H, ArH), 7.24 (d, J = 7.9 Hz, 
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2H, ArH), 7.00 (d, J = 9.0 Hz, 2H, ArH), 6.96 (d, J = 4.3 Hz, 2H, ArH), 6.93 (d, J = 4.4 Hz, 2H, 
ArH), 6.78 (d, J = 9.0 Hz, 2H, ArH), 6.14 (dd, J = 5.0, 1.9 Hz, 1H, H-2), 5.28 (d, J = 1.6 Hz, 1H, 
H-1'), 5.23 (t, J = 2.7 Hz, 1H, H-3'), 5.09 – 5.03 (m, 1H, H-4'), 5.00 (dd, J = 7.1, 5.1 Hz, 1H, H-
3), 4.90 (d, J = 1.9 Hz, 1H, H-1), 4.76 (dd, J = 11.3, 1.5 Hz, 1H, H-5), 4.64 – 4.52 (m, 2H, H-5, 
H-4), 4.28 (ddd, J = 7.7, 4.4, 1.7 Hz, 1H, H-5'), 3.92 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.85 (s, 
3H, OCH3), 3.82 (s, 3H, OCH3), 3.54 (dd, J = 13.0, 8.1 Hz, 1H, H-6'), 3.42 – 3.36 (m, 1H, H-2'), 
3.32 (dd, J = 13.0, 4.5 Hz, 1H, H-6'), 2.30 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): δ 166.0 
(C=O), 165.0 (C=O), 164.8 (C=O), 164.1 (C=O), 163.94 (Ar-C), 163.86 (Ar-C), 163.6 (Ar-C), 
142.2 (Ar-C), 136.6 (Ar-C), 132.3 (Ar-C), 132.1 (Ar-C), 131.9 (Ar-C), 131.7 (Ar-C), 130.0 (Ar-
C), 124.6 (Ar-C), 122.1 (Ar-C), 121.1 (Ar-C), 121.0 (Ar-C), 120.6 (Ar-C), 113.94 (Ar-C), 
113.86 (Ar-C), 113.8 (Ar-C), 113.7 (Ar-C), 100.1 (C-1), 99.1 (C-1'), 81.6 (C-4), 75.9 (C-3), 74.1 
(C-5'), 70.1 (C-2), 69.1 (C-3'), 65.7 (C-4'), 62.7 (C-5), 56.7 (C-2'), 55.54 (OCH3), 55.46 (OCH3), 
55.4 (OCH3), 50.7 (C-6'); ESI-HRMS: m/z calcd. for C50H48N6NaO16S [M+Na]
+ 1043.2745; 
found, 1043.2717. 
5-O--[2’’’’,6’’’’-Diazido-2’’’,5,3’’’’4’’’’-tetra(4-methoxybenzoyl) paromobiosyl]-
6,2’’,3’’,6’’-tetra-O-acetyl-1,3,2′,4′′-tetraazido-6′,7′-oxazolidino-apramycin (132). A 
suspension of donor 131 (140 mg, 0.14 mmol), acceptor 124 (150 mg, 0.18 mmol) and activated 
4 Å MS in dry DCM (2 mL) was stirred at rt for 1 h before addition of freshly distilled triflic 
anhydride (33 L, 0.2 mmol). After 5 h of stirring at rt, the reaction was quenched with 
triethylamine (0.1 mL) and filtered through Celite® then concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (20% EtOAc/toluene) to 
afford 132 (113 mg, 48%) as a white foam; [α]D25= +84.9 (c 0.3, DCM); 1H NMR (600 MHz, 
CDCl3): δ 8.10 – 8.04 (m, 4H, ArH), 8.02 (d, J = 8.9 Hz, 2H, ArH), 7.83 (d, J = 8.9 Hz, 2H, 
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ArH), 7.01 – 6.94 (m, 4H, ArH), 6.92 (d, J = 8.9 Hz, 2H, ArH), 6.82 (d, J = 9.0 Hz, 2H, ArH), 
5.58 (d, J = 3.5 Hz, 1H, H-1'), 5.44 (d, J = 1.7 Hz, 1H, H-1'''), 5.39 (t, J = 10.0 Hz, 1H, H-3''), 
5.33 (d, J = 3.8 Hz, 1H, H-1''), 5.24 – 5.18 (m, 2H, H-2''', H-3''''), 5.14 (d, J = 1.5 Hz, 1H, H-1''''), 
5.07 – 5.04 (m, 1H, H-4''''), 4.89 – 4.80 (m, 4H, H-2'', H-5''', H-6, H-8'), 4.77 – 4.72 (m, 2H, H-
3''', H-6'), 4.50 – 4.44 (m, 2H, H-4''', H-5'''), 4.43 (dd, J = 10.4, 3.3 Hz, 1H, H-5'), 4.32 – 4.26 (m, 
2H, H-5'''', H-6''), 4.20 (dd, J = 12.2, 5.4 Hz, 1H, H-6''), 3.87 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
3.83 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.75 – 3.68 (m, 3H, H-5, H-5'', H-7'), 3.64 – 3.49 (m, 
4H, H-3, H-4', H-4'', H-6''''), 3.41 – 3.30 (m, 4H, H-1, H-2'''', H-4, H-6''''), 3.12 (dt, J = 12.9, 4.1 
Hz, 1H, H-2'), 2.92 (s, 3H, NCH3), 2.38 (dt, J = 12.9, 4.4 Hz, 1H, H-2), 2.17 – 2.12 (m, 1H, H-
3'), 2.11 – 2.07 (m, 9H, 3COCH3), 2.03 (s, 3H, COCH3), 1.88 – 1.81 (m, 1H, H-3'), 1.44 (q, J = 
12.6 Hz, 1H, H-2); 13C NMR (151 MHz, CDCl3): δ 170.4 (C=O), 170.1 (C=O), 169.9 (C=O), 
169.6 (C=O), 165.9 (C=O), 165.5 (C=O), 165.0(C=O), 164.1(C=O), 164.0 (Ar-C), 163.9 (Ar-C), 
163.8 (Ar-C), 163.6 (Ar-C), 157.1(C=O), 132.3 (Ar-C), 132.1 (Ar-C), 131.8 (Ar-C), 122.2 (Ar-
C), 121.1 (Ar-C), 121.0 (Ar-C), 120.7 (Ar-C), 113.9 (Ar-C), 113.9 (Ar-C), 113.9 (Ar-C), 113.8 
(Ar-C), 106.8 (C-1'''), 99.3 (C-1''''), 96.9 (C-1'), 96.6 (C-8'), 94.1 (C-1''), 81.4 (C-5), 79.9 (C-4'''), 
78.0 (C-4), 75.7 (C-3'''), 74.9 (C-6), 74.5 (C-5''''), 74.2 (C-3''), 70.8 (C-3''''), 70.5 (C-6'), 69.9 (C-
2''), 69.2 (C-2'''), 69.0 (C-5''), 65.7 (C-4''''), 65.6 (C-5'), 63.0 (C-5'''), 62.9 (C-6''), 60.1 (C-7', C-3), 
58.8 (C-4''), 58.1 (C-1), 56.8 (C-2''''), 56.6 (C-2'), 55.5 (OCH3), 55.5 (OCH3), 50.7 (C-6''''), 31.2 
(C-2'), 30.4 (C-3'), 30.0 (NCH3), 21.0 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3); 
ESI-HRMS: m/z calcd. for C73H79N19NaO31 [M+Na]
+ 1740.5087; found, 1740.5109. 
5-O--(Paromobiosyl) apramycin heptaacetate salt (133). A stirred solution of 
compound 132 (40 mg, 0.02 mmol) in dioxane (0.5 mL) was treated with 3N NaOH (0.5 mL) 
and heated at 120 °C for 2 h. The reaction mixture was cooled to rt and neutralized with glacial 
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acetic acid before it was concentrated in vacuo. The crude product was purified with silica gel 
column chromatography (eluent: 5%-15% methanol/DCM) to give a residue that was directly 
subjected to Staudinger reaction by dissolving in THF (0.6 mL) followed by the addition of 0.3N 
NaOH (0.3 mL) and 1M P(CH3)3 in THF (0.3 mL).  The reaction mixture was stirred at 55 °C for 
2h, then concentrated and purified by column chromatography (eluent: 5% to 50% 
ammonia/MeOH). The product-containing fractions were concentrated and dissolved in D.I. 
water (1 mL), acidified by glacial acetic acid till pH = 3-4 and loaded to Sephadex column (CM 
Sephadex C-25) from which the product was flushed with D.I. water (20 mL), then gradient 
elution of 0.1% - 1.0% NH4OH in D.I. water. The fractions containing the product were 
combined, acidified with glacial acetic acid and lyophilized to afford 133 (8 mg, 35%) as a 
peracetate salt in the form of a white foam; [α]D25 = +54.4 (c 0.5, H2O); 1H NMR (600 MHz, 
D2O): δ 5.68 (d, J = 3.9 Hz, 1H, H-1'), 5.32 (d, J = 3.9 Hz, 1H, H-1''), 5.22 (d, J = 2.4 Hz, 1H, H-
1'''), 5.10 (d, J = 1.4 Hz, 1H, H-1''''), 5.03 (d, J = 8.5 Hz, 1H, H-8'), 4.41 (s, 1H, H-6'), 4.31 (t, J = 
5.7 Hz, 1H, H-3'''), 4.21 (dd, J = 3.8, 2.8 Hz, 1H, H-2'''), 4.15 – 4.09 (m, 1H, H-5''''), 4.08 – 4.00 
(m, 2H, H-3'''', H-4'''), 3.83 (t, J = 9.7 Hz, 1H, H-4), 3.79 (dt, J = 10.2, 3.9 Hz, 1H, H-5''), 3.77 – 
3.65 (m, 5H, H-5''', H-3'', H-4', H-5, H-6''), 3.65 – 3.58 (m, 2H, H-4'''', H-6''), 3.58 – 3.44 (m, 5H, 
H-6, H-2', H-5', H-2'', H-5'''), 3.39 (s, 1H, H-2''''), 3.32 – 3.25 (m, 1H, H-3), 3.25 – 3.19 (m, 2H, 
H-7', H-6''''), 3.19 – 3.12 (m, 2H, H-1, H-6''''), 3.09 (t, J = 10.3 Hz, 1H, H-4''), 2.60 (s, 3H, 
NCH3), 2.27 (dt, J = 11.8, 3.1 Hz, 1H, H-2), 2.22 – 2.13 (m, 1H, H-3'), 1.87 (dd, J = 24.1, 11.8 
Hz, 1H, H-3'), 1.64 (q, J = 13.0 Hz, 1H, H-2); 13C NMR (151 MHz, D2O): δ 110.1 (C-1'''), 95.3 
(C-1''''), 94.5 (C-1'), 94.4 (C-1''), 92.8 (C-8'), 84.9 (C-5), 81.3 (C-4'''), 76.0 (C-4), 75.2 (C-3'''), 
73.4 (C-2'''), 72.5 (C-2''), 70.2 (C-5''''), 70.1 (C-5''), 69.7 (C-6), 69.5 (C-5'), 68.4 (C-3''), 67.5 (C-
3''''), 67.2 (C-4''''), 65.9 (C-4'), 62.6 (C-6'), 60.2 (C-5'''), 60.0 (C-6''), 59.3 (C-7'), 52.0 (C-4''), 50.7 
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(C-2''''), 49.8 (C-1), 48.4 (C-3), 47.8 (C-2'), 40.3 (C-6''''), 30.0 (NCH3), 28.6 (C-2), 26.7 (C-3'); 
ESI-HRMS: m/z calcd. for C32H62N7O18 [M+H]
+ 832.4151; found, 832.4131. 
3-O-(2-Azidoethyl)-5-O-benzyl-1,2-O-isopropylidene-D-ribofuranose (135). 5-O-
Benzyl-1,2-O-isopropylidene--D-ribofuranose164 134 (1000 mg, 3.57 mmol) was dissolved in 
dry THF (3 mL) and NaH (214 mg, 5.36 mmol) was added under argon. After stirring for 15 
min, a solution of 2-azidoethyl tosylate163 (1.72 g, 7.14 mmol) in dry THF (3 mL) was added 
dropwise followed by stirring for 12 h. More NaH (150 mg, 3.75 mmol) and 2-azidoethyl 
tosylate (860 mg, 3.57 mmol) were added and stirring continued for 24 h. After completion, the 
reaction was quenched with methanol and concentrated in vacuo and the crude product was 
purified by column chromatography (eluent: 5% to 30% EtOAc/hexanes) to give 135 (974 mg, 
78%) as a gum; [α]D25 = = +71.2 (c = 1.0); 1H NMR (400 MHz, CDCl3): δ 7.37 – 7.26 (m, 5H, 
ArH), 5.81 (d, J = 3.8 Hz, 1H, H-1), 4.67 – 4.61 (m, 2H, H-2, PhCH2), 4.55 (d, J = 12.2 Hz, 1H, 
PhCH2), 4.12 (ddd, J = 9.0, 3.7, 2.1 Hz, 1H, H-4), 3.89 – 3.84 (m, 2H, H-3, H-5), 3.81 (dd, J = 
11.5, 2.2 Hz, 1H, OCH2), 3.67 – 3.58 (m, 2H, OCH2, H-5 ), 3.45 (ddd, J = 13.3, 7.4, 3.5 Hz, 1H, 
CH2N3), 3.28 (ddd, J = 13.3, 5.6, 3.5 Hz, 1H, CH2N3), 1.57 (s, 3H, CH3), 1.35 (s, 3H, CH3);
 13C 
NMR (101 MHz, CDCl3): δ 137.99 (Ar-C), 128.37 (Ar-C), 127.78 (Ar-C), 127.68 (Ar-C), 
112.98 (CMe2), 104.13 (C-1), 78.61 (C-2), 77.89 (C-3), 77.17 (C-4), 73.52 (PhCH2), 69.38 (C-
5), 67.65 (OCH2), 50.59 (CH2N3), 26.69 (CH3), 26.58 (CH3); ESI-HRMS: m/z calcd for 
C17H23N3O5Na [M+Na]
+ 372.1535, found 372.1533. 
3-O-(2-Azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)--D-ribofuranose (136). A 
solution of 135 (822 mg, 2.36 mmol) in a 1:3 mixture of 1 N aqueous hydrochloric acid and p-
dioxane (16 mL) was stirred for 1.5 h at ambient temperature then was concentrated and dried 
under reduce pressure. The residue was diluted with pyridine (40 mL) and treated with 4-
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dimethylaminopyridine (30 mg, 0.236 mmol) and p-nitrobenzoyl chloride (1.53 g, 8.26 mmol) at 
ambient temperature and stirred for 10 h. The reaction mixture was concentrated and the residue 
was purified by silica gel column chromatography (hexane: ethyl acetate 8:1 to 4:1). to give 136 
as a white foam (643 mg, 1.06 mmol, 45%); [α]D25 = +66.9 (c = 1.0); 1H NMR (600 MHz, 
CDCl3)  = 8.26 (s, 4H, ArH); 8.20 (d, J = 8.8 Hz, ArH); 8.12 (d, J = 8..8 Hz, ArH); 7.39-7.26 
(m, 5H, ArH); 6.80 (d, J = 4.4 Hz, 1H, H-1); 5.45 (dd, J = 4.4 Hz, 6.6 Hz, 1H, H-2); 4.65 (d, J = 
11.7 Hz, 1H, PhCH); 4.58 (d, J = 11.7 Hz, 1H, PhCH2); 4.58 (m, 1H, H-4); 3.86 (dd, J = 6.6 Hz, 
2.9 Hz, 1H, H-3); 3.74-3.65 (m, 4H, H-5, CH2CH2N3); 3.33 (m, 1H, CH2CH2N3); 3.28 (m, 1H, 
CH2CH2N3); 13C NMR (150 MHz, CDCl3)  = 163.72, 163.56, 150.84, 150.79, 137.47, 131.00, 
130.80, 128.55, 127.96, 127.70, 123.65 (18C, ArC.); 95.82 (C-1); 84.70 (C-4); 76.91 (C-3); 
73.73 (PhCH2); 73.14 (C-2); 70.33 (-CH2CH2N3); 69.38 (C-5); 51.12 (CH2CH2N3); ESI-HRMS: 
m/z calcd for C28H25N5O11Na [M+Na]+ 630.1448, found 630.1453. 
-O--3’’’-O-(2-Azidoethyl)-5’’’-O-benzyl-2’’’-O-(4-nitrobenzoyl)-D-
ribofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin 
(137) and -O--3’’’-O-(2-Azidoethyl)-5’’’-O-benzyl-2’’’-O-(4-nitrobenzoyl)-D-
ribofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin 
(137) 3-O-(2-Azidoethyl)-5-O-benzyl-1,2-di-O-(4-nitrobenzoyl)--D-ribofuranose 136 (181 
mg, 0.30 mmol) and apramycin derivative 124 (100 mg, 0.12 mmol) was were charged to a 
round bottom flask, co-evaporated with toluene three times and dried in vacuo overnight. The 
flask was purged with argon and the mixture dissolved in dry DCM (1.5 mL) before cooling to 0 
°C, treatment with BF3.OEt2 (0.23 mL, 0.63 mmol) and stirring for 12 h. The reaction was 
quenched with triethylamine (0.2 mL), diluted with EtOAc and washed with aqueous NaHCO3 
and brine then concentrated. The crude product was purified using silica gel column 
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chromatography (eluent: 20% - 40% EtOAc/hexanes) to give 137α (35 mg, 23%) and 137β (31 
mg, 20%); anomer: [α]D25= +79.1 (c 1.1, DCM); 1H NMR (600 MHz, CDCl3): δ 8.32 (d, J = 
8.6 Hz, 2H, ArH), 8.23 (d, J = 8.9 Hz, 2H, ArH), 7.36 – 7.29 (m, 5H, ArH), 5.68 – 5.65 (m, 1H, 
H-2'''), 5.56 (d, J = 3.8 Hz, 1H, H-1'''), 5.38 (t, J = 10.0 Hz, 1H, H-3''), 5.32 (d, J = 3.8 Hz, 1H, 
H-1''), 5.15 (d, J = 3.5 Hz, 1H, H-1'), 4.94 – 4.87 (m, 3H, H-2'', H-6, H-8'), 4.75 (dd, J = 8.4, 3.1 
Hz, 1H, H-6'), 4.66 (dd, J = 10.5, 3.1 Hz, 1H, H-5'), 4.60 (d, J = 11.9 Hz, 1H, CH2Ph), 4.54 (d, J 
= 12.0 Hz, 1H, CH2Ph), 4.31 (dd, J = 12.1, 1.8 Hz, 1H, H-6''), 4.25 (dt, J = 7.0, 3.3 Hz, 1H, H-
4'''), 4.21 (dd, J = 12.2, 5.2 Hz, 1H, H-6''), 4.04 (dd, J = 7.6, 5.1 Hz, 1H, H-3'''), 3.79 (dd, J = 8.4, 
3.0 Hz, 1H, H-7'), 3.75 – 3.69 (m, 4H, H-4', H-5, H-5', H-5''), 3.68 – 3.62 (m, 1H, H-3), 3.62 – 
3.57 (m, 3H, H-5''', H-4'', OCH2CH2), 3.56 – 3.48 (m, 3H, H-1, H-4, OCH2CH2), 3.29 (dt, J = 
12.8, 4.1 Hz, 1H, H-2'), 3.18 (t, J = 4.9 Hz, 2H, OCH2CH2), 2.91 (s, 3H, NCH3), 2.42 (dt, J = 
12.9, 4.4 Hz, 1H, H-2), 2.25 (dt, J = 10.6, 4.3 Hz, 1H, H-3'), 2.13 (s, 3H, COCH3), 2.11 (s, 3H, 
COCH3), 2.09 (m, 6H, COCH3), 1.86 (q, J = 11.5 Hz, 1H, H-3'), 1.55 (q, J = 12.6 Hz, 1H, H-2); 
13C NMR (151 MHz, CDCl3): δ 170.3 (C=O), 169.9 (C=O), 169.8 (C=O), 164.3 (C=O), 156.9 
(C=O), 150.9 (Ar-C), 137.5 (Ar-C), 134.6 (Ar-C), 131.1 (Ar-C), 128.5 (Ar-C), 127.9 (Ar-C), 
127.8 (Ar-C), 123.8 (Ar-C), 102.8 (C-1'''), 97.8 (C-1'), 95.0 (C-8'), 94.2 (C-1''), 82.5 (C-5), 80.4 
(C-4'''), 80.1 (C-4), 77.2 (C-3'''), 73.6 (C-6), 73.6 (CH2Ph), 71.3 (C-2'''), 70.7 (C-3''), 70.0 (C-2''), 
69.9 (C-6'), 69.9 (OCH2CH2), 68.9 (C-5'''), 68.7 (C-5''), 65.5 (C-5'), 65.2 (C-4'), 62.8 (C-6''), 60.2 
(C-7'), 60.1 (C-4''), 58.3 (C-3), 58.1 (C-1), 56.7 (C-2'), 50.6 (OCH2CH2), 31.4 (C-2), 30.3 (C-3'), 
29.8 (NCH3), 21.2 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z 
calcd. for C51H59N17O23 [M+Na]
+ 1300.3867; found, 1300.3887; anomer: [α]D25= +70.8 (c 1.8, 
DCM); 1H NMR (600 MHz, CDCl3): δ 8.28 (d, J = 8.6 Hz, 2H, ArH), 8.20 (d, J = 8.7 Hz, 2H, 
ArH), 7.46 – 7.26 (m, 5H, ArH), 5.79 (d, J = 3.4 Hz, 1H, H-1'), 5.42 (t, J = 10.0 Hz, 1H, H-3''), 
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5.38 (s, 1H, H-1'''), 5.37 (d, J = 3.8 Hz, 1H, H-1''), 5.23 (d, J = 4.2 Hz, 1H, H-2'''), 4.92 (t, J = 9.7 
Hz, 1H, H-6), 4.86 (dd, J = 10.3, 3.8 Hz, 1H, H-2''), 4.81 (d, J = 4.4 Hz, 1H, H-8'), 4.76 (dd, J = 
7.5, 3.2 Hz, 1H, H-6'), 4.60 (d, J = 11.9 Hz, 1H, CH2Ph), 4.51 (d, J = 11.9 Hz, 1H, CH2Ph), 4.39 
(dd, J = 10.3, 3.2 Hz, 1H, H-5'), 4.33 (d, J = 12.0 Hz, 1H, H-6''), 4.26 – 4.16 (m, 2H, H-6'', H-
4'''), 4.14 (dd, J = 7.1, 4.5 Hz, 1H, H-3'''), 3.84 – 3.71 (m, 3H, H-5, H-7', H-5''), 3.71 – 3.52 (m, 
8H, H-4, H-4', H-4'', H-3, H-5''', OCH2CH2), 3.47 – 3.37 (m, 1H, H-1), 3.17 (m, 2H, OCH2CH2), 
3.09 (dt, J = 12.8, 3.9 Hz, 1H, H-2'), 2.94 (s, 3H, NHCH3), 2.41 (dt, J = 12.9, 4.3 Hz, 1H, H-2), 
2.19 – 1.99 (m, 13H, 4COCH3, H-3'), 1.88 (q, J = 11.8 Hz, 1H, H-3'), 1.57 (q, J = 12.6 Hz, 1H, 
H-2); 13C NMR (151 MHz, CDCl3): δ 170.4(C=O), 170.1(C=O), 169.8 (C=O), 169.7 (C=O), 
163.8 (C=O), 157.1 (C=O), 150.8 (Ar-C), 137.7 (Ar-C), 134.5 (Ar-C), 131.1 (Ar-C), 130.9 (Ar-
C), 128.5 (Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 123.7 (Ar-C), 123.6 (Ar-C), 106.9 (C-1'''), 97.3 
(C-1'), 96.4 (C-8'), 94.2 (C-1''), 82.0 (C-5), 80.5 (C-4'''), 77.8 (C-4), 76.8 (C-3'''), 75.7 (C-6), 75.0 
(CH2Ph), 73.4 (C-2'''), 71.0 (C-3''), 70.4 (C-2''), 70.2 (C-6'), 70.0 (OCH2CH2), 69.7 (C-5'''), 69.1 
(C-5''), 65.9 (C-5'), 65.7 (C-4'), 62.9 (C-6''), 60.2 (C-7'), 60.1 (C-4''), 59.1 (C-3), 58.1 (C-1), 56.5 
(C-2'), 50.6 (OCH2CH2), 31.3 (C-2), 30.1 (C-3'), 29.7(NCH3), 20.9 (COCH3), 20.8 (COCH3), 
20.7 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. for C51H59N17O23 [M+Na]
+ 1300.3867; 
found, 1300.3835. 
-O--3-O-(2-Aminoethyl)-D-ribofuranosyl] apramycin hexaacetate salt (138). A 
stirred solution of compound 137 (30 mg, 0.02 mmol) in dioxane (0.5 mL) was treated with 3N 
NaOH (0.25 mL) and heated at 100 °C for 18 h. The reaction mixture was cooled to rt and 
neutralized with glacial acetic acid and concentrated in vacuo. The crude product was passed 
through a silica gel column (eluent: 50% methanol/DCM). The product-containing fractions was 
concentrated and dissolved in THF (0.6 mL) followed by the addition of 0.3N NaOH (0.3 mL) 
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and 1M P(CH3)3 in THF (0.3 mL). The reaction mixture was stirred at 55 °C for 2 h then 
concentrated and purified by column chromatography (eluent: 5% to 50% ammonia/MeOH). The 
product-containing fractions were concentrated, dissolved in dioxane:water:glacial acetic acid = 
1:2:0.2 (0.3 mL).  Pd(OH)2/C (0.5 equiv) was added and the reaction mixture was stirred at room 
temperature under 1 atm of hydrogen (balloon) for 4 h. After completion, the reaction mixture 
was filtered over Celite®, concentrated to dryness and dissolved in aqueous acetic acid solution 
(pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column 
was flushed with D.I. water (20 mL), then eluted with a gradient of 0.1% - 1.0% NH4OH in D.I. 
water. The fractions containing the product were combined, acidified with glacial acetic acid and 
lyophilized to afford 138 (21 mg, 85%) as peracetate salt in the form of a white solid; [α]D25= 
+52.3 (c 1.1, H2O); 
1H NMR (600 MHz, D2O): δ 5.65 (d, J = 3.4 Hz, 1H, H-1'), 5.33 (s, 1H, H-
1''), 5.24 (d, J = 4.4 Hz, 1H, H-1'''), 5.03 (d, J = 8.4 Hz, 1H, H-8'), 4.40 (s, 1H, H-6'), 4.23 – 4.18 
(m, 1H, H-2'''), 4.16 (q, J = 3.6 Hz, 1H, H-4'''), 3.87 – 3.80 (m, 1H, H-4), 3.80 – 3.64 (m, 8H, H-
3'', H-4', H-5, H-5'', H-3''', H-6'', OCH2CH2), 3.64 – 3.41 (m, 7H, H-6'', H-5', H-6, H-5''', H-2', H-
5', H-2''), 3.29 – 3.11 (m, 3H, H-1, H-3, H-7'), 3.05 (m, 3H, OCH2CH2, H-4''), 2.60 (s, 3H, 
NCH3), 2.29 – 2.16 (m, 2H, H-2, H-3'), 1.91 – 1.80 (m, 1H, H-3'), 1.66 – 1.56 (m, 1H, H-2); 13C 
NMR (151 MHz, D2O): δ 102.8 (C-1'''), 95.1 (C-1'), 94.4 (C-1''), 92.9 (C-8''), 84.3 (C-5), 83.2 
(C-4'''), 78.4 (C-4), 78.0 (C-3'''), 71.6 (C-6), 70.9 (C-2'''), 70.3 (C-5''), 69.8 (C-2''), 68.7 (C-4'), 
66.8 (OCH2CH2), 66.0 (C-5'), 62.8 (C-6'), 61.5 (C-5'''), 60.3 (C-6''), 59.5 (C-7'), 52.0 (C-4''), 50.0 
(C-3), 48.6 (C-1), 47.8 (C-2'), 39.1 (OCH2CH2), 30.1 (NCH3), 29.2 (C-2), 27.0 (C-3'); ESI-
HRMS: m/z calcd. for C28H55N6O15 [M+H]
+ 715.3725; found, 715.3742. 
-O--3’’’-O-(2-Aminoethyl)-D-ribofuranosyl) apramycin hexaacetate salt (138). 
Substrate 137 (35 mg, 0.03 mmol) was deprotected in the same manner as compound 137 to 
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yield 138 (30 mg, 95%) as a pentaacetate salt in the form of a white solid; [α]D25= 68.92 (c 0.5, 
H2O); 
1H NMR (600 MHz, D2O): δ 5.64 (d, J = 3.6 Hz, 1H, H-1'), 5.28 (d, J = 3.7 Hz, 1H, H-1''), 
5.16 (s, 1H, H-1'''), 5.00 (d, J = 8.5 Hz, 1H, H-8'), 4.37 (s, 1H, H-6'), 4.19 (d, J = 2.9 Hz, 1H, H-
2'''), 3.97 – 3.88 (m, 1H, H-4'''), 3.86 – 3.54 (m, 12H, H-4, H-3''', H-3'', H-5''', H-6'', H-5'', H-4', 
H-5, H-2', OCH2CH2), 3.53 – 3.39 (m, 5H, H-2', H-5', H-5''', H-2'', H-6), 3.31 – 3.21 (m, 1H, H-
3), 3.18 (d, J = 8.4 Hz, 1H, H-7'), 3.16 – 3.08 (m, 1H, H-1), 3.05 (t, J = 10.3 Hz, 1H, H-4''), 3.01 
(t, J = 4.8 Hz, 2H, OCH2CH2), 2.57 (s, 3H, NHCH3), 2.24 (dd, J = 8.6, 4.0 Hz, 1H, H-2), 2.20 – 
2.09 (m, 1H, H-3'), 1.84 (q, J = 11.9 Hz, 1H, H-3'), 1.66 – 1.59 (m, 1H, H-2); 13C NMR (151 
MHz, D2O): δ 110.5 (C-1'''), 94.5 (C-1'), 94.3 (C-1''), 92.8 (C-8'), 84.9 (C-5), 81.0 (C-4'''), 77.0 
(C-3'''), 75.8 (C-4), 73.2 (C-2'''), 72.5 (C-6), 70.2 (C-5''), 69.6 (C-2''), 69.5 (C-3''), 68.4 (C-4'), 
66.0 (C-5'), 65.9 (OCH2CH2), 62.6 (C-6'), 61.0 (C-5'''), 60.2 (C-6''), 59.3 (C-7'), 51.9 (C-4''), 49.8 
(C-3), 48.3 (C-1), 47.8 (C-2'), 39.2 (OCH2CH2), 30.0 (NCH3), 28.5 (C-2), 26.7 (C-3); ESI-
HRMS: m/z calcd. for C28H55N6O15 [M+H]
+ 715.3725; found, 715.3690.  
5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-O-isopropylidene--D-ribofuranose (139). 5-
O-benzyl-1,2-O-isopropylidene--D-ribofuranose164 134 (1000 mg, 3.57 mmol) was dissolved in 
dry THF (20 mL) and NaH (185 mg, 4.64 mmol) was added under argon. After stirring for 15 
min, 2-benzyloxyethyl tosylate166 (1.31 g, 4.29 mmol) was added and stirring continued for 12 h. 
More NaH (185 mg, 4.64 mmol) and 2-benzyloxyethyl tosylate (1.31 g, 4.29 mmol) were added 
and the mixture stirred for 24 h. After completion, the reaction was quenched with methanol, 
diluted with EtOAc and washed with aqueous NaHCO3 and brine. The organic layer was dried 
over Na2SO4 and concentrated. The crude product was purified using silica gel column 
chromatography (eluent: 5% to 12% EtOAc/hexanes) to give 139 (1.24 g, 83%) in the form of a 
colorless oil; [α]D25= +42.22 (c 2.2, DCM); 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.26 (m, 10H, 
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ArH), 5.77 (d, J = 3.7 Hz, 1H, H-1), 4.63 (d, J = 4.1 Hz, 1H, H-2), 4.61 (d, J = 4.1 Hz, 1H, 
CH2Ph), 4.58 – 4.52 (m, 3H, CH2Ph), 4.14 (ddd, J = 9.1, 4.1, 2.0 Hz, 1H, H-4), 3.92 – 3.76 (m, 
3H, H-3, H-5, CH2CH2), 3.76 – 3.56 (m, 4H, H-5, 3H-CH2CH2), 1.57 (s, 3H, CH3), 1.35 (s, 3H, 
CH3); 
13C NMR (101 MHz, CDCl3): δ 138.2 (ArC), 138.1 (ArC), 128.4 (ArC), 128.3 (ArC), 
127.73 (ArC), 127.69 (ArC), 127.67 (ArC), 127.63 (ArC), 127.59 (ArC), 112.8 (C(CH3)2), 104.0 
(C-1), 79.0 (C-3), 77.9 (C-4), 77.5 (C-2), 73.5 (CH2Ph), 73.2 (CH2Ph), 70.7 (CH2CH2), 70.1 
(CH2CH2), 68.2 (C-5), 26.8 (CH3), 26.5 (CH3); ESI-HRMS: m/z calcd. for C24H30NaO6 [M+Na]
+ 
437.1940; found, 437.1939. 
5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-di-O-(4-nitrobenzoyl)--D-ribofuranose 
(140) and 5-O-Benzyl-3-O-(2-benzyloxyethyl)-1,2-di-O-(4-nitrobenzoyl)--D-ribofuranose 
(140). To a stirred solution of compound 139 (600 mg, 1.45 mmol) in dioxane (10 mL), 1 N 
HCl (5 mL) was added and the reaction mixture was heated at 80 °C for 45 min. The reaction 
mixture was cooled, neutralized with solid NaHCO3 then the solvent was evaporated. The 
residue was dissolved in EtOAc and washed with water and brine. The organic layer was dried 
over Na2SO4 and concentrated. To a solution of the residue in dry pyridine (10 mL), p-
nitrobenzoyl chloride (672 mg, 3.6 mmol) and a catalytic amount of DMAP were added followed 
by stirring overnight. The reaction mixture was concentrated then diluted with EtOAc and 
washed with aqueous NaHCO3, brine, dried with Na2SO4 and concentrated. The crude product 
was purified using silica gel column chromatography (eluent: 5% - 25% EtOAc/hexanes) to give 
140 = 1:1.5 (820 g, 84%, yellow oil). Further purification was done to separate analytical 
sample of anomers: 140 (86 mg, 9%, yellow oil), 140 (63 mg, 6%, yellow oil); anomer: 
[α]D25= +74.69 (c 5.7, DCM); 1H NMR (400 MHz, CDCl3): δ 8.26 – 8.21 (m, 2H, ArH), 8.19 – 
8.14 (m, 2H, ArH), 8.11 – 8.07 (m, 4H, ArH), 7.42 – 7.27 (m, 5H, ArH), 7.27 – 7.22 (m, 3H, 
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ArH), 7.20 – 7.06 (m, 2H, ArH), 6.81 (d, J = 4.4 Hz, 1H, H-1), 5.47 (dd, J = 6.3, 4.4 Hz, 1H, H-
2), 4.66 – 4.53 (m, 3H, H-4, CH2Ph), 4.49 – 4.41 (m, 2H, CH2Ph), 4.38 (dd, J = 6.3, 2.8 Hz, 1H, 
H-3), 3.81 – 3.73 (m, 2H, CH2CH2), 3.71 – 3.65 (m, 2H, H-5), 3.66 – 3.56 (m, 2H, CH2CH2); 13C 
NMR (101 MHz, CDCl3): δ 163.7 (C=O), 163.6 (C=O), 150.7 (ArC), 150.7 (ArC), 137.8 (ArC), 
137.6 (ArC), 135.1 (ArC), 134.5 (ArC), 131.0 (ArC), 130.7 (ArC), 128.5 (ArC), 128.4 (ArC), 
127.9 (ArC), 127.7 (ArC), 127.3 (ArC), 123.6 (ArC), 96.0 (C-1), 85.0 (C-4), 76.9 (C-3), 73.7 
(CH2Ph), 73.4 (CH2Ph), 73.2 (C-2), 71.2 (CH2CH2), 69.9 (CH2CH2), 69.5 (C-5); ESI-HRMS: 
m/z calcd. for C35H32N2NaO12 [M+Na]
+ 695.1853; found, 695.1859; anomer: [α]D25= -11.33 
(c 0.042, DCM); 1H NMR (400 MHz, CDCl3): δ 8.22 (m, 4H, ArH), 8.12 – 8.05 (m, 2H, ArH), 
8.05 – 7.99 (m, 2H, ArH), 7.29 – 7.16 (m, 10H, ArH), 6.55 (s, 1H, H-1), 5.74 (d, J = 4.4 Hz, 1H, 
H-2), 4.66 (dd, J = 7.7, 4.4 Hz, 1H, H-3), 4.51 (s, 2H, CH2Ph), 4.46 – 4.39 (m, 3H, H-4, CH2Ph), 
3.85 (dd, J = 11.0, 2.7 Hz, 1H, H-5), 3.83 – 3.75 (m, 2H, CH2CH2), 3.72 (dd, J = 11.1, 3.5 Hz, 
1H, H-5), 3.64 – 3.53 (m, 2H, CH2CH2); 13C NMR (101 MHz, CDCl3): δ 163.6 (C=O), 163.0 
(C=O), 150.7 (ArC), 150.6 (ArC), 137.9 (ArC), 137.8 (ArC), 134.6 (ArC), 131.0 (ArC), 130.9 
(ArC), 128.4 (ArC), 128.3 (ArC), 127.7 (ArC), 127.6 (ArC), 127.5 (ArC), 123.6 (ArC), 123.5 
(ArC), 99.5 (C-1), 82.2 (C-4), 77.3 (C-3), 75.2 (C-2), 73.5 (CH2Ph), 73.2 (CH2Ph), 71.1 
(CH2CH2), 69.7 (CH2CH2), 68.8 (C-5); ESI-HRMS: m/z calcd. for C35H32N2NaO12 [M+Na]
+ 
695.1853; found, 695.1846. 
-O--5’’’-O-Benzyl-3’’’-O-(2-benzyloxyethyl)-1’’’,2’’’-di-O-(4-nitrobenzoyl)-D-
ribofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin 
(141). Donor 140 (161 mg, 0.24 mmol), acceptor 124 (67 mg, 0.08 mmol) and activated 4 Å MS 
were stirred in dry DCM at rt for 1 h before cooling to 0 °C. BF3.OEt2 (100 L, 0.27 mmol) was 
added and reaction mixture was stirred for 48 h at 0 °C. The reaction was quenched with 
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triethylamine (0.5 mL) and filtered through Celite® before dilution with EtOAc and washing with 
aqueous NaHCO3 and brine and concentration. The crude product was purified using silica gel 
column chromatography (eluent: 0.6% - 1.5% methanol/DCM) to give the  anomer 141 (14 mg, 
13%) as a white solid; [α]D25= +56.85 (c 0.7, DCM); 1H NMR (600 MHz, CDCl3): δ 8.20 – 8.11 
(m, 4H, ArH), 7.40 –7.30 (m, 5H, ArH), 7.24 – 7.10 (m, 5H, ArH), 5.80 (d, J = 3.6 Hz, 1H, H-
1’), 5.43 (t, J = 10.0 Hz, 1H, H-3’’), 5.39 – 5.34 (m, 2H, H-1’’, H-1’’’), 5.26 (d, J = 4.3 Hz, 1H, 
H-2’’’), 4.91 (t, J = 9.7 Hz, 1H, H-6), 4.87 (dd, J = 10.3, 3.9 Hz, 1H, H-2’’), 4.81 (d, J = 4.5 Hz, 
1H, H-8’), 4.76 (dd, J = 7.4, 3.3 Hz, 1H, H-6’), 4.57 (d, J = 12.0 Hz, 1H, CH2Ph), 4.51 (d, J = 
12.0 Hz, 1H, CH2Ph), 4.39 (dd, J = 10.3, 3.4 Hz, 1H, H-5’), 4.37 – 4.31 (m, 3H, CH2Ph, H-6’’), 
4.27 – 4.19 (m, 2H, H-6’’, H-4’’’), 4.14 (dd, J = 7.5, 4.4 Hz, 1H, H-3’’’), 3.87 – 3.71 (m, 4H, H-
5, H-7’, H-5’’, H-5’’’), 3.71 – 3.63 (m, 3H, H-4, CH2CH2), 3.63 – 3.52 (m, 4H, H-3, H-5’’ H-4’, 
H-4’’), 3.51 – 3.37 (m, 3H, H-1, CH2CH2), 3.08 (dt, J = 12.9, 4.2 Hz, 1H, H-2’), 2.95 (s, 3H, 
NHCH3), 2.41 (dt, J = 13.1, 4.5 Hz, 1H, H-2), 2.23 – 1.97 (m, 13H, 4COCH3, H-3’), 1.87 (q, J = 
11.7 Hz, 1H, H-3’), 1.57 (q, J = 12.6 Hz, 1H, H-2); 13C NMR (151 MHz, CDCl3): δ 170.3 
(C=O), 170.1 (C=O), 169.8 (C=O), 169.7 (C=O), 163.8 (C=O), 157.1 (ArC), 150.7 (ArC), 137.9 
(ArC), 137.9 (ArC), 134.7 (ArC), 130.8 (ArC), 128.5 (ArC), 128.2 (ArC), 127.7 (ArC), 127.6 
(ArC), 127.5 (ArC), 127.4 (ArC), 123.6 (ArC), 107.2 (C-1’’’), 97.3 (C-8’), 96.4 (C-1’), 94.2 (C-
1’’), 82.0 (C-5), 80.7 (C-4’’’), 77.8 (C-4), 77.7 (C-3’’’), 75.7 (C-2’’), 75.0 (C-6), 73.4 (CH2Ph), 
73.0 (CH2Ph), 71.0 (C-6’), 70.8 (C-3’’), 70.4 (CH2CH2), 70.3 (C-5’’’), 69.9 (C-2’’), 69.2 (C-5’’), 
69.1 (CH2CH2), 65.9 (C-5’), 65.7 (C-4’), 62.9 (C-6’’), 60.20 (C-4’’), 60.17 (C-7’), 59.1 (C-3), 
58.1 (C-1), 56.5 (C-2’), 31.3 (C-2), 30.1 (C-3’), 29.7 (NCH3), 20.9 (COCH3), 20.8 (COCH3), 
20.7 (COCH3); ESI-HRMS: m/z calcd. for C58H66N14NaO24 [M+Na]
+ 1365.4272; found, 
1365.4260. 
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-O--[3’’’-O-(2-Hydroxyethyl)-D-ribofuranosyl] apramycin pentaacetate salt (142). 
A stirred solution of compound 141 (10 mg, 0.01 mmol) in dioxane (0.5 mL) was treated with 
3N NaOH (0.25 mL) and heated at 100 °C for 3 h. The reaction mixture was cooled to rt and 
neutralized with Amberlyst® before concentration in vacuo. The crude product was dissolved in 
dioxane:water:glacial acetic acid = 1:2:0.2 (0.3 mL) and Pd(OH)2/C (0.5 equiv) was added. The 
reaction mixture was stirred at room temperature under 50 psi of hydrogen for 12 h. After 
completion, the reaction mixture was filtered through Celite® and concentrated to dryness. The 
residue was then dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to 
a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), 
then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The fractions containing the 
product were combined, acidified with glacial acetic acid and lyophilized to afford 142 (3.5 mg, 
48%) as peracetate salt in the form of a white solid; [α]D25= +72.0 (c 0.1, H2O); 1H NMR (600 
MHz, D2O): δ 5.72 (d, J = 3.6 Hz, 1H, H-1’), 5.34 (d, J = 3.8 Hz, 1H, H-1’’), 5.20 (s, 1H, H-
1’’’), 5.06 (d, J = 8.5 Hz, 1H, H-8’), 4.43 (s, 1H, H-6’), 4.21 (d, J = 4.3 Hz, 1H, H-2’’’), 3.97 – 
3.92 (m, 1H, H-4’’’), 3.91 – 3.86 (m, 1H, H-4), 3.86 – 3.79 (m, 2H, H-5’’, H-3’’’), 3.78 – 3.66 
(m, 7H, H-5, H-4’, H-5’’’, H-6’’, H-3’’, CH2CH2), 3.63 (dd, J = 12.4, 4.6 Hz, 1H, H-6’’), 3.60 – 
3.55 (m, 3H, H-2’’,CH2CH2), 3.55 – 3.45 (m, 4H, H-6, H-2’, H-6’, H-5’’’), 3.42 – 3.33 (m, 1H, 
H-3), 3.24 (d, J = 8.9 Hz, 1H, H-7’), 3.21 – 3.09 (m, 2H, H-, H-1, H-4’’), 2.63 (s, 3H, NCH3), 
2.32 (dt, J = 12.3, 3.8 Hz, 1H, H-2), 2.23 – 2.15 (m, 1H, H-3’), 1.94 – 1.90 (m, 1H, H-3’), 1.70 
(q, J = 12.8 Hz, 1H, H-2); 13C NMR (151 MHz, D2O): δ 110.4 (C-1’’’), 94.6 (C-1’), 94.4 (C-
1’’), 92.8 (C-8’), 84.8 (C-5), 81.1 (C-4’’’), 77.0 (C-3’’’), 75.2 (C-4), 73.4 (C-2’’’), 72.4 (C-6), 
71.4 (CH2CH2), 70.2 (C-5’’), 69.7 (C-2’’), 69.3 (C-3’’), 68.2 (C-4’), 66.0 (C-5’), 62.6 (C-6’), 
60.9 (C-5’’’), 60.5 (CH2CH2), 60.3 (C-6’’), 59.3 (C-7’), 52.0 (C-4’’), 49.7 (C-3), 48.3 (C-1), 
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47.8 (C-2’), 30.0 (NCH3), 28.0 (C-2), 26.6 (C-3’); ESI-HRMS: m/z calcd. for C28H54N5O16 
[M+H]+ 716.3566; found, 716.3541. 
2,3-O-Isopropylidene--D-erythrofuranosyl trichloroacetimidate (144). 2,3-O-
Isopropylidene--D-erythrofuranose169 143 (300 mg, 1.88 mmol) and trichloroacetonitrile (2 
mL) were dissolved with stirring in dry DCM (2 mL) and ice-cooled before addition of DBU (2 
drops). The reaction mixture was stirred at rt for 5 min and concentrated. The crude mixture was 
passed through a silica gel column that had been basified with 0.5% triethylamine/hexanes, 
eluting with 0.5% triethylamine in EtOAc/hexanes to give 144 (564 mg, quant.) in the form of a 
yellow oil; [α]D25= -84.04 (c 0.5, DCM);1H NMR (400 MHz, CDCl3): δ 8.58 (s, 1H, NH), 6.29 
(s, 1H, H-1), 4.93 (dd, J = 5.9, 3.5 Hz, 1H, H-3), 4.83 (d, J = 5.9 Hz, 1H, H-2), 4.20 (d, J = 10.5 
Hz, 1H, H-4), 4.09 (dd, J = 10.6, 3.6 Hz, 1H, H-4), 1.50 (s, 3H, CH3), 1.35 (s, 3H, CH3); 
13C 
NMR (101 MHz, CDCl3): δ 160.7(C=N), 113.1 (C(CH3)2), 105.4 (C-1), 84.4 (C-2), 79.4 (C-3), 
74.0 (C-4), 26.2 (CH3), 24.9 (CH3); ESI-HRMS: m/z calcd. for C9H12Cl3NNaO4 [M+Na]
+ 
325.9730; found, 325.9722. 
-O--2''',3'''-O-Isopropylidene-D-erythrofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-
1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin (145). Donor 144 (109 mg, 0.36 mmol), 
acceptor 124 (100 mg, 0.12 mmol) and activated 4 Å MS were added to a flame-dried round-
bottom flask and  stirred in dry DCM (2.5 mL) at rt for 1 h before cooling to -78 °C,  addition of 
BF3.OEt2 (200 L, 0.54 mmol) and stirring for 1.5 h at -30 °C. The reaction was allowed to 
warm up to 0 °C before quenching with triethylamine (0.5 mL) and filtered through Celite®. The 
reaction mixture was diluted with EtOAc, and washed with aqueous NaHCO3 and brine then 
concentrated. The crude product was purified using silica gel column chromatography (eluent: 
0.4% - 0.8% Methanol/DCM) to give 145 (112 mg, 96%) as white solid; [α]D25= +77.97 (c 0.7, 
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DCM); 1H NMR (400 MHz, CDCl3): δ 5.45 – 5.35 (m, 3H, H-1’, H-1’’, H-3’’), 5.23 (s, 1H, H-
1’’’), 4.93 (t, J = 9.8 Hz, 1H, H-6), 4.87 – 4.80 (m, 2H, H-8’, H-2’’), 4.76 (dd, J = 7.5, 3.5 Hz, 
1H, H-6’), 4.72 (dd, J = 5.9, 3.5 Hz, 1H, H-3’’’), 4.45 – 4.36 (m, 2H, H-5’, H-2’’’), 4.31 (dd, J = 
12.2, 2.3 Hz, 1H, H-6’’), 4.20 (dd, J = 12.2, 5.2 Hz, 1H, H-6’’), 4.04 (d, J = 10.7 Hz, 1H, H-
4’’’), 3.90 (dd, J = 10.8, 3.6 Hz, 1H, H-4’’’), 3.79 – 3.68 (m, 3H, H-5, H-7’, H-5’’), 3.68 – 3.62 
(m, 2H, H-4, H-4’), 3.61 – 3.51 (m, 2H, H-3, H-4’’), 3.45 (ddd, J = 12.3, 10.1, 4.3 Hz, 1H, H-1), 
3.11 (dt, J = 12.8, 4.0 Hz, 1H, H-2’), 2.92 (s, 3H, NCH3), 2.42 (dt, J = 13.1, 4.6 Hz, 1H, H-2), 
2.24 (dt, J = 11.1, 4.4 Hz, 1H, H-3’), 2.19 (s, 3H, COCH3), 2.14 – 2.04 (m, 6H, 2*COCH3), 2.05 
(s, 3H, COCH3), 2.03 – 1.93 (m, 1H, H-3’), 1.59 (q, J = 12.6 Hz, 1H, H-2), 1.40 (s, 3H, CH3), 
1.25 (s, 3H, CH3); 
13C NMR (101 MHz, CDCL3): δ 170.4 (C=O), 170.1 (C=O), 169.8 (C=O), 
156.9 (C=O), 112.5 (C(CH3)2), 109.9 (C-1’’’), 97.7 (C-8’), 97.4 (C-1’), 94.3 (C-1’’), 85.6 (C-
2’’’), 80.9 (C-5), 79.7 (C-3’’’), 77.2 (C-4), 75.6 (C-6), 73.4 (C-4’’’), 71.0 (C-6’), 70.3 (C-3’’), 
69.9 (C-2’’), 69.1 (C-5’’), 66.2 (C-5’), 65.8 (C-4’), 62.8 (C-6’’), 60.2 (C-7’), 60.1 (C-4’’), 59.1 
(C-3), 57.9 (C-1), 55.9 (C-2’), 31.5 (C-2), 30.2 (NCH3), 29.4 (C-3’), 26.2 (CH3), 24.8 (CH3), 
20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. for C37H49N13NaO19 
[M+Na]+ 1002.3165; found, 1002.3137. 
Erythrolactone-2,3-dibenzoate (148). An aqueous solution of isoascorbic acid (7.04 g, 
40 mmol) in water (100 mL) was ice-cooled and Na2CO3 (8.48 g, 80 mmol) was added slowly 
followed by aqueous solution of H2O2 (30%, 9.2 mL). The reaction mixture was stirred at 42 °C 
for 30 min after which charcoal (2 g) was added and the mixture stirred at 75 °C for 30 min to 
destroy excess H2O2. The reaction mixture was filtered while hot and neutralized with 6 N HCl 
then concentrated till dryness. The resulting residue was dissolved in dry pyridine (50 mL) and 
cooled to 0 °C before addition of benzoyl chloride dropwise (11.6 mL, 100 mmol). The reaction 
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mixture was stirred at rt for 12 h before it was diluted with EtOAc and washed with aqueous 
NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated. The residue was 
purified by gradient chromatography over silica gel (eluent: 10% to 35% EtOAc in hexanes) to 
give 148 (9.0 g, 69%) as a white solid; [α]D25= -145.78 (c 1.2, DCM); 1H NMR (400 MHz, 
CDCl3): δ 7.97 (m, 4H), 7.65 – 7.50 (m, 2H, ArH), 7.41 (m, 2H, ArH), 7.35 (m, 2H, ArH), 6.07 – 
5.95 (m, 2H, H-2, H-3), 4.73 (dd, J = 11.4, 3.1 Hz, 1H, H-4), 4.65 (d, J = 11.4 Hz, 1H, H-4); 13C 
NMR (101 MHz, CDCL3): δ 170.3 (C=O), 165.3 (ArC), 164.9 (ArC), 133.9 (ArC), 130.1 (ArC), 
129.8 (ArC), 128.6 (ArC), 128.5 (ArC), 128.5 (ArC), 128.0 (ArC), 69.9 (C-4), 69.7 (C-2), 
67.7(C-3); ESI-HRMS: m/z calcd. for C18H14NaO6 [M+Na]
+ 349.0688; found, 349.0691. 
2,3-Di-O-benzoyl--D-erythrofuranose (149). A stirred solution of erythrolactone-
2,3-dibenzoate 148 (1000 mg, 3.06 mmol) in dry THF was cooled to -78 °C and DIBAL (1 M in 
hexanes, 6 mL) was added. The mixture was stirred for 4 h before it was quenched with 
methanol (20 mL). The so-formed residue was filtered through Celite® and the filtrate was 
concentrated and dissolved in EtOAc. The organic layer was washed with aqueous NaHCO3 and 
brine. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by 
gradient chromatography over silica gel (eluent: 10% to 25% EtOAc in hexanes) to give 149 
(360 mg, 36%) as an mixture (0.5:1) in the form of a gum; [α]D25= -29.1 (c 0.3, DCM); 1H 
NMR (400 MHz, CDCl3): δ 8.18 – 8.01 (m, 2H, ArH), 8.00 – 7.93 (m, 2H, ArH), 7.92 – 7.84 (m, 
2H, ArH), 7.57 – 7.42 (m, 2H, ArH), 7.42 – 7.24 (m, 7H, ArH), 5.90 – 5.78 (m, 1.5H, H-3b, H-
3), 5.74 (dd, J = 7.2, 4.7 Hz, 0.5H, H-1), 5.72 – 5.67 (m, 1H, H-1), 5.59 (dd, J = 5.3, 1.6 Hz, 
1H, H-2), 5.33 (dd, J = 5.9, 4.7 Hz, 0.5H, H-2), 4.72 – 4.63 (m, 1H, OH), 4.58 (dd, J = 10.0, 
6.0 Hz, 1H, H-4), 4.37 – 4.26 (m, 1H, H-4), 4.13 (dd, J = 10.0, 4.2 Hz, 1H, H-4); 13C NMR 
(101 MHz, CDCl3): δ 165.8 (C=O), 165.7 (C=O), 133.5 (ArC), 133.5 (ArC), 133.4 (ArC), 133.4 
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(ArC), 133.3 (ArC), 130.00 (ArC), 139.95 (ArC), 129.9 (ArC), 129.83 (ArC), 129.79 (ArC), 
129.7 (ArC), 129.18 (ArC), 129.15 (ArC), 128.6 (ArC), 128.51 (ArC), 128.45 (ArC), 128.41 
(ArC), 128.36 (ArC), 100.4 (C-1), 94.9 (C-1), 77.0 (C-2), 76.9 (C-2), 72.3 (C-3), 72.2 (C-
3), 69.9 (C-4), 69.8 (C-4); ESI-HRMS: m/z calcd. for C18H16NaO6 [M+Na]+ 349.0688; 
found, 349.0691. 
2,3-Di-O-benzoyl--D-erythrofuranosyl trichloroacetimidate (150). 2,3-O-Dibenzoyl-
-D-erythrofuranose (149) (360 mg, 1.10 mmol) and trichloroacetonitrile (2 mL) were 
dissolved in dry DCM (2 mL) and ice-cooled before addition of DBU (2 drops). The reaction 
mixture was stirred at rt for 5 min and concentrated. The crude mixture was passed through a 
silica gel column that had been basified with 0.5% triethylamine/hexanes, eluting with 0.5% 
triethylamine in EtOAc/hexanes to give compound 150 (458 mg, 88%) as a gum; [α]D25= -78.9 (c 
1.6, DCM); 1H NMR (400 MHz, CDCl3): δ 8.69 (s, 1H, NH), 8.05 – 7.97 (m, 2H, ArH), 7.93 – 
7.86 (m, 2H, ArH), 7.54 (m, 2H, ArH), 7.40 (m, 2H, ArH), 7.32 (m, 2H, ArH), 6.58 (s, 1H, H-1), 
5.94 – 5.84 (m, 2H, H-2, H-3), 4.66 – 4.58 (m, 1H, H-4), 4.30 (dd, J = 9.8, 3.4 Hz, 1H, H-4); 13C 
NMR (101 MHz, CDCl3): δ 165.6 (ArC), 165.1 (ArC), 160.8 (C=N), 133.6 (ArC), 133.4 (ArC), 
129.9 (ArC), 129.7 (ArC), 128.9 (ArC), 128.8 (ArC), 128.5 (ArC), 128.4 (ArC), 103.2 (C-1), 
77.2 (CCl3), 75.5 (C-2), 71.8 (C-4), 71.5 (C-3); ESI-HRMS: m/z calcd. for C20H16Cl3NaO6 
[M+Na]+ 493.9941; found, 493.9945. 
-O--2''',3'''-Di-O-benzoyl-D-erythrofuranosyl]-6,2’’,3’’,6’’-tetra-O-acetyl-
1,3,2’,4’’-tetraazido-6’,7’-oxazolidino-apramycin (151). Donor 150 (109 mg, 0.36 mmol), 
acceptor 124 (100 mg, 0.12 mmol) and activated 4 Å MS were stirred in dry DCM (2.5 mL) at rt 
for 1 h before cooling to -78 °C. BF3.OEt2 (200 L, 0.54 mmol) was added and reaction mixture 
was stirred for 3 h at -78 °C. The reaction was quenched at -78 °C with triethylamine (0.5 mL) 
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and filtered through Celite® before it was diluted with EtOAc. The organic layer was washed 
with NaHCO3 and brine then concentrated. The crude product was purified using silica gel 
column chromatography (eluent: 0.4% - 0.8% Methanol/DCM) to give the  anomer 151 (68 mg, 
50%) in the form of white solid; [α]D25= +64.1 (c 4.5, DCM); 1H NMR (400 MHz, CDCl3): δ 
7.90 (m, 4H, ArH), 7.53 (m, 2H, ArH), 7.35 (m, 4H, ArH), 5.63 (m, 2H, H-3''', H-1'''), 5.54 (d, J 
= 3.5 Hz, 1H, H-1'), 5.51 (dd, J = 5.0, 1.4 Hz, 1H, H-2'''), 5.44 (t, J = 10.0 Hz, 1H, H-3''), 5.39 
(d, J = 3.8 Hz, 1H, H-1''), 5.02 (t, J = 9.9 Hz, 1H, H-6), 4.93 – 4.86 (m, 2H, H-2'', H-8'), 4.82 
(dd, J = 7.7, 3.3 Hz, 1H, H-6'), 4.62 – 4.50 (m, 2H, H-5', H-4'''), 4.33 (dd, J = 12.1, 1.9 Hz, 1H, 
H-6''), 4.23 (dd, J = 12.2, 5.3 Hz, 1H, H-6''), 4.16 (dd, J = 9.9, 4.9 Hz, 1H, H-4'''), 3.93 (t, J = 9.2 
Hz, 1H, H-5), 3.84 – 3.70 (m, 4H, H-4, H-4', H-5'', H-7'), 3.70 – 3.54 (m, 2H, H-3, H-4''), 3.49 
(ddd, J = 12.5, 10.5, 4.3 Hz, 1H, H-1), 3.34 (dt, J = 12.9, 4.1 Hz, 1H, H-2'), 2.94 (s, 3H, NCH3), 
2.47 (dt, J = 12.9, 4.5 Hz, 1H, H-2), 2.33 – 2.23 (m, 1H, H-3'), 2.11 (m, 12H, 4COCH3), 1.97 (q, 
J = 11.8 Hz, 1H, H-3'), 1.65 (q, J = 12.5 Hz, 1H, H-2); 13C NMR (101 MHz, CDCl3): δ 170.4 
(C=O), 170.2 (C=O), 169.8 (C=O), 169.6 (C=O), 165.5 (Ar-C), 165.3 (Ar-C), 157.0 (Ar-C), 
133.6 (Ar-C), 133.4 (Ar-C), 129.6 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-
C), 106.4 (C-1'''), 97.4 (C-1'), 96.8 (C-8'), 94.1 (C-1''), 79.2 (C-5), 78.1 (C-4), 75.8 (C-2'''), 74.8 
(C-6), 71.6 (C-3'''), 70.8 (C-6'), 70.6 (C-2''), 70.4 (C-4'''), 69.9 (C-3''), 69.1 (C-5''), 66.0 (C-5'), 
65.6 (C-4'), 62.9 (C-6''), 60.2 (C-7'), 60.1 (C-3), 59.0 (C-4''), 58.2 (C-1), 56.5 (C-2'), 31.5 (C-2), 
30.1 (NCH3), 29.7(C-3') 20.9 (2COCH3), 20.8 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. 
for C48H53N13NaO21 [M+Na]
+ 1170.3377; found, 1170.3353. 
-O--D-Erythrofuranosyl) apramycin pentaacetate salt (152). A stirred solution of 
compound 151 (60 mg, 0.02 mmol) in dioxane (1mL) was treated with 3N NaOH (1 mL) and 
heated at 100 °C for 2 h. The reaction mixture was cooled to 55 °C and 1M P(CH3)3 in THF (0.3 
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mL) was added and stirring continued for 2 h. The reaction mixture was neutralized with glacial 
acetic acid, concentrated in vacuo, the residue dissolved in aqueous acetic acid solution (pH 4, 1 
mL) and was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with 
D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The fractions 
containing the product were combined, acidified with glacial acetic acid, and lyophilized to 
afford compound 152 (35 mg, 71%) as peracetate salt in the form of white solid; [α]D25= +58.71 
(c 2.3, H2O); 
1H NMR (600 MHz, D2O): δ 5.67 (d, J = 4.1 Hz, 1H, H-1'), 5.28 (d, J = 3.9 Hz, 
1H, H-1’’), 5.18 (d, J = 3.8 Hz, 1H, H-1'''), 5.00 (d, J = 8.5 Hz, 1H, H-8'), 4.38 (s, 1H, H-6'), 4.16 
(q, J = 4.4 Hz, 1H, H-3'''), 4.04 (dd, J = 9.6, 4.9 Hz, 1H, H-4'''), 3.98 (t, J = 4.2 Hz, 1H, H-2'''), 
3.85 (t, J = 9.7 Hz, 1H, H-4), 3.77 (dt, J = 10.2, 3.9 Hz, 1H, H-5''), 3.74 – 3.65 (m, 3H, H-4', H-
5, H-3''), 3.74 – 3.65 (m, 2H, H-4''', H-6''), 3.57 (dd, J = 12.5, 4.5 Hz, 1H, H-6''), 3.54 – 3.43 (m, 
4H, H-2', H-2'', H-5', H-6), 3.34 – 3.27 (m, 1H, H-3), 3.18 (dd, J = 8.5, 2.7 Hz, 1H, H-7'), 3.13 
(td, J = 12.0, 4.2 Hz, 1H, H-1), 3.08 (t, J = 10.4 Hz, 1H, H-4''), 2.57 (s, 3H, NCH3), 2.26 (dt, J = 
12.5, 4.1 Hz, 1H, H-2), 2.16 (dt, J = 9.7, 4.4 Hz, 1H, H-3'), 1.86 – 1.80 (m, 1H, H-3'), 1.65 (q, J 
= 12.6 Hz, 1H, H-2); 13C NMR (151 MHz, D2O): δ 110.0 (C-1'''), 94.3 (C-1'), 93.9 (C-1''), 92.7 
(C-8'), 84.4 (C-5), 75.6 (C-2'''), 75.1 (C-4), 72.4 (C-6), 71.4 (C-4'''), 70.1 (C-5''), 69.6 (C-2''), 
69.6 (C-4'), 69.3 (C-3''), 68.1 (C-3'''), 65.7 (C-5'), 62.5 (C-6'), 60.2 (C-6''), 59.2 (C-7'), 51.9 (C-
4''), 49.4 (C-3), 48.4 (C-1), 47.4 (C-2'), 29.9 (NCH3), 28.0 (C-2), 26.8 (C-3'); ESI-HRMS: m/z 
calcd. for C25H48N5O14 [M+H]
+ 642.3198; found, 642.3182. 
1,2,3-Tri-O-acetyl-5-deoxy-5-phthalimido--D-ribofuranose (154). 1,2,3-Tri-O-
acetyl-5-O-p-tolylsulfonyl-D-ribofuranose171 153 (1000 mg, 2.3 mmol) was dissolved in dry 
DMF (20 mL) and treated with potassium phthalimide (1000 mg, 5.4 mmol). The reaction 
mixture was stirred at 50 °C for 12 h before it was diluted with water and extracted with DCM 
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three times. The organic layer wash then washed with 5% aqueous NaOH and brine, dried over 
Na2SO4, and concentrated. The residue was purified using silica gel column chromatography 
(eluent: 15% - 35% EtOAc/hexanes) to give 154 (566 mg, 60%) as a white solid; [α]D25= +49.66 
(c 1.3, DCM); 1H NMR (400 MHz, CDCl3): δ 7.80 – 7.73 (m, 2H, ArH), 7.70 – 7.62 (dd, J = 5.4, 
3.1 Hz, 2H, ArH), 6.34 (d, J = 4.5 Hz, 1H, H-1), 5.23 (dd, J = 6.8, 4.5 Hz, 1H, H-2), 5.15 (dd, J 
= 6.7, 3.4 Hz, 1H, H-3), 4.48 (td, J = 6.8, 3.4 Hz, 1H, H-4), 3.86 (dd, J = 6.8, 5.2 Hz, 2H, H-5), 
2.03 – 1.95 (m, 9H, COCH3); 13C NMR (101 MHz, CDCl3): δ 169.9 (C=O), 169.4 (C=O), 169.2 
(C=O), 168.0 (C=O), 134.1 (ArC), 131.8 (ArC), 123.4 (ArC), 93.7 (C-1), 80.4 (C-4), 70.7 (C-3), 
69.6 (C-2), 39.3 (C-5), 20.9 (COCH3), 20.5 (COCH3), 20.2 (COCH3); ESI-HRMS: m/z calcd. for 
C19H19NNaO9 [M+Na]
+ 428.0958; found, 428.0964. 
2,3-Di-O-acetyl-5-deoxy-5-phthalimido-D-ribofuranose trichloroacetimidate (155). 
To an ice-cooled solution of 154 (550 mg, 1.36 mmol) in DCM (5 mL), 33% HBr/acetic acid 
(0.7 mL, 4.07 mmol) was added followed by stirring for 45 min. After completion, solid 
NaHCO3 was added to neutralize the reaction, then water was added and the aqueous layer was 
extracted with DCM three times. The organic layer was washed with brine, dried over Na2SO4 
and concentrated. The residue was purified using silica gel column chromatography (eluent: 20% 
- 60% EtOAc/hexanes) to give 2,3-di-O-acetyl-5-deoxy-5-phthalimido--D-ribofuranose as a 
mixtureof anomers (200 mg, 41%) that was used directly in the next step. 2,3-Di-O-
acetyl-5-deoxy-5-phthalimido--D-ribofuranose (190 mg, 0.53 mmol) and trichloroacetonitrile 
(2 mL) were dissolved in dry DCM (2 mL) and ice-cooled before addition of DBU (2 drops). 
The reaction mixture was stirred at rt for 5 min and concentrated. The crude product was passed 
through a silica gel column, basified with 0.5% triethylamine/hexanes, eluting with 0.5% 
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triethylamine in EtOAc/hexanes to give compound 155 (270 mg, quant) which was used in the 
next step without further purification. 
-O--(2''',3'''-Di-O-acetyl-5'''-deoxy-5'''-phthalimido-D-ribofuranosyl)-6,2’’,3’’,6’’-
tetra-O-acetyl-1,3,2',4''-tetraazido-6’,7’-oxazolidino-apramycin (156). Donor 155 (190 mg, 
0.52 mmol), acceptor 124 (701 mg, 0.84 mmol) and activated 4 Å MS were stirred in dry DCM 
(3 mL) at rt for 1 h before cooling to 0 °C. BF3.OEt2 (400 L, 1.08 mmol) was added and 
reaction mixture was stirred for 2 h at 0 °C. The reaction was quenched with triethylamine (0.5 
mL) and filtered through Celite® before it was diluted with EtOAc and washed with aqueous 
NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated. The crude 
product was purified using silica gel column chromatography (eluent: 0.6% - 1.5% 
methanol/DCM) to give the glycoside 156 (470 mg, 76%) as the  anomer in the form of white 
solid; [α]D25= +131.96 (c 5.3, DCM); 1H NMR (400 MHz, CDCl3): δ 7.95 – 7.88 (m, 2H, ArH), 
7.77 – 7.70 (m, 2H, ArH), 5.39 (t, J = 9.9 Hz, 1H, H-3’’), 5.34 (d, J = 3.8 Hz, 2H, H-1’, H-1’’), 
5.30 (s, 1H, H-1’’’), 5.12 (d, J = 4.9 Hz, 1H, H-2’’’), 5.06 (dd, J = 7.2, 4.8 Hz, 1H, H-3’’’), 4.95 
– 4.88 (m, 2H, H-8’, H-2’’), 4.83 (dd, J = 8.2, 2.9 Hz, 1H, H-6’), 4.66 (dd, J = 10.5, 2.9 Hz, 1H, 
H-5’), 4.46 (t, J = 9.9 Hz, 1H, H-6), 4.42 – 4.29 (m, 2H, H-6’’, H-4’’’), 4.22 (dd, J = 12.2, 5.2 
Hz, 1H, H-6’’), 3.96 (d, J = 5.0 Hz, 2H, H-5’’’), 3.84 – 3.68 (m, 3H, H-4’, H-6’, H-5’’), 3.65 – 
3.53 (m, 3H, H-3, H-4, H-4’’), 3.46 – 3.28 (m, 3H, H-1, H-5, H-2’), 2.94 (s, 3H, NCH3), 2.41 (dt, 
J = 12.6, 4.3 Hz, 1H, H-2), 2.23 (s, 4H, H-3’, COCH3), 2.13 – 1.98 (m, 15H, 5*COCH3), 1.78 (q, 
J = 11.7 Hz, 1H, H-3’), 1.43 (q, J = 12.6 Hz, 1H, H-2); 13C NMR (101 MHz, CDCl3): δ 170.3 
(C=O), 170.2 (C=O), 169.9 (C=O), 169.8 (C=O), 169.5 (C=O), 168.2 (C=O), 157.2 (C=O), 
134.1 (ArC), 132.0 (ArC), 123.7 (ArC), 106.9 (C-1’’’), 97.0 (C-1’), 94.8 (C-8’), 93.8 (C-1’’), 
79.8 (C-5), 79.1 (C-4’’’), 78.9 (C-4), 74.0 (2’’’), 73.4 (C-6), 72.6 (C-3’’’), 70.7 (C-6’), 70.3 (C-
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3’’), 69.9 (C-2’’), 68.9 (C-5’’), 65.4 (C-5’), 65.3 (C-4’), 62.9 (C-6’’), 60.21 (C-7’), 60.16 (C-
4’’), 58.4 (C-3), 58.2 (C-1), 57.7 (C-2), 39.5 (C-5’’’), 31.4 (C-2), 31.3 (C-3’), 29.9 (NCH3), 20.9 
(COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.6 (COCH3), 20.4 (COCH3); ESI-
HRMS: m/z calcd. for C47H54N14NaO23 [M+Na]
+ 1205.3384; found, 1205.3359. 
-O--(5'''-Formamido-5'''-deoxy-D-ribofuranosyl) apramycin pentaacetate salt 
(157). To a stirred solution of compound 156 (50 mg, 0.04 mmol) in an IPA:water mixture (7:3, 
1.5 mL), NaBH4 (90 mg, 2.4 mmol) was added followed by stirring for 2 h. The reaction mixture 
was diluted with methanol and glacial acetic acid was added dropwise until effervescence 
stopped. The reaction mixture was concentrated in vacuo followed by the addition of 3 N NaOH 
(0.5 mL) and water (0.5 mL). The reaction mixture was heated at 100 °C for 1 h before it was 
cooled, neutralized with glacial acetic acid and concentrated. The crude mixture was desalted 
using a Sephadex column and the product-containing fractions were concentrated. A part of the 
solid residue (8.2 mg, 0.009 mmol) was dissolved in water (0.2 mL) and treated with N-
(diethylcarbamoyl)-N-methoxyformamide172 (2.4 L, 0.014 mmol) and triethylamine (1L). 
The reaction mixture was stirred for 2 h and quenched with ammonium hydroxide (0.25 mL) 
followed by addition of 1M P(CH3)3 in THF (0.3 mL) and stirring at 60 °C for 3h. The reaction 
mixture was then concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 
mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed 
with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The 
fractions containing the product were combined, acidified with acetic acid and lyophilized to 
afford 157 in (4.5 mg, 42%) as peracetate salt in the form of a white solid; [α]D25= +82.2 (c 0.2, 
H2O); 
1H NMR (600 MHz, D2O): δ 7.98 (s, 1H, CHO), 5.67 (d, J = 3.9 Hz, 1H, H-1’), 5.34 (d, J 
= 3.9 Hz, 1H, H-1’’), 5.14 (d, J = 2.9 Hz, 1H, H-1’’’), 5.06 (d, J = 8.5 Hz, 1H, H-8’), 4.46 – 4.39 
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(m, 1H, H-6’), 4.02 (dd, J = 4.4, 3.2 Hz, 1H, H-2’’’), 3.94 (t, J = 5.3 Hz, 1H, H-3’’’), 3.90 (q, J = 
5.7 Hz, 1H, H-3’’’), 3.85 – 3.67 (m, 6H, H-4, H-5, H-4’, H-3’’, H-5’’, H-6), 3.63 (dd, J = 12.5, 
4.6 Hz, 1H, H-6’’), 3.56 (dd, J = 9.8, 3.8 Hz, 1H, H-2’’), 3.54 – 3.50 (m, 3H, H-6, H-2’, H-5’), 
3.42 (dd, J = 14.6, 4.2 Hz, 1H, H-5’’’), 3.32 (dd, J = 14.6, 6.2 Hz, 1H, H-5’’’), 3.29 – 3.23 (m, 
1H, H-3), 3.22 (dd, J = 8.5, 2.7 Hz, 1H, H-7’), 3.16 (td, J = 11.6, 10.9, 4.3 Hz, 1H, H-1), 3.10 (t, 
J = 10.3 Hz, 1H, H-4’’), 2.63 (s, 3H, NCH3), 2.30 – 2.16 (m, 2H, H-2, H-3’), 1.94 – 1.83 (m, 1H, 
H-3’), 1.68 – 1.55 (m, 1H, H-2); 13C NMR (151 MHz, D2O): δ 164.7(CHO), 110.0 (C-1’’’), 94.4 
(C-1’’), 94.0 (C-1’), 92.9 (C-8’), 85.1 (C-5), 80.9 (C-4’’’), 76.4 (C-4), 74.7 (C-2’’’), 72.5 (C-6), 
70.8 (C-3’’’), 70.2 (C-2’’), 69.7 (C-5’’), 69.7 (C-4’), 68.6 (C-3’’), 65.9 (C-5’), 62.7 (C-6’), 60.3 
(C-6’’), 59.4 (C-7’), 52.0 (C-4’’), 49.8 (C-3), 48.5 (C-1), 47.7 (C-2’), 40.0 (C-5’’’), 30.0 
(NCH3), 28.9 (C-2), 26.8 (C-3’); ESI-HRMS: m/z calcd. for C27H51N6O15 [M+H]+ 699.3412; 
found, 699.3410. 
5-Azido-3-O-(2-benzyloxyethyl)-5-deoxy-1,2-O-isopropylidene--D-ribofuranose 
(159). 5-Azido-5-deoxy-1,2-O-isopropylidene--D-ribofuranose173 158 (4.0 g, 18.6 mmol) was 
dissolved in dry THF (100 mL) and NaH (100 mg, 24.5 mmol) was added. After stirring for 15 
min, 2-benzyloxyethyl tosylate (6.83 g, 22.3 mmol) was added and stirring continued for 36 h. 
After completion, the reaction was quenched with methanol, diluted with EtOAc and washed 
with aqueous NaHCO3 and brine then concentrated. The crude product was purified using silica 
gel column chromatography (eluent: 10% to 20% EtOAc/hexanes) to give 159 (3.08 g, 47%) in 
the form of a colorless oil; [α]D25= +119.83 (c 1.2, DCM); 1H NMR (400 MHz, CDCl3): δ 7.45 – 
7.21 (m, 5H, ArH), 5.76 (d, J = 3.5 Hz, 1H, H-1), 4.64 (t, J = 3.9 Hz, 1H, H-2), 4.56 (s, 2H, 
CH2Ph), 4.14 (dt, J = 8.5, 3.2 Hz, 1H, H-4), 3.91– 3.71 (m, 2H, H-3, CH2CH2), 3.76 – 3.64 (m, 
4H, H-, CH2CH2, CH2CH2, H-5), 3.32 (dd, J = 13.5, 4.0 Hz, 1H, H-5), 1.57 (s, 3H, CH3), 1.35 (s, 
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3H, CH3); 
13C NMR (101 MHz, CDCl3): δ 138.0 (ArC), 128.4 (ArC), 127.7 (ArC), 
113.2(C(CH3)2), 103.9 (C-1), 79.5 (C-3), 77.4 (C-4), 77.3 (C-2), 73.3 (CH2Ph), 70.1 (CH2CH2), 
69.7 (CH2CH2), 50.6 (C-5), 26.8(CH3), 26.5(CH3). ; ESI-HRMS: m/z calcd. for C17H23N3NaO5 
[M+Na]+ 372.1535; found, 372.1538. 
5-Benzyloxycarbonylamino-5-deoxy-3-O-(2-hydroxyethyl)-1,2-O-isopropylidene--
D-ribofuranose (160). To a solution of compound (159) (3.0 g, 8.6 mmol) in dioxane:water = 
5:1 (30 mL), 20% Pd(OH)2/C (3.0 g, 0.5 equiv) was added and the reaction mixture stirred at 
room temperature under 50 psi of hydrogen for 18 h. After completion, the reaction mixture was 
filtered over Celite®, concentrated to dryness and dissolved in dioxane:water = 3:1 (50 mL). 
K2CO3 (6.0 g, 43.5 mmol) and benzyloxychloroformate (2.5 mL, 17.2 mmol) were added and the 
reaction mixture was stirred for 4 h. After completion, the reaction mixture was concentrated and 
purified using silica gel column chromatography (eluent: 0.8% to 1% methanol/DCM) to give 
160 (1.67 g, 53%) as a colorless oil; [α]D25= +35.47 (c 1.5, DCM); 1H NMR (400 MHz, CDCl3): 
δ 7.41 – 7.28 (m, 5H, ArH), 5.73 (d, J = 3.8 Hz, 1H, H-1), 5.10 (d, J = 1.4 Hz, 2H (CH2Ph)), 
4.60 (t, J = 4.1 Hz, 1H, H-2), 4.03 (dt, J = 9.0, 3.6 Hz, 1H, H-4), 3.77 – 3.61 (m, 5H, CH2CH2, 
CH2CH2, H-5), 3.55 (dd, J = 9.0, 4.4 Hz, 1H, H-3), 3.45 (dt, J = 14.6, 4.2 Hz, 1H, H-5), 3.04 (t, J 
= 5.8 Hz, 1H, OH), 1.56 (s, 3H, CH3), 1.35 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): δ 156.9 
(C=O), 136.3 (ArC), 128.5 (ArC), 128.2 (ArC), 113.1(C(CH3)2), 104.1 (C-1), 79.3 (C-3), 77.1 
(C-2), 77.0 (C-4), 72.0 (CH2CH2), 67.0 (CH2Ph), 61.6 (CH2CH2), 40.6 (C-5), 26.6 (CH3), 26.5 
(CH3); ESI-HRMS: m/z calcd. for C18H25NNaO7 [M+Na]
+ 390.1529; found, 390.1537. 
3-O-(2-Azidoethyl)-5-benzyloxycarbonylamino-5-deoxy-1,2-O-isopropylidene--D-
ribofuranose (161). To a stirred solution of the alcohol 160 (1.0 g, 2.7 mmol) in dry THF (5 
mL), triethylamine (2.8 mL, 20.4 mmol).  The reaction mixture was ice-cooled before addition of 
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p-tolylsulfonyl chloride (975 mg, 5.13 mmol) in dry THF (5 mL). The reaction mixture was 
stirred at 30 °C for 48 h before it was concentrated in vacuo. The crude product was dissolved in 
EtOAc and washed with aqueous NaHCO3 and brine, dried over Na2SO4, and concentrated. The 
resulted solid was dissolved in dry DMF (10 mL) and treated with NaN3 (1.05 g, 16.3 mmol) and 
stirred at 40 °C for 48 h. After completion, the reaction mixture was diluted with acetone and 
excess NaN3 was filtered off. The solvent was partially removed under vacuum and the residue 
was diluted with EtOAc, washed with brine, dried over Na2SO4, and filtered. The solvent was 
removed under vacuum and the resulting product was purified using silica gel column 
chromatography (eluent: 10% to 25% EtOAc/hexanes) to give 161 (900 mg, 84% over two steps) 
as a viscous oil; [α]D25= +35.38 (c 1.9, DCM); 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.27 (m, 
5H, ArH), 5.73 (d, J = 3.7 Hz, 1H, H-1), 5.10 (s, 2H, CH2Ph), 4.60 (t, J = 4.1 Hz, 1H, H-2), 4.05 
(dt, J = 8.6, 4.1 Hz, 1H, H-4), 3.82 (ddd, J = 10.1, 6.0, 3.8 Hz, 1H, CH2O), 3.67 (ddd, J = 10.3, 
6.5, 3.9 Hz, 1H, CH2O), 3.63 – 3.47 (m, 3H, H-3, H-5), 3.47 – 3.32 (m, 2H, CH2N3), 1.56 (s, 3H, 
CH3), 1.34 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): δ 156.5 (C=O), 136.4 (ArC), 128.5 
(ArC), 128.1 (ArC), 113.3(C(CH3)2), 104.1 (C-1), 80.0 (C-3), 77.1 (C-2), 77.0 (C-4), 69.4 
(CH2O), 66.9 (CH2Ph), 50.7 (CH2N3), 41.1 (C-5), 26.7 (CH3), 26.6 (CH3); ESI-HRMS: m/z 
calcd. for C18H24N4NaO6 [M+Na]
+ 415.1594; found, 415.1589. 
3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-O-isopropylidene--
D-ribofuranose (162). A stirred solution of the compound 161 (200 mg, 0.51 mmol) in dry THF 
(8 mL) and HMPA (2 mL), was cooled to -78 °C under argon before KHMDS (0.5 M in toluene, 
1.5 mL, 0.66 mmol) and benzyloxychloroformate (0.3 mL, 2.1 mmol) were added. The reaction 
mixture was stirred at -78 °C for 2 h before additional KHMDS (0.5 M in toluene, 3 mL, 1.5 
mmol) was added. The reaction was stirred for 30 min and quenched with NH4Cl, diluted with 
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EtOAc, and washed with aqueous NaHCO3 and brine. The organic layer was dried over Na2SO4 
and concentrated. The crude product was purified using silica gel column chromatography 
(eluent: 10% to 25% EtOAc/hexanes) to give 162 (272 mg, quant) [α]D25= +14.73 (c 1.5, DCM); 
1H NMR (400 MHz, CDCl3): δ 7.48 – 7.28 (m, 10H, ArH), 5.70 (d, J = 3.8 Hz, 1H, H-1), 5.42 – 
5.12 (m, 4H, CH2Ph), 4.56 (t, J = 4.1 Hz, 1H, H-2), 4.20 (dt, J = 8.9, 5.4 Hz, 1H, H-4), 4.07 (dd, 
J = 5.4, 1.2 Hz, 2H, H-5), 3.72 (ddd, J = 9.9, 6.0, 4.0 Hz, 1H, CH2O), 3.57 (dd, J = 8.8, 4.4 Hz, 
1H, H-3), 3.45 (ddd, J = 10.1, 6.3, 4.2 Hz, 1H, CH2O), 3.34 – 3.16 (m, 2H, CH2N3), 1.51 (s, 3H, 
CH3), 1.33 (s, 3H, CH3); 
13C NMR (101 MHz, CDCl3): δ 153.6 (C=O), 135.2 (ArC), 128.5 
(ArC), 128.3 (ArC), 128.2 (ArC), 128.1 (ArC), 113.1(C(CH3)2), 104.2 (C-1), 81.3 (C-3), 77.4 
(C-2), 77.1 (C-4), 68.9 (CH2O), 68.8 (CH2Ph), 66.9 (CH2Ph), 50.5 (CH2N3), 47.1 (C-5), 26.7 
(2CH3); ESI-HRMS: m/z calcd. for C26H30N4NaO8 [M+Na]
+ 549.1961; found, 549.1962. 
3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-1,2-di-O-(p-
nitrobenzoyl)--D-ribofuranose (163). To a stirred solution of compound 162 (268 mg, 0.51 
mmol) in dioxane (10 mL), 1 N HCl (4 mL) was added and the reaction mixture was heated at 80 
°C for 2 h. The reaction mixture was cooled, neutralized with solid NaHCO3 and the solvent was 
evaporated. The residue was dissolved in EtOAc and washed with water and brine, dried with 
Na2SO4 and evaporated. To a solution of the crude mixture in dry pyridine (10 mL), p-
nitrobenzoyl chloride (672 mg, 3.6 mmol) and a catalytic amount of DMAP were added followed 
by stirring overnight. The reaction mixture was diluted with EtOAc and washed with NaHCO3, 
brine, dried with Na2SO4 then concentrated. The crude product was purified using silica gel 
column chromatography (eluent: 15% - 40% EtOAc/hexanes) to give the isomer (235 mg, 
59%) as a white solid and the isomer (165 mg, 41%) as a white solid; isomer: [α]D25= 
+13.85 (c 0.4, DCM); 1H NMR (400 MHz, CDCl3): δ 8.31 – 8.17 (m, 6H, ArH), 8.12 (d, J = 8.8 
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Hz, 2H, ArH), 7.48 – 7.17 (m, 10H, ArH), 6.64 (d, J = 4.4 Hz, 1H, H-1), 5.36 (dd, J = 6.6, 4.4 
Hz, 1H, H-2), 5.34 – 5.21 (m, 4H, 2*CH2Ph), 4.61 (td, J = 6.2, 3.8 Hz, 1H, H-4), 4.18 (dd, J = 
6.6, 3.8 Hz, 1H, H-3), 4.15 – 3.99 (m, 2H, H-5), 3.47 (t, J = 4.8 Hz, 2H, CH2CH2O), 3.20 – 3.12 
(m, 2H, CH2N3). 
13C NMR (101 MHz, CDCl3): δ 163.6 (C=O), 163.3 (C=O), 153.5 (C=O), 150.9 
(ArC), 150.8 (ArC), 148.4 (ArC), 137.3 (ArC), 134.9 (ArC), 134.8 (ArC), 134.1 (ArC), 131.0 
(ArC), 130.9 (ArC), 130.8 (ArC), 128.6 (ArC), 128.4 (ArC), 123.7 (ArC), 123.4 (ArC), 95.4 (C-
1), 82.6 (C-4), 77.3 (C-3), 72.4 (C-2), 70.1 (CH2CH2O), 69.3 (CH2Ph), 50.9 (CH2N3), 47.7 (C-5); 
ESI-HRMS: m/z calcd. for C37H32N6NaO14 [M+Na]
+ 807.1874; found, 807.1852;  isomer: 
[α]D25= -32.63 (c 0.5, DCM); 1H NMR (400 MHz, CDCl3): δ 8.53 – 7.91 (m, 8H, ArH), 7.29 (s, 
10H, ArH), 6.52 (s, 1H, H-1), 5.71 (d, J = 4.1 Hz, 1H, H-2), 5.19 (q, J = 12.3 Hz, 4H, 2*CH2Ph), 
4.46 (dt, J = 8.1, 4.9 Hz, 1H, H-4), 4.39 (dd, J = 8.0, 4.2 Hz, 1H, H-3), 4.30 – 4.14 (m, 2H, H-5), 
3.73 (ddd, J = 9.9, 6.8, 3.3 Hz, 1H, CH2CH2O), 3.57 (ddd, J = 9.5, 6.0, 3.3 Hz, 1H, CH2O), 3.30 
– 3.04 (m, 2H, CH2N3); 13C NMR (101 MHz, CDCl3): δ 163.5 (C=O), 162.9 (C=O), 153.9 
(C=O), 150.9 (ArC), 150.7 (ArC), 134.9 (ArC), 134.4 (ArC), 134.3 (ArC), 131.1 (ArC), 131.0 
(ArC), 128.6 (ArC), 128.5 (ArC), 128.2 (ArC), 128.1 (ArC), 123.7 (ArC), 123.6 (ArC), 99.6 (C-
1), 80.2 (C-4), 79.2 (C-3), 74.5 (C-2), 70.4 (CH2CH2O), 69.2 (CH2Ph), 50.6 (CH2N3), 47.2 (C-5); 
ESI-HRMS: m/z calcd. for C37H32N6NaO14 [M+Na]
+ 807.1874; found, 807.1877. 
5-O--[3-O-(2-Azidoethyl)-5-di(benzyloxycarbonyl)amino-5-deoxy-2-O-p-
nitrobenzoyl-D-ribofuranose]-6,2’’,3’’,6’’-tetra-O-acetyl-1,3,2’,4’’-tetraazido-6’,7’-
oxazolidino-apramycin (164). Donor 163 ( isomer, 165 mg, 0.21 mmol), acceptor 124 (440 
mg, 0.52 mmol) and activated 4 Å MS were stirred in dry DCM (3 mL) at rt for 1 h before 
cooling to 0 °C. BF3.OEt2 (300 L, 0.78 mmol) was added and reaction mixture was stirred for 
48 h at 0 °C. The reaction was quenched with triethylamine (0.5 mL) and filtered through Celite® 
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before it was diluted with EtOAc. The organic layer was washed with aqueous NaHCO3 and 
brine then concentrated. The crude product was purified using silica gel column chromatography 
(eluent: 0.6% - 1.5% Methanol/DCM) to give the glycoside 164 (136 mg, 45%) as the  anomer 
in the form of a white solid;  [α]D25= +46.26 (c 0.9, DCM); 1H NMR (600 MHz, CDCl3): δ 8.29 
– 8.21 (m, 2H, ArH), 8.19 – 8.09 (m, 2H, ArH), 7.39 – 7.32 (m, 4H, ArH), 7.32 – 7.25 (m, 6H, 
ArH), 5.43 – 5.35 (m, 3H, H-1’, H-3’’, H-1’’), 5.32 (d, J = 3.9 Hz, 1H, H-1’’’), 5.31 – 5.26 (m, 
4H, 2*CH2Ph), 5.25 (d, J = 4.1 Hz, 1H, H-2’’’), 4.89 (dd, J = 10.3, 3.9 Hz, 1H, H-2’’), 4.87 (d, J 
= 3.4 Hz, 1H, H-8’), 4.84 (t, J = 9.8 Hz, 1H, H-6), 4.78 (dd, J = 8.2, 3.2 Hz, 1H, H-6’), 4.60 (dd, 
J = 10.5, 3.2 Hz, 1H, H-5’), 4.31 (dd, J = 12.3, 2.3 Hz, 1H, H-6’’), 4.28 – 4.18 (m, 2H, H-6’’, H-
4’’’), 4.18 – 4.10 (m, 2H, H-5’’’), 4.08 (dd, J = 7.8, 4.5 Hz, 1H, H-3’’’), 3.79 (dd, J = 8.2, 3.5 
Hz, 1H, H-7’), 3.71 (ddd, J = 10.7, 5.3, 2.3 Hz, 1H, H-5’’), 3.66 (td, J = 10.9, 4.3 Hz, 1H, H-4’), 
3.63 – 3.52 (m, 4H, H-3, H-5, H-4’’, CH2CH2O), 3.49 – 3.43 (m, 2H, H-4, CH2CH2O), 3.39 
(ddd, J = 12.5, 10.2, 4.2 Hz, 1H, H-1), 3.27 (dt, J = 12.8, 4.3 Hz, 1H, H-2’), 3.12 (ddd, J = 13.3, 
7.3, 3.2 Hz, 1H, CH2N3), 3.02 (ddd, J = 13.3, 5.7, 3.2 Hz, 1H, CH2N3), 2.92 (s, 3H, NCH3), 2.38 
(dt, J = 12.9, 4.5 Hz, 1H, H-2), 2.20 (s, 3H, COCH3), 2.17 – 2.11 (m, 1H, H-3’), 2.08 (d, J = 4.4 
Hz, 6H, 2*COCH3), 2.04 (s, 3H, COCH3), 1.77 (q, J = 11.8 Hz, 1H, H-3’), 1.41 (q, J = 12.6 Hz, 
1H, H-2); 13C NMR (151 MHz, CDCl3): δ 170.3 (C=O), 170.0 (C=O), 169.9 (C=O), 169.4 
(C=O), 163.9 (C=O), 157.0 (ArC), 153.7 (ArC), 150.8 (ArC), 135.3 (ArC), 134.4 (ArC), 130.9 
(ArC), 128.5 (ArC), 128.2 (ArC), 127.9 (ArC), 123.7 (ArC), 106.7 (C-1’’’), 96.8 (C-1’), 95.4 (C-
8’), 94.0 (C-1’’), 80.4 (C-5), 79.5 (C-3’’’), 79.3 (C-4), 79.1 (C-4’’’), 74.8 (C-2’’’), 74.3 (C-6), 
70.6 (C-3’’), 70.3 (C-6’), 70.0 (CH2CH2O), 69.9 (C-2’’), 68.9 (2*CH2Ph), 65.6 (C-5’), 65.3 (C-
4’), 62.9 (C-6’’), 60.14 (C-7’), 60.11 (C-4’’), 58.3 (C-3), 58.1 (C-1), 57.4 (C-2’), 50.6 (CH2N3), 
48.2 (C-5’’’), 31.3 (C-3’), 31.0 (C-2), 29.9 (NCH3), 21.0 (COCH3), 20.9 (COCH3), 20.8 
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(COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. for C60H66N18NaO26 [M+Na]
+ 1477.4293; 
found, 1477.4232. 
5-O--[5-Amino-3-O-(2-aminoethyl)-5-deoxy-D-ribofuranosyl] apramycin 
heptaacetate salt (165). A stirred solution of substrate 164 (67 mg, 0.046 mmol) in dioxane (1.5 
mL) was treated with 3 N NaOH (1.5 mL) and heated at 100 °C for 18 h. The reaction mixture 
was cooled to 0 °C and neutralized with glacial acetic acid before it was concentrated in vacuo. 
The crude mixture was passed through a silica gel column (eluent: 25% methanol/DCM). The 
resulting solid (20 mg, 0.023 mmol) was dissolved in a water methanol:water mixture (1:1, 0.5 
mL) and treated with N-(diethylcarbamoyl)-N-methoxyformamide172 (30 L, 0.17 mmol) and 
triethylamine (2L). The reaction mixture was stirred for 2 h and quenched with aqueous 
ammonium hydroxide (0.25 mL) and concentrated. The crude product was purified using silica 
gel column chromatography (eluent: 5% to 15% ammonical MeOH in DCM). A part of the solid 
residue (12 mg, 0.014 mmol) dissolved in dioxane (3 mL) followed by the addition of 1 N NaOH 
(0.5 mL) and 1 M P(CH3)3 in THF (0.2 mL), and stirred at 50 °C for 45 min. The reaction 
mixture was then concentrated to dryness and dissolved in aqueous acetic acid (pH 4, 1 mL) 
before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with 
D.I. water (20 mL), then gradient eluted of 0.1% - 1.0% NH4OH in D.I. water. The fractions 
containing the products were combined, acidified with glacial acetic acid and lyophilized to 
afford 165 in (14.5 mg, 56%) as a white solid; [α]D25= +72.53 (c 0.7, H2O); 1H NMR (600 MHz, 
D2O): δ 5.73 (d, J = 4.0 Hz, 1H, H-1’), 5.31 (d, J = 3.7 Hz, 1H, H-1’’), 5.26 (s, 1H, H-1’’’), 5.03 
(d, J = 8.6, 1H, H-8’), 4.40 (s, 1H, H-6’), 4.26 (d, J = 4.4 Hz, 1H, H-2’’’), 4.03 (td, J = 7.5, 3.8 
Hz, 1H, H-4’’’), 3.93 – 3.86 (m, 2H, H-4, H-3’’’), 3.83 – 3.71 (m, 4H, H-5, H-4’, H-3’’, H-5’’), 
3.69 – 3.57 (m, 4H, CH2CH2O, H-6’’), 3.56 – 3.44 (m, 4H, H-6, H-2’, H-5’, H-2’’), 3.35 – 3.26 
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(m, 1H, H-3), 3.23 – 3.11 (m, 3H, H-1, H-7’, H-5’’’), 3.11 – 2.99 (m, 4H, H-4’’, H-5’’’, 
CH2CH2O), 2.59 (s, 3H, NCH3), 2.24 (dt, J = 13.1, 4.4 Hz, 1H, H-2), 2.20 (dt, J = 10.1, 4.7 Hz, 
1H, H-3’), 1.93 – 1.83 (m, 1H, H-3’), 1.68 – 1.59 (m, 1H, H-2); 13C NMR (151 MHz, D2O): δ 
108.9 (C-1’’’), 94.4 (C-1’), 92.7 (C-1’’), 92.5 (C-8’), 83.2 (C-5), 79.2 (C-3’’’), 77.0 (C-4’’’), 
73.6 (C-4), 72.7 (C-2’’’), 72.0 (C-6), 70.2 (C-2’’), 69.5 (C-5’’, C-5’), 68.3 (C-3’’), 65.9 (C-4’), 
65.8 (CH2CH2O), 62.6 (C-6’), 60.2 (C-6’’), 59.5 (C-7’), 52.0 (C-4’’), 50.0 (C-1), 48.7 (C-3), 
47.6 (C-2’), 42.1 (C-5’’’), 39.2 (CH2CH2O), 30.0 (NCH3), 28.2 (C-2), 27.0 (C-3’); ESI-HRMS: 
m/z calcd. for C28H56N7O14 [M+H]
+ 714.3885; found, 714.3868. 
5-O--[3-O-(2-Aminoethyl)-5-deoxy-5-formamido-D-ribofuranosyl] apramycin 
hexaacetate salt (166). A stirred solution of substrate 164 (67 mg, 0.046 mmol) in dioxane (1.5 
mL) was treated with 3 N NaOH (1.5 mL) and heated at 100 °C for 18 h. The reaction mixture 
was cooled to 0 °C and neutralized with glacial acetic acid before it was concentrated in vacuo. 
The crude mixture was passed through a silica gel column (eluent: 25% methanol/DCM). The 
resulting solid (20 mg, 0.023 mmol) was dissolved in a water methanol:water mixture (1:1, 0.5 
mL) and treated with N-(diethylcarbamoyl)-N-methoxyformamide172 (30 L, 0.17 mmol) and 
triethylamine (2L). The reaction mixture was stirred for 2 h and quenched with aqueous 
ammonium hydroxide (0.25 mL) and concentrated. The crude product was purified using silica 
gel column chromatography (eluent: 5% to 15% ammonical MeOH in DCM). A part of the solid 
residue (20 mg, 0.022 mmol) was dissolved in dioxane:water (1:1, 0.6 mL) followed by the 
addition 1 M P(CH3)3 in THF (0.3 mL), and stirred at 50 °C for 45 min. The reaction mixture 
was then concentrated to dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) 
before it was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with 
D.I. water (20 mL), then gradient elution of 0.1% - 1.0% NH4OH in D.I. water. The fractions 
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containing the product were combined, acidified with acetic acid, and lyophilized to afford 166 
in (13.9 mg, 57%) as a white solid; [α]D25= +55.35 (c 0.2, H2O); 1H NMR (600 MHz, D2O): δ 
7.94 (s, 1H, CHO), 5.69 (d, J = 3.9 Hz, 1H, H-1’), 5.30 (d, J = 4.0 Hz, 1H, H-1’’), 5.15 (d, J = 
3.0 Hz, 1H, H-1’’’), 5.03 (d, J = 8.6 Hz, 1H, H-8’), 4.40 (t, J = 2.7 Hz, 1H, H-6’), 4.16 (dd, J = 
4.9, 3.0 Hz, 1H, H-2’’’), 3.97 (q, J = 5.6 Hz, 1H, H-4’’’), 3.88 (t, J = 9.6 Hz, 1H, H-4), 3.83 – 
3.68 (m, 5H, H-5, H-4’, H-3’’, H-5’’, H-3’’’), 3.68 – 3.55 (m, 4H, H-6’’, CH2CH2O), 3.54 – 3.44 
(m, 4H, H-6, H-2’, H-5’, H-2’’), 3.40 (dd, J = 14.5, 4.6 Hz, 1H, H-5’’’), 3.33 (ddd, J = 14.3, 
10.4, 4.3 Hz, 1H, H-3), 3.29 (dd, J = 14.5, 6.1 Hz, 1H, H-5’’’), 3.20 (dd, J = 8.6, 2.8 Hz, 1H, H-
7’), 3.18 – 3.12 (m, 1H, H-1), 3.10 (t, J = 10.3 Hz, 1H, H-4’’), 3.05 – 2.98 (m, 2H, CH2CH2O), 
2.59 (s, 3H, NCH3), 2.28 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 2.18 (dt, J = 11.2, 4.6 Hz, 1H, H-3’), 
1.88 (d, J = 11.8 Hz, 1H, H-3’), 1.72 – 1.63 (m, 1H, H-2); 13C NMR (151 MHz, D2O): δ 164.8 
(CHO), 110.3 (C-1’’’), 94.4 (C-1’), 93.6 (C-1’’), 92.8 (C-8’), 84.8 (C-5), 79.3 (C-4’’’), 78.8 (C-
3’’’), 74.8 (C-4), 73.1 (C-2’’’), 72.3 (C-6), 70.2 (C-2’’), 69.7 (C-5’’), 69.3 (C-5’), 68.2 (C-3’’), 
65.9 (C-4’), 65.8 (CH2CH2O), 62.6 (C-6’), 60.2 (C-6’’), 59.3 (C-7’), 52.0 (C-4’’), 49.6 (C-1), 
48.5 (C-3), 47.6 (C-2’), 40.1 (C-5’’’), 39.2 (CH2CH2O), 30.0 (NCH3), 27.9 (C-2), 26.7 (C-3’); 
ESI-HRMS: m/z calcd. for C29H56N7O15 [M+H]
+ 742.3834; found, 742.3861.  
3-O-(2-Azidoethyl)-5-(benzyloxy)-5-deoxy-1,2,4-tri-O-(p-nitrobenzoyl)-1,5-imino-D 
ribopyranose (170). To a stirred solution of compound 161 (350 mg, 0.89 mmol) in dioxane (10 
mL), 1 N HCl (4 mL) was added and the reaction mixture was heated at 80 °C for 45 min. The 
reaction mixture was cooled, neutralized with solid NaHCO3 and the solvent was evaporated. 
The residue was dissolved in EtOAc and washed with water and brine, dried with Na2SO4 and 
concentrated in vacuo. A solution of the crude product in dry pyridine (10 mL), was treated with 
p-nitrobenzoyl chloride (560 mg, 3.01 mmol) and a catalytic amount of DMAP and stirred 
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overnight. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO3 and 
brine, dried with Na2SO4 then concentrated. The crude product was purified using silica gel 
column chromatography (eluent: 10% - 40% EtOAc/hexanes) to give  (69 mg, 10 %) as a 
yellow oil; [α]D25= +15.99 (c 3.3, DCM); 1H NMR (400 MHz, CDCl3): δ 8.40 – 8.25 (m, 8H, 
ArH), 8.25 – 8.19 (m, 2H, ArH), 8.12 – 8.02 (m, 2H, ArH), 7.37 (dd, J = 37.0, 19.9 Hz, 5H, 
ArH), 5.42 (dd, J = 4.2, 3.0 Hz, 1H, H-2), 5.32 (ddd, J = 11.4, 5.2, 2.5 Hz, 1H, H-4), 5.26 (d, J = 
12.4 Hz, 1H, OCH2Ph), 5.18 (d, J = 12.3 Hz, 1H, OCH2Ph), 4.70 (br s, 1H, H-1), 4.49 (t, J = 2.9 
Hz, 1H, H-3), 4.39 (br s, 1H, H-5), 3.93 – 3.74 (m, 3H, H-5, CH2O), 3.42 – 3.23 (m, 2H, 
CH2N3);
 13C NMR (101 MHz, CDCl3): δ 151.0 (ArC), 131.0 (ArC), 130.8 (ArC), 128.6 (ArC), 
123.9 (ArC), 123.8 (ArC), 76.0 (C-3), 75.4 (C-1), 72.6 (CH2CH2O), 70.2 (C-2), 69.6 (C-4), 68.8 
(OCH2Ph), 51.4 (CH2CH2O), 37.5 (C-5); ESI-HRMS: m/z calcd. for C36H29N7NaO15 [M+Na]
+ 
822.1619; found, 822.1601. 
5,2'',3'',6''-Tetra-O-acetyl-6-O-allyl-1,3,2′,4′′-tetraazido-6′,7′-oxazolidino-apramycin 
(172). 6,2’’,3’’,6’’-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-6′,7′-oxazolidino-apramycin 124 (100 mg, 
0.12 mmol) was dissolved in dry DCM (0.5 mL) and treated with allyl bromide (0.5 mL, 5.9 
mmol) and silver oxide (400 mg, 1.7 mmol). The reaction mixture was cover with aluminium foil 
and stirred at rt for 12 h. After completion, the reaction was filtered through Celite® and 
concentrated to dryness. The crude product was purified by column chromatography (eluent: 5% 
to 30% EtOAc/hexanes) to give 172 (60 mg, 59%) as a white solid; [α]D25= +60.0 (c 0.2, DCM); 
1H NMR (400 MHz, CDCl3): δ 5.86 (ddt, J = 16.3, 10.3, 5.9 Hz, 1H, CH2CHCH2O), 5.45 – 5.34 
(m, 1H, H-3’’), 5.32 (d, J = 3.8 Hz, 1H, H-1’’), 5.25 (dd, J = 17.2, 1.5 Hz, 1H, CH2CHCH2O), 
5.22 – 5.16 (m, 1H, CH2CHCH2O), 5.05 (t, J = 9.9 Hz, 1H, H-5), 4.99 – 4.90 (m, 2H, H-8’, H-
2’’), 4.87 (d, J = 3.6 Hz, 1H, H-1’), 4.81 (dd, J = 8.6, 3.2 Hz, 1H, H-6’), 4.74 (dd, J = 10.5, 3.2 
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Hz, 1H, H-5’), 4.36 – 4.17 (m, 3H, H-6’’, CH2CHCH2O), 4.09 (dd, J = 12.2, 6.1 Hz, 1H, 
CH2CHCH2O), 3.92 – 3.82 (m, 2H, H-4’, H-7’), 3.82 – 3.76 (m, 1H, H-3), 3.76 – 3.67 (m, 1H, 
H-5’’), 3.66 – 3.52 (m, 2H, H-1, H-4’’), 3.48 (t, J = 9.9 Hz, 1H, H-4), 3.39 (dt, J = 12.7, 4.1 Hz, 
1H, H-2’), 3.19 (t, J = 9.8 Hz, 1H, H-6), 2.92 (s, 3H, NCH3), 2.46 (dt, J = 13.1, 4.6 Hz, 1H, H-2), 
2.26 (dt, J = 10.7, 4.1 Hz, 1H, H-3’), 2.21 – 2.02 (m, 12H, 4*COCH3), 1.85 (q, J = 11.4 Hz, 1H, 
H-3’), 1.49 (q, J = 12.5 Hz, 1H, H-2); 13C NMR (101 MHz, CDCl3): δ 170.3 (C=O), 170.3 
(C=O), 170.0 (C=O), 169.4 (C=O), 156.9 (C=O), 133.6 (CH2CHCH2O), 118.1 (CH2CHCH2O), 
99.1 (C-1’), 94.2 (C-8’, C-1’’), 81.9 (C-6), 80.3 (C-4), 74.3 (CH2CHCH2O), 74.0 (C-5), 70.7 (C-
3’’), 69.9 (C-2’’), 69.7 (C-6’), 68.8 (C-5’’), 65.4 (C-5’), 65.2 (C-4’), 62.9 (C-6’’), 60.2 (C-4’’), 
60.0 (C-7’), 59.7 (C-1), 58.4 (C-3), 56.6 (C-2’), 32.1 (C-2), 30.0 (NCH3), 29.8 (C-3’), 21.1 
(COCH3), 21.0 (COCH3), 20.8 (COCH3), 20.7 (COCH3); ESI-HRMS: m/z calcd. for 
C33H43N13NaO16 [M+Na]
+ 900.2848; found, 900.2841. 
6-O-Propyl apramycin pentaacetate salt (173). To a solution of compound 172 (20 mg, 
0.02 mmol) in dry methanol (0.4 mL), sodium methoxide (5 mg, 0.03 mmol) was added and 
reaction mixture was stirred for 3 h. The reaction was quenched with glacial acetic acid, filtered 
and the solvent was evaporated in vacuo. The crude mixture was purified using silica gel column 
chromatography (eluent: 0.5% - 3.5% methanol/DCM) and the product-containing fractions were 
concentrated in vacuo. The resulting solid was dissolved in dioxane:water:glacial acetic acid = 
1:2:0.2 (0.3 mL) and 10% Pd/C (15 mg) was added. The reaction was stirred at room 
temperature under 1 atm of hydrogen (balloon) for 12 h. After completion, the reaction mixture 
was filtered over Celite® and filtrate concentrated to dryness. The residue was dissolved in 
dioxane (0.5 mL) and treated with 3N NaOH (0.25 mL) and heated at 100 °C for 2 h. The 
reaction mixture was cooled to rt and neutralized with glacial acetic acid before concentration in 
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vacuo. The crude product was dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it 
was charged to a Sephadex column (CM Sephadex C-25). The column was flushed with D.I. 
water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The fractions 
containing the product were combined, acidified with glacial acetic acid and lyophilized to afford 
173 (9.2 mg, 46%) as a white solid; [α]D25= +93.33 (c 0.2, H2O); 1H NMR (600 MHz, D2O): δ 
5.57 (d, J = 3.8 Hz, 1H, H-1’), 5.33 (d, J = 4.0 Hz, 1H, H-1’’), 5.05 (d, J = 8.5 Hz, 1H, H-8’), 
4.40 (s, 1H, H-6’), 3.84 – 3.72 (m, 4H, H-4, H-4’, H-3’’, H-5’’), 3.72 – 3.52 (m, 5H, H-5, H-5’, 
H-2’’, H-6’’, CH3CH2CH2O), 3.52 – 3.42  (m, 2H, H-2’, CH3CH2CH2O), 3.34 – 3.24 (m, 2H, H-
3, H-6), 3.24 – 3.10 (m, 3H, H-1, H-7’, H-4’’), 2.62 (s, 3H, NCH3), 2.32 (dt, J = 12.5, 4.3 Hz, 
1H, H-2), 2.20 (dt, J = 10.6, 4.7 Hz, 1H, H-3’), 1.69 (q, J = 12.5 Hz, 1H, H-2), 1.44 (h, J = 7.2 
Hz, 2H, CH3CH2CH2O), 0.69 (t, J = 7.4 Hz, 3H, CH3CH2CH2O); 
13C NMR (151 MHz, D2O): δ 
95.3 (C-1’), 94.4 (C-1’’), 92.8 (C-8’), 80.5 (C-6), 77.7 (C-4), 75.6 (CH3CH2CH2O), 75.2 (C-5), 
70.1 (C-2’’), 69.6 (C-5’), 69.3 (C-5’’), 68.2 (C-3’’), 66.0 (C-4’), 62.7 (C-6’), 60.2 (C-6’’), 59.3 
(C-7’), 52.0 (C-4’’), 48.8 (C-1), 48.3  (C-3), 47.8 (C-2’), 28.2 (C-2), 26.7 (C-3’), 30.0 (NCH3), 
22.5 (CH3CH2CH2O), 9.3 (CH3CH2CH2O); ESI-HRMS: m/z calcd. for C24H48N5O11 [M+H]
+ 
582.3350; found, 582.3342. 
5,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-6-O-(2,3-dihydroxypropyl)-6′,7′-
oxazolidino-apramycin (174). A stirred solution of compound 172 (20 mg, 0.02 mmol) in THF 
(0.4 mL) and water (0.1 mL) was treated with N-Methylmorpholine-N-oxide (8 mg, 0.07 mmol) 
and 2.5% OsO4 in tert-butanol (60 L mg, 0.005 mmol). The reaction mixture was stirred at rt 
for 4 h. After completion, the reaction mixture was diluted with EtOAc and the organic layer was 
washed with aqueous NaHCO3 followed by brine, dried with Na2SO4, and concentrated. The 
crude product was purified via silica gel chromatography eluting with 0.7% to 3% methanol in 
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DCM to give 174 (15 mg, 71%) as a white solid; [α]D25= +63.75 (c 1.3, DCM); 1H NMR (400 
MHz, CDCl3): δ 5.38 (t, J = 9.9 Hz, 1H, H-3’), 5.32 (d, J = 3.8 Hz, 1H, H-1’’), 5.08 – 5.01 (m, 
1H, H-5), 4.98 – 4.91 (m, 2H, H-8’, H-2’’), 4.88 (d, J = 3.0 Hz, 1H, H-1’), 4.80 (dd, J = 8.6, 3.1 
Hz, 1H H-6’), 4.71 (dd, J = 10.5, 3.1 Hz, 1H, H-5’), 4.36 – 4.27 (m, 1H, H-6’’), 4.22 (dd, J = 
12.2, 5.0 Hz, 1H, H-6’’), 3.90 – 3.68 (m, 6H, H-3, H-4’, H-7’, H-5’’, CH2OHCHOHCH2O, 
CH2OHCHOHCH2O), 3.66 – 3.43 (m, 6H, H-1, H-4, H-4’’, CH2OHCHOHCH2O, 
CH2OHCHOHCH2O), 3.37 (dt, J = 12.6, 3.6 Hz, 1H, H-2’), 3.19 (t, J = 9.8 Hz, 1H, H-6), 2.91 
(s, 3H, NCH3), 2.48 (dt, J = 12.7, 4.2 Hz, 1H, H-2), 2.29 – 2.23 (m, 1H, H-3’), 2.17 – 2.07 (m, 
12H, 4*COCH3), 1.90 – 1.80 (m, 1H, H-3’), 1.59 – 1.46 (m, 1H, H-2); 13C NMR (101 MHz, 
CDCl3): δ 170.4 (C=O), 170.2 (C=O), 170.0 (C=O), 157.0 (C=O), 99.1 (C-1’), 94.5 (C-8’), 94.3 
(C-1’’), 82.9 (C-6), 80.0 (C-4), 74.8 (C-5), 74.4 (CH2OHCHOHCH2O), 70.7 (C-3’’), 70.6 (C-
2’’), 69.9 (CH2OHCHOHCH2O), 69.7 (C-6’), 68.8 (C-5’’), 65.4 (C-5’), 65.2 (C-4’), 63.1 
(CH2OHCHOHCH2O), 62.9 (C-6’’), 60.1 (C-4’’), 60.0 (C-7’), 59.6 (C-1), 58.2 (C-3), 56.4 (C-
2’), 31.8 (C-2), 29.9 (NCH3), 29.8 (C-3’), 21.1 (COCH3), 20.9 (COCH3), 20.9 (COCH3), 20.7 
(COCH3); ESI-HRMS: m/z calcd. for C33H45N13NaO18 [M+Na]
+ 934.2903; found, 934.2905. 
6-O-(2,3-Dihydroxypropyl)-apramycin pentaacetate salt (175). A stirred solution of 
compound 174 (14 mg, 0.015 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) 
and heated at 100 °C for 2 h. 1M P(CH3)3 in THF (0.15 mL) was added and the reaction mixture 
was stirred at 55 °C for 2 h. The reaction mixture was cooled to 0 °C, neutralized with glacial 
acetic acid and concentrated. The crude product was dissolved in aqueous acetic acid solution 
(pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column was flushed 
with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The 
fractions containing the product were combined, acidified with glacial acetic acid, and 
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lyophilized to afford 175 (5.5 mg, 39%) as peracetate salt in the form of a white solid; [α]D25= 
+100.96 (c 0.2, H2O); 
1H NMR (600 MHz, D2O): δ 5.51 (s, 1H, H-1’), 5.28 (d, J = 4.0 Hz, 1H, 
H-1’’), 5.00 (dd, J = 8.4, 1.5 Hz, 1H, H-8’), 4.35 (s, 1H, H-6’), 3.86 – 3.66 (m, 6H, H-4, H-4’, 
H-3’’, H-5’’, CH2OHCHOHCH2O, CH2OHCHOHCH2O), 3.66 – 3.52 (m, 5H, H-5, H-5’, H-6’’, 
CH2OHCHOHCH2O), 3.50 (dd, J = 9.3, 3.9 Hz, 1H, H-2’’), 3.48 – 3.34 (m, 4H, H-2’, 
CH2OHCHOHCH2O), 3.32 – 3.22 (m, 2H, H-3, H-6), 3.23 – 3.14 (m, 2H, H-1, H-7’), 3.08 (t, J 
= 10.2 Hz, 1H, H-4’’), 2.57 (s, 3H, NCH3), 2.31 – 2.23 (m, 1H, H-2), 2.19 – 2.10 (m, 1H, H-3’), 
1.66 (q, J = 12.6 Hz, 1H, H-2); 13C NMR (151 MHz, D2O) δ 95.4 (C-1’), 94.3 (C-1’’), 92.7 (C-
8’), 81.3 (C-6), 77.7 (C-4), 75.2 (C-5), 73.7 (CH2OHCHOHCH2O), 70.3 (CH2OHCHOHCH2O), 
70.1 (C-2’’), 69.6 (C-5’), 69.2 (C-5’’), 68.2 (C-3’’), 65.9 (C-4’), 62.6 (C-6’), 62.1 
(CH2OHCHOHCH2O), 60.2 (C-6’’), 59.3 (C-7’), 52.0 (C-4’’), 48.8 (C-1), 48.2 (C-3), 47.8 (C-
2’), 29.9 (NCH3), 28.1 (C-2), 26.6 (C-3’); ESI-HRMS: m/z calcd. for C24H48N5O13 [M+H]+ 
614.3249; found, 614.3242. 
5,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-6-O-(2-hydroxyethyl)-6′,7′-
oxazolidino-apramycin (176). To a stirred solution of compound 174 (22 mg, 0.024 mmol) in 
THF (0.4 mL) and water (0.1 mL), NaIO4 (15.5 mg, 0.07 mmol) was added and the reaction 
mixture was stirred at rt for 12 h. The reaction mixture was diluted with EtOAc and washed with 
aqueous NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated. To a 
solution of the residue in in THF (0.4 mL) and water (0.1 mL), NaBH4 (1.8 mg, 0.048 mmol) and 
the reaction mixture was stirred at rt for 45 min. The reaction mixture was diluted with EtOAc 
and washed with aqueous NaHCO3, brine, dried with Na2SO4 and concentrated. The crude 
product was purified using silica gel column chromatography (eluent: 0.75% - 3% 
methanol/DCM) to give 176(11 g, 52%) as a white solid; [α]D25= +60.6 (c 0.3, DCM); 1H NMR 
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(600 MHz, CD3OD): δ 5.47 – 5.40 (m, 1H, H-3’’), 5.38 (d, J = 3.8 Hz, 1H, H-1’’), 5.13 (d, J = 
2.1 Hz, 1H, H-8’), 5.02 (t, J = 9.7 Hz, 1H, H-5), 4.97 (dd, J = 10.3, 3.8 Hz, 1H, H-2’’), 4.92 – 
4.86 (m, 3H, H-1’, H-5’, H-6’), 4.35 (d, J = 12.1 Hz, 1H, H-6’’), 4.25 (dd, J = 12.3, 4.1 Hz, 1H, 
H-6’’), 4.10 (dd, J = 8.9, 2.1 Hz, 1H, H-7’), 3.89 – 3.79 (m, 4H, H-4’, H-4’’, H-5’’, 
CH2OHCH2O), 3.79 – 3.73 (m, 1H, H-3), 3.72 – 3.63 (m, 2H, H-4, CH2OHCH2O), 3.63 – 3.54 
(m, 3H, H-1, CH2OHCH2O), 3.57 – 3.49 (m, 1H, H-2’), 3.37 (t, J = 9.8 Hz, 1H, H-6), 2.91 (s, 
3H, NCH3), 2.44 (dt, J = 12.7, 4.6 Hz, 1H, H-2), 2.28 (dt, J = 8.8, 4.2 Hz, 1H, H-3’), 2.18 – 2.04 
(m, 12H, 4*COCH3), 1.85 – 1.79 (m, 1H, H-3’), 1.61 (q, J = 12.5 Hz, 1H, H-2); 13C NMR (151 
MHz, CD3OD): δ 170.9 (C=O), 170.5 (C=O), 170.4 (C=O), 158.2 (C=O), 99.1 (C-1’), 93.9 (C-
1’’), 93.0 (C-8’), 82.5 (C-6), 80.2 (C-4), 74.5 (C-5), 74.1  (CH2OHCH2O), 70.9 (C-3’’), 70.2 (C-
2’’), 70.0 (C-6’), 68.7 (C-5’’), 65.1 (C-5’), 65.1 (C-4’), 62.9 (C-6’’), 60.8 (CH2OHCH2O), 60.1 
(C-4’’), 59.9 (C-7’), 59.8 (C-1), 58.2 (C-3), 56.6 (C-2’), 31.1 (C-2), 30.1 (C-3’), 28.6 (NCH3), 
20.1 (COCH3), 20.0 (COCH3), 19.4 (COCH3), 19.2 (COCH3); ESI-HRMS: m/z calcd. for 
C32H43N13NaO17 [M+Na]
+ 904.2798; found, 904.2801. 
6-O-(2-hydroxyethyl)-apramycin pentaacetate salt (177). A stirred solution of 
compound 176 (10 mg, 0.011 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) 
and heated at 100 °C for 1 h. 1M P(CH3)3 in THF (0.15 mL) was added and the reaction mixture 
was stirred at 55 °C for 2 h. The reaction mixture was cooled to 0 °C, neutralized with glacial 
acetic acid and concentrated. The crude product was dissolved in aqueous acetic acid solution 
(pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column was flushed 
with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. water. The 
fractions containing the product were combined, acidified with glacial acetic acid, and 
lyophilized to afford 177 (6.3 mg, 63%) as peracetate salt in the form of a white solid; [α]D25= 
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+107.38 (c 0.4, H2O); 
1H NMR (600 MHz, D2O): δ 5.52 (d, J = 3.8 Hz, 1H, H-1’), 5.32 (d, J = 
4.0 Hz, 1H, H-1’’), 5.04 (d, J = 8.5 Hz, 1H, H-8’), 4.38 (s, 1H, H-6’), 3.90 – 3.84 (m, 1H, 
CH2OHCH2O), 3.80 – 3.66 (m, 5H, H-4, H-4’, H-3’’, H-5’’, H-6’’), 3.66 – 3.55 (m, 6H, H-5, H-
5’, H-6’’, CH2OHCH2O, CH2OHCH2O), 3.54 (dd, J = 9.7, 4.0 Hz, 1H, H-2’’), 3.47 (dt, J = 13.0, 
4.1 Hz, 1H, H-2’), 3.33 (t, J = 9.7 Hz, 1H, H-6), 3.27 – 3.15 (m, 3H, H-1, H-3, H-7’), 3.08 (t, J = 
10.3 Hz, 1H, H-4’’), 2.61 (s, 3H, NCH3), 2.31 – 2.24 (m, 1H, H-2), 2.20 (dt, J = 8.7, 3.9 Hz, 1H, 
H-3’), 1.86 (q, J = 11.6 Hz, 1H, H-3’), 1.64 (q, J = 11.7, 11.0 Hz, 1H, H-2); 13C NMR (151 MHz, 
D2O): δ 95.6 (C-1’), 94.4 (C-1’’), 92.9 (C-8’), 81.5 (C-6), 79.0 (C-4), 75.3 (C-5), 74.0  
(CH2OHCH2O), 70.2 (C-2’’), 69.7 (C-5’), 69.6 (C-5’’), 68.6 (C-3’’), 66.0 (C-4’), 62.8 (C-6’), 
60.8  (CH2OHCH2O), 60.3 (C-6’’), 59.4 (C-7’), 52.0 (C-4’’), 49.1 (C-1), 48.3 (C-3), 47.9 (C-2’), 
30.0 (NCH3), 28.9 (C-2), 26.8 (C-3’); ESI-HRMS: m/z calcd. for C24H48N5O13 [M+H]+ 
584.3143; found, 584.3129. 
5,6,2’’,3’’,6’’-Penta-O-acetyl-1,3,2′,4′′-tetraazido-5-epi-6′,7′-oxazolidino-apramycin 
(178). To a stirred solution of compound 124 (100 mg, 0.12 mmol) in dry DCM (1.5 mL), 
pyridine (0.1 mL) was added and reaction mixture was cooled to 0 °C before triflic anhydride 
(40 L, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional triflic 
anhydride (40 L, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into an 
iced aqueous solution of NaHCO3 and extracted with EtOAc. The organic layer was washed with 
brine and dried over Na2SO4 and concentrated in vacuo. The crude was dissolved in dry DMF (1 
mL), treated with potassium acetate (174 mg, 1.78 mmol) and stirred at 50 °C for 1 h. After 
completion, the reaction was diluted with EtOAc and washed with NaHCO3 and brine then 
concentrated. The crude was purified using silica gel column chromatography (eluent: 0.6% - 
1.0% methanol/DCM) to give compound 178 (75 mg, 72%) as a white solid; [α]D25= +154.25 (c 
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1.2, DCM); 1H NMR (400 MHz, CDCl3): δ 5.75 (t, J = 2.7 Hz, 1H, H-5), 5.51 – 5.38 (m, 2H, H-
1’’, H-3’’), 5.06 (d, J = 3.5 Hz, 1H, H-1’), 4.87 – 4.68 (m, 4H, H-6, H-6’, H-8’, H-2’), 4.34 (dd, 
J = 12.3, 2.2 Hz, 1H, H-6’’), 4.22 (dd, J = 12.2, 5.4 Hz, 1H, H-6’’), 3.97 (dd, J = 10.2, 3.7 Hz, 
1H, H-5’), 3.91 – 3.83 (m, 2H, H-1, H-3), 3.80 (dd, J = 10.2, 2.6 Hz, 1H, H-4), 3.78 – 3.71 (m, 
2H, H-7’, H-5’’), 3.66 (td, J = 10.8, 4.4 Hz, 1H, H-4’), 3.56 (t, J = 10.1 Hz, 1H, H-4’’), 3.20 (dt, 
J = 12.7, 4.0 Hz, 1H, H-2’), 2.97 (s, 3H, NCH3), 2.38 (dt, J = 13.5, 4.7 Hz, 1H, H-2), 2.27 (dt, J 
= 11.4, 4.4 Hz, 1H, H-3’), 2.17 (s, 3H, COCH3), 2.12 (d, J = 6.5 Hz, 6H, 2*COCH3), 2.08 – 1.94 
(m, 7H, H-3’, 2*COCH3), 1.41 (q, J = 12.6 Hz, 1H, H-2); 13C NMR (101 MHz, CDCl3): δ 170.4 
(C=O), 170.2 (C=O), 169.7 (C=O), 169.6 (C=O), 169.5 (C=O), 156.9 (C=O), 99.9 (C-8’), 94.1 
(C-1’’), 93.8 (C-1’), 74.6 (C-4), 72.9 (C-6), 71.8, (C-6’) 69.9 (C-3’’, 2’’), 69.4 (C-5’’), 66.9 (C-
5’), 66.1 (C-5), 65.9 (C-4’), 62.8 (C-6’’), 60.2 (C-4’’), 60.1 (C-7’), 58.0 (C-1), 56.2 (C-3), 55.5 
(C-2’), 32.2 (C-2), 30.5 (NCH3), 28.1 (C-3’), 20.7 (COCH3), 20.6 (COCH3), 20.5 (COCH3); ESI-
HRMS: m/z calcd. for C32H41N13NaO17 [M+Na]
+ 902.2641; found, 902.2639. 
5-Epi-apramycin pentaacetate salt (179). A stirred solution of compound (178) (60 mg, 
0.057 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 100 °C for 
2 h. The reaction mixture was treated with 1M P(CH3)3 in THF (0.15 mL) and stirred at 55 °C 
for 2h. The reaction mixture was then concentrated and dissolved in aqueous acetic acid solution 
(pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-25). The column 
was flushed with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. 
water. The fractions containing the product were combined, acidified with glacial acetic acid, 
and lyophilized to afford 179 (39 mg, 65%) as peracetate salt in the form of a white solid; 
[α]D25= +90.0 (c 0.7, H2O); 1H NMR (600 MHz, D2O): δ 5.29 (d, J = 4.0 Hz, 1H, H-1’’), 5.21 (d, 
J = 3.8 Hz, 1H, H-1’), 5.02 (d, J = 8.5 Hz, 1H, H-8’), 4.34 (s, 1H, H-6’), 4.29 (s, 1H, H-5), 3.82 
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– 3.69 (m, 4H, H-4, H-4’, H-3’’, H-5’’), 3.65 (dd, J = 12.5, 3.5 Hz, 1H, H-6’’), 3.58 (dd, J = 
13.0, 4.5 Hz, 1H, H-6’’), 3.56 – 3.47 (m, 4H, H-3, H-6, H-2’, H-2’’), 3.44 (dd, J = 10.0, 2.6 Hz, 
1H, H-5’), 3.34 (ddd, J = 12.3, 10.6, 4.5 Hz, 1H, H-1), 3.15 (dd, J = 8.5, 2.8 Hz, 1H, H-7’), 3.09 
(t, J = 10.4 Hz, 1H, H-4’’), 2.58 (s, 3H, NCH3), 2.27 (dt, J = 12.5, 4.4 Hz, 1H, H-2), 2.20 (dt, J = 
11.4, 4.6 Hz, 1H, H-3’), 1.92 – 1.86 (m, 1H, H-3’), 1.55 (q, J = 12.5 Hz, 1H, H-2); 13C NMR 
(151 MHz, D2O): δ 94.3 (C-1’’), 92.7 (C-8’), 89.9 (C-1’), 72.9 (C-4), 70.1 (C-6), 69.8 (C-2’’), 
69.4 (C-5’), 69.3 (C-5’’), 68.2 (C-3’’), 66.0 (C-5), 65.8 (C-4’), 62.5 (C-6’), 60.2 (C-6’’), 59.4 (C-
7’), 52.0 (C-4’’), 48.1 (C-1), 47.4 (C-2’), 46.7 (C-3), 29.9 (NCH3), 28.1 (C-2), 26.9 (C-3’); ESI-
HRMS: m/z calcd. for C21H42N5O11 [M+H]
+ 540.2881; found, 540.2855. 
6,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-5-epi-6′,7′-oxazolidino-apramycin 
(180). To a stirred solution of compound 124 (100 mg, 0.12 mmol) in dry DCM (1.5 mL), 
pyridine (0.1 mL) was added and reaction mixture was cooled to 0 °C before triflic anhydride 
(40 L, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional triflic 
anhydride (40 L, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into an 
iced aqueous solution of NaHCO3 and extracted with EtOAc. The organic layer was washed with 
brine and dried over Na2SO4 and concentrated in vacuo. The crude product was dissolved in dry 
DMF (1 mL), treated with sodium nitrite (40 mg, 0.60 mmol) and stirred at 50 °C for 1 h. After 
completion, the reaction was diluted with EtOAc and washed with brine then concentrated. The 
crude product was purified using silica gel column chromatography (eluent: 0.6% - 1.0% 
Methanol/DCM) to give compound 180 (60 mg, 60%) as a white solid; [α]D25= +100.5 (c 0.6, 
DCM); 1H NMR (600 MHz, CDCl3): δ 5.43 (t, J = 10.1 Hz, 1H, H-3’’), 5.39 (d, J = 3.8 Hz, 1H, 
H-1’’), 4.99 (d, J = 3.5 Hz, 1H, H-1’), 4.83 (dd, J = 10.4, 3.8 Hz, 1H, H-2’’), 4.81 – 4.76 (m, 2H, 
H-6’, H-8’), 4.64 (dd, J = 10.4, 2.6 Hz, 1H, H-6), 4.39 (q, J = 2.7 Hz, 1H, H-5), 4.32 (dd, J = 
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12.2, 2.2 Hz, 1H, H-6’’), 4.25 – 4.19 (m, 2H, H-6’’, H-5’), 4.01 (ddd, J = 12.3, 10.4, 4.7 Hz, 1H, 
H-1), 3.92 (ddd, J = 12.4, 9.9, 4.9 Hz, 1H, H-3), 3.77 (dd, J = 7.3, 5.0 Hz, 1H, H-7’), 3.72 (ddd, J 
= 10.6, 5.3, 2.2 Hz, 1H, H-5’’), 3.67 (td, J = 10.9, 4.4 Hz, 1H, H-4’), 3.61 (dd, J = 9.9, 2.7 Hz, 
1H, H-4), 3.57 (t, J = 10.2 Hz, 1H, H-4’’), 3.45 (dt, J = 12.6, 4.1 Hz, 1H, H-2’), 3.13 (d, J = 2.7 
Hz, 1H, OH), 2.94 (s, 3H, NCH3), 2.36 – 2.26 (m, 2H, H-2, H-3’), 2.16 (s, 3H, COCH3), 2.15 – 
2.05 (m, 6H, 2*COCH3), 1.99 (dd, J = 23.9, 12.0 Hz, 1H, H-3’), 1.33 (q, J = 12.7 Hz, 1H, H-2); 
13C NMR (151 MHz, CDCl3): δ 170.4 (C=O), 170.2 (C=O), 169.7 (C=O), 157.1 (C=O), 98.0 (C-
8’), 94.5 (C-1’), 94.2 (C-1’’), 78.6 (C-4), 74.8 (C-6), 71.3 (C-6’), 70.1 (C-2’’), 69.9 (C-3’’), 69.3 
(C-5’’), 66.7 (C-5), 66.6 (C-5’), 65.6 (C-4’), 62.8 (C-6’’), 60.2 (C-7’), 60.1 (C-4’’), 57.15 (C-3), 
57.07 (C-2’), 55.7 (C-1), 32.0 (C-2), 30.2 (NCH3), 29.4 (C-3’), 20.9 (COCH3), 20.7 (COCH3), 
20.7 (COCH3); ESI-HRMS: m/z calcd. for C30H39N13NaO16 [M+Na]
+ 860.2535; found, 
860.2530. 
6,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-5-deoxy-5-fluoro-6′,7′-oxazolidino-
apramycin (181). A stirred ice-cooled solution of compound 180 (36 mg, 0.04 mmol) in dry 
DCM (0.2 mL), was treated with diethylaminosulfur trifluoride (45 L, 0.34 mmol) and stirred at 
0 °C for 1 h and at rt for 30 min. After completion, the reaction mixture was purified by gradient 
chromatography over silica gel (eluent: 0.7% to 0.8% MeOH in DCM) to give 181 (29 mg, 81%) 
as a white solid; [α]D25= +127.76 (c 1.9, DCM); 1H NMR (400 MHz, CDCl3): δ 5.40 (t, J = 10.0 
Hz, 1H, H-3’’), 5.35 (d, J = 3.8 Hz, 1H, H-1’’), 5.21 – 5.07 (m, 2H, H-6, H-1’), 4.96 – 4.86 (m, 
2H, H-8’, H-2’’), 4.82 (dd, J = 8.2, 3.4 Hz, 1H, H-6’), 4.57 (dd, J = 10.4, 3.3 Hz, 1H, H-5’), 4.45 
(dt, J = 50.3, 9.1 Hz, 1H, H-5), 4.34 (dd, J = 12.2, 2.4 Hz, 1H, H-6’’), 4.23 (dd, J = 12.2, 5.1 Hz, 
1H, H-6’’), 3.86 – 3.66 (m, 5H, H-3, H-4, H-4’, H-7’, H-5’’), 3.65 – 3.58 (m, 1H, H-4’’), 3.53 
(ddd, J = 12.3, 10.2, 4.4 Hz, 1H, H-1), 3.30 (dt, J = 12.9, 4.1 Hz, 1H, H-2’), 2.94 (s, 3H, NCH3), 
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2.47 (dt, J = 13.2, 4.4 Hz, 1H, H-2), 2.27 (dt, J = 11.4, 4.4 Hz, 1H, H-3’), 2.20 – 2.06 (m, 12H, 
4*COCH3), 1.94 (q, J = 11.5 Hz, 1H, H-3’), 1.67 (q, J = 12.5 Hz, 1H, H-2); 13C NMR (101 
MHz, CDCl3): δ 170.3 (C=O), 170.0 (C=O), 169.9 (C=O), 169.5 (C=O), 156.9 (C=O), 98.6 (C-
1’), 96.1 (C-8’), 94.6 (C-1’’), 93.34 (d, J = 187.8 Hz, C-5), 79.78 (d, J = 17.1 Hz, C-4), 73.05 (d, 
J = 18.5 Hz, C-6), 70.6 (C-3’’), 70.2 (C-2’’), 70.0 (C-6’), 69.0 (C-5’’), 65.8 (C-5’), 65.4 (C-4’), 
62.8 (C-6’’), 60.2 (C-7’), 60.1 (C-4’’), 57.58 (d, J = 10.6 Hz, C-3), 57.00 (d, J = 9.3 Hz, C-1), 
56.4 (C-2’), 31.7 (C-2), 30.0 (NCH3), 29.7 (C-3’), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 
20.7 (COCH3); 
19F NMR (376 MHz, CDCl3): δ -196.30 (dt, J = 50.4, 11.5 Hz); ESI-HRMS: m/z 
calcd. for C30H38FN13NaO15 [M+Na]
+ 862.2492; found, 862.2511. 
5-Deoxy-5-fluoro apramycin pentaacetate salt (182). A stirred solution of compound 
181 (29 mg, 0.035 mmol) in dioxane (0.2 mL) was treated with 3N NaOH (0.2 mL) and heated at 
100 °C for 2 h. 1M P(CH3)3 in THF (0.3 mL) was added and the reaction mixture was stirred at 
55 °C for 2h. The reaction mixture was then concentrated and dissolved in aqueous acetic acid 
solution (pH 4, 1 mL) then charged to a Sephadex column (CM Sephadex C-25). The column 
was flushed with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% NH4OH in D.I. 
water. The fractions containing the product were combined, acidified with glacial acetic acid, 
and lyophilized to afford 182 (16 mg, 56%) as peracetate salt in the form of a white solid; 
[α]D25= +89.91 (c 1.1, H2O); 1H NMR (600 MHz, D2O): δ 5.35 (d, J = 3.4 Hz, 1H, H-1’), 5.28 (d, 
J = 3.8 Hz, 1H, H-1’’), 5.00 (d, J = 8.5 Hz, 1H, H-8’), 4.43 (dt, J = 50.8, 9.0 Hz, 1H, H-5), 4.35 
(s, 1H, H-6’), 4.04 (q, J = 9.6 Hz, 1H, H-4), 3.79 – 3.69 (m, 4H, H-6, H-4’, H-3’’, H-5’’), 3.63 
(dd, J = 12.3, 2.9 Hz, 1H, H-6’’), 3.56 (dd, J = 12.5, 4.5 Hz, 1H, H-6’’), 3.52 (d, J = 10.3 Hz, 
1H, H-5’), 3.49 (dd, J = 9.8, 3.9 Hz, 1H, H-2’’), 3.44 (dt, J = 12.3, 3.9 Hz, 1H, H-2’), 3.34 (td, J 
= 11.7, 10.9, 4.0 Hz, 1H, H-3), 3.21 – 3.14 (m, 2H, H-1, H-7’), 3.07 (t, J = 10.4 Hz, 1H, H-4’’), 
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2.57 (s, 3H, NCH3), 2.29 (dt, J = 12.8, 4.3 Hz, 1H, H-2), 2.15 (dt, J = 10.1, 4.5 Hz, 1H, H-3’), 
1.87 – 1.83 (m, 1H, H-3’), 1.73 – 1.66 (m, 1H, H-2); 13C NMR (151 MHz, D2O): δ 95.33 (d, J = 
190.2 Hz, C-5), 94.8 (C-1’), 94.3 (C-1’’), 92.7 (C-8’), 75.72 (d, J = 16.8 Hz, C-4), 70.27 (d, J = 
20.5 Hz, C-6), 70.2 (C-2’’), 69.5 (C-5’), 69.3 (C-5’’), 68.2 (C-3’’), 65.8 (C-4’), 62.6 (C-6’), 60.2 
(C-6’’), 59.3 (C-7’), 52.0 (C-4’’), 48.67 (d, J = 11.5 Hz, C-1), 47.6 (C-2’), 47.34 (d, J = 11.3 Hz, 
C-3), 29.9 (NCH3), 28.0 (C-2), 26.6 (C-3’). 19F NMR (376 MHz, D2O): δ -195.08 (dt, J = 50.9, 
11.7 Hz); ESI-HRMS: m/z calcd. for C21H41FN5O10 [M+H]
+ 542.2837; found, 542.2838. 
6,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-5-deoxy-5-epifluoro-6′,7′-
oxazolidino-apramycin (183). To a stirred ice-cooled solution of compound 124 (50 mg, 0.06 
mmol) in dry DCM (0.2 mL), diethylaminosulfur trifluoride (65 l, 0.48 mmol) was added, and 
the reaction mixture was stirred at rt for 3 h. After completion, the reaction mixture was purified 
by gradient chromatography over silica gel (eluent: 0.7% to 0.8% MeOH in DCM) to give 183 
(37 mg, 74%) as a white solid; [α]D25= +104.39 (c 2.5, DCM); 1H NMR (600 MHz, CDCl3): δ 
5.42 (t, J = 10.0 Hz, 1H, H-3’’), 5.38 (d, J = 3.8 Hz, 1H, H-1’’), 5.09 – 4.96 (m, 2H, H-5, H-1’), 
4.90 – 4.84 (m, 2H, H-8’, H-2’’), 4.80 (dd, J = 7.7, 3.5 Hz, 1H, H-6’), 4.70 (ddd, J = 27.3, 10.5, 
1.8 Hz, 1H, H-6), 4.35 (dd, J = 10.4, 3.4 Hz, 1H, H-5’), 4.32 (dd, J = 12.2, 2.2 Hz, 1H, H-6’’), 
4.21 (dd, J = 12.2, 5.3 Hz, 1H, H-6’’), 4.02 – 3.92 (m, 2H, H-1, H-3), 3.80 (dd, J = 7.6, 4.3 Hz, 
1H, H-7’), 3.78 – 3.69 (m, 2H, H-4’, H-5’’), 3.67 – 3.55 (m, 2H, H-4, H-4’’), 3.34 (dt, J = 12.8, 
4.0 Hz, 1H, H-2’), 2.94 (s, 3H, NCH3), 2.45 (dt, J = 13.5, 4.9 Hz, 1H, H-2), 2.29 (dt, J = 11.3, 
4.4 Hz, 1H, H-3’), 2.17 (s, 3H, COCH3), 2.10 (d, J = 10.8 Hz, 6H, 2*COCH3), 2.06 (s, 3H, 
COCH3), 2.01 – 1.94 (m, 1H, H-3’), 1.42 (q, J = 12.7 Hz, 1H, H-2); 13C NMR (151 MHz, 
CDCl3): δ 170.4 (C=O), 169.9 (C=O), 169.7 (C=O), 156.9 (C=O), 96.7 (C-8’), 96.2 (C-1’), 94.1 
(C-1’’), 87.65 (d, J = 184.1 Hz, C-5), 77.55 (d, J = 17.9 Hz, C-4), 73.45 (d, J = 17.1 Hz, C-6), 
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70.6 (C-6’), 70.3 (C-3’’), 69.8 (C-2’’), 69.1 (C-5’’), 66.4 (C-5’), 65.5 (C-4’), 62.9 (C-6’’), 60.2 
(C-4’’), 60.0 (C-7’), 57.03 (d, J = 3.8 Hz, C-3), 56.0 (C-2’), 55.76 (d, J = 4.1 Hz, C-1), 32.0 (C-
2), 30.1 (NCH3), 29.2 (C-3’), 20.7 (COCH3), 20.7 (COCH3), 20.7 (COCH3); 19F NMR (376 
MHz, CDCl3): δ -213.48 (dt, J = 52.6, 26.8 Hz); ESI-HRMS: m/z calcd. for C30H38FN13NaO15 
[M+Na]+ 862.2492; found, 862.2502. 
5-Deoxy-5-epi-fluoro apramycin pentaacetate salt (184). A stirred solution of 
compound 183 (37 mg, 0.044 mmol) in dioxane (0.2 mL) was treated with 3 N NaOH (0.2 mL) 
and heated at 100 °C for 2 h. 1 M P(CH3)3 in THF (0.3 mL) was added and the reaction mixture 
stirred at 55 °C for 2h. The reaction mixture was then concentrated and dissolved in aqueous 
acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-
25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% 
NH4OH in D.I. water. The fractions containing the product were combined, acidified with glacial 
acetic acid, and lyophilized to afford 184 (22 mg, 59%) as peracetate salt in the form of a white 
solid; [α]D25= +152.0 (c 0.1, H2O); 1H NMR (600 MHz, D2O): δ 5.25 (d, J = 3.9 Hz, 1H, H-1’’), 
5.24 (d, J = 3.8 Hz, 1H, H-1’), 5.13 (d, J = 51.7 Hz, 1H, H-5), 4.98 (d, J = 8.5 Hz, 1H, H-8’), 
4.31 (s, 1H, H-6’), 3.94 (dd, J = 26.1, 10.7 Hz, 1H, H-4), 3.78 – 3.63 (m, 4H, H-6, H-4’, H-3’’, 
H-5’’), 3.61 (dd, J = 12.5, 3.5 Hz, 1H, H-6’’), 3.57 – 3.50 (m, 2H, H-3, H-6’’), 3.49 – 3.44 (m, 
2H, H-2’, H-2’’), 3.42 (dd, J = 10.1, 2.6 Hz, 1H, H-5’), 3.33 (td, J = 11.7, 4.3 Hz, 1H, H-1), 3.12 
(dd, J = 8.5, 2.8 Hz, 1H, H-7’), 3.05 (t, J = 10.4 Hz, 1H, H-4’’), 2.54 (s, 3H, NCH3), 2.29 (dt, J = 
12.6, 4.4 Hz, 1H, H-2), 2.19 – 2.10 (m, 1H, H-3’), 1.90 – 1.82 (m, 1H, H-3’), 1.59 (q, J = 12.6 
Hz, 1H, H-2); 13C NMR (151 MHz, D2O): δ 94.3 (C-1’’), 92.7 (C-8’), 90.3 (C-1’), 87.37 (d, J = 
181.7 Hz, C-5), 72.01 (d, J = 17.8 Hz, C-4), 70.1 (C-2’’), 69.5 (C-5’), 69.2 (C-5’’), 68.55 (d, J = 
17.2 Hz, C-6), 68.1 (C-3’’), 65.7 (C-4’), 62.5 (C-6’), 60.2 (C-6’’), 59.3 (C-7’), 52.0 (C-4’’), 
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48.09 (d, J = 4.4 Hz, C-1), 47.3 (C-2’), 46.61 (d, J = 4.2 Hz, C-3), 29.9 (NCH3), 27.9 (C-2), 26.7 
(C-3’); 19F NMR (376 MHz, D2O): δ -217.88 (dt, J = 51.8, 27.2 Hz); ESI-HRMS: m/z calcd. for 
C21H41FN5O10 [M+H]
+ 542.2837; found, 542.2825.  
6,2'',3'',6''-Tetra-O-acetyl-1,3,2′,4′′-tetraazido-5-deoxy-5-epiiodo-6′,7′-oxazolidino-
apramycin (185). To a stirred solution of compound 124 (100 mg, 0.12 mmol) in dry DCM (1.5 
mL), pyridine (0.1 mL) was added and reaction mixture was cooled to 0 °C before triflic 
anhydride (40 L, 0.24 mmol) was added. The reaction mixture was stirred for 1 h and additional 
triflic anhydride (40 L, 0.24 mmol) was added. After 2 h, the reaction mixture was poured into 
an iced aqueous solution of NaHCO3 and extracted with EtOAc. The organic layer was washed 
with brine and dried over Na2SO4 and concentrated in vacuo. The crude product was dissolved in 
dry acetone (25 mL), heated to reflux under stirring with sodium iodide (266 mg, 1.78 mmol) for 
12 h. After completion, the reaction mixture was concentrated, diluted with EtOAc and washed 
with brine then concentrated. The crude product was purified using silica gel column 
chromatography (eluent: 0.6% - 1.0% Methanol/DCM) to give compound 185 (93 mg, 89%) as a 
white solid; [α]D25= +172.23 (c 6.2, DCM); 1H NMR (600 MHz, CDCl3): δ 5.46 – 5.38 (m, 2H, 
H-1’’, H-3’’), 4.92 (d, J = 3.4 Hz, 1H, H-1’), 4.84 (t, J = 3.2 Hz, 1H, H-5), 4.80 – 4.72 (m, 3H, 
H-6’, H-8’, H-2’’), 4.31 (dd, J = 12.3, 2.2 Hz, 1H, H-6’’), 4.20 (dd, J = 12.2, 5.4 Hz, 1H, H-6’’), 
4.04 – 3.98 (m, 2H, H-3, H-4), 3.98 – 3.90 (m, 2H, H-1, H-5’), 3.80 – 3.70 (m, 2H, H-7’, H-5’’), 
3.66 (td, J = 10.8, 4.5 Hz, 1H, H-4’), 3.55 (t, J = 10.2 Hz, 1H, H-4’’), 3.25 (dt, J = 12.8, 3.9 Hz, 
1H, H-2’), 3.06 (dd, J = 9.7, 3.6 Hz, 1H, H-6), 2.94 (s, 3H, NCH3), 2.28 (ddt, J = 12.6, 8.7, 4.6 
Hz, 2H, H-2, H-3’), 2.15 (s, 3H, COCH3), 2.13 – 2.03 (m, 7H, H-3’, 2*COCH3), 2.01 (s, 3H, 
COCH3), 1.41 – 1.29 (m, 1H, H-2); 13C NMR (151 MHz, CDCl3): δ 170.4 (C=O), 170.2 (C=O), 
169.6 (C=O), 169.6 (C=O), 156.8 (C=O), 99.8 (C-8’), 94.3 (C-1’’), 93.9 (C-1’), 74.1 (C-6), 72.6 
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(C-4), 71.7 (C-6’), 69.9 (C-2’’), 69.8 (C-3’’), 69.4 (C-5’’), 67.2 (C-5’), 65.8 (C-4’), 62.8 (C-6’’), 
60.6 (C-1), 60.2 (C-4’’), 60.1 (C-7’), 59.2 (C-3), 55.4 (C-2’), 32.8 (C-5), 32.6 (C-2), 30.4 
(NCH3), 28.0 (C-3’), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3); ESI-HRMS: 
m/z calcd. for C30H38IN13NaO15 [M+Na]
+ 970.1553; found, 970.1571. 
5-Deoxy-apramycin pentaacetate salt (186). To a solution of compound 185 (45 mg, 
0.05 mmol) in dry methanol (5 mL), sodium methoxide (10 mg, 0.06 mmol) was added and 
reaction mixture was stirred for 30 min. The reaction was quenched with Amberlyst®, filtered 
and the solvent was evaporated in vacuo. The crude product was dissolved in 
dioxane:water:glacial acetic acid = 1:2:0.2 (0.3 mL) and 10% Pd/C (60 mg, 1.1 equiv.) was 
added. The reaction was stirred at room temperature under 1 atm of hydrogen (balloon) for 12 h. 
After completion, the reaction mixture was filtered over Celite® and filtrate concentrated to 
dryness. The residue was dissolved in dioxane (0.5 mL) and treated with 3N NaOH (0.25 mL) 
and heated at 100 °C for 30 min. The reaction mixture was cooled to rt and neutralized with 
glacial acetic acid before concentration in vacuo. The crude product was dissolved in aqueous 
acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM Sephadex C-
25). The column was flushed with D.I. water (20 mL), then gradient eluted with 0.1% - 1.0% 
NH4OH in D.I. water. The fractions containing the product were combined, acidified with glacial 
acetic acid and lyophilized to afford 186  (18.5 mg, 47%) as a white solid; [α]D25= +105.0 (c 0.2, 
H2O); 1H NMR (600 MHz, D2O): δ 5.35 (d, J = 4.0 Hz, 1H, H-1’’), 5.23 (d, J = 3.8 Hz, 1H, H-
1’), 5.07 (d, J = 8.5 Hz, 1H, H-8’), 4.40 (s, 1H, H-6’), 3.87 – 3.73 (m, 4H, H-4, H-4’, H-3’’, H-
5’’), 3.70 (dd, J = 12.5, 3.3 Hz, 1H, H-6’’), 3.63 (dd, J = 12.5, 4.7 Hz, 1H, H-6’’), 3.62 – 3.52 
(m, 2H, H-6, H-2’’), 3.52 (dt, J = 12.8, 4.3 Hz, 1H, H-2’), 3.48 (dd, J = 10.0, 3.0 Hz, 1H, H-5’), 
3.34 (ddd, J = 12.4, 10.1, 4.1 Hz, 1H, H-3), 3.21 (dd, J = 8.5, 2.9 Hz, 1H, H-7’), 3.17 – 3.10 (m, 
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2H, H-1, H-4’’), 2.63 (s, 3H, NCH3), 2.55 (dt, J = 12.2, 4.3 Hz, 1H, H-5), 2.33 (dt, J = 12.6, 4.3 
Hz, 1H, H-2), 2.23 (dt, J = 10.8, 4.5 Hz, 1H, H-3’), 1.90 (q, J = 11.8, 11.0 Hz, 1H, H-3’), 1.61 
(q, J = 12.5 Hz, 1H, H-2), 1.34 (q, J = 11.7 Hz, 1H, H-5); 13C NMR (151 MHz, D2O): δ 94.3 (C-
1’’), 92.7 (C-8’), 90.1 (C-1’), 70.8 (C-4), 70.2 (C-6), 69.4 (C-2’’), 69.3 (C-5’), 68.2 (C-5’’), 67.2 
(C-3’’), 65.8 (C-4’), 62.6 (C-6’), 60.2 (C-6’’), 59.4 (C-7’), 52.5 (C-1), 52.0 (C-4’’), 50.8 (C-3), 
47.3 (C-2’), 33.8 (C-5), 30.0 (NCH3), 28.5 (C-2), 26.9 (C-3’); ESI-HRMS: m/z calcd. for 
C21H42N5O10 [M+H]
+ 524.2932; found, 524.2924. 
1,2′,4′′-Triazido-apramycin (188). Trifluoromethanesulfonyl azide was prepared fresh 
for each reaction as described here. Sodium azide (995.0 mg, 14.5 mmol) was dissolved in water 
(5.0 mL) and an equal volume of dichloromethane (5.0 mL) was added while stirring at room 
temperature. The resulting suspension was cooled to 0 ºC and Tf2O (2.0 g, 7.4 mol) was added 
drop wise over 45 min with vigorous stirring. The mixture was stirred at 0 ºC for 3 h before sat. 
NaHCO3 (5.0 mL) was added to quench the reaction. The organic layer was separated and the 
aqueous layer was extracted with dichloromethane (5.0 mL). The organic layers were combined 
(triflyl azide solution) and kept at 0 ºC until needed. In a 100 mL round bottom flask, 3-N-
(benzyloxycarbonyloxy) apramycin152 187 (500.0 mg, 0.74 mmol), NaHCO3 (524.0 mg, 6.20 
mmol) and CuSO4.5H2O (18.0 mg, 0.17 mmol) were dissolved in H2O (3.0 mL) and cooled to 0 
ºC. Triflyl azide solution (freshly prepared dichloromethane solution) was added slowly to the 
reaction mixture at 0 oC over 0.5 h, followed by drop wise addition of MeOH (5.0 mL) over 0.5 
h. The reaction mixture was allowed to come to room temperature and was stirred for 8 h before 
n-butylamine (500.0 mg) was added to quench the excess TfN3. The solvent was evaporated 
under vacuum and the residue was purified by column chromatography over silica gel to give 2 
(135.0 mg, 43%) as a white solid and which used for further without any characterization. A 
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stirred solution of 2 (134.0 mg, 0.18 mmol) in p-dioxane (2 mL) was treated with 3N NaOH (2.0 
mL) at rt. The resulting reaction mixture was stirred at 100 ºC for 2 h and was quenched with 
glacial acetic acid. The reaction mixture was concentrated to afford a yellow oil that was purified 
by chromatography over silica gel eluting with gradient of 10% to 40% ammonical methanol in 
dichloromethane to give 3 (92.0 mg, 84%) as a white foam. [α]D25 = +114.28 (c 0.14, MeOH); 1H 
NMR (600 MHz, CD4OD): δ 5.68 (d, J = 3.5 Hz, 1H), 5.32 (d, J = 3.9 Hz, 1H), 4.99 (d, J = 8.3 
Hz, 1H), 4.31 (t, J = 2.8 Hz, 1H), 3.87-3.78 (m, 2H), 3.80-3.74 (m, 1H), 3.70-3.62 (m, 2H), 3.59-
3.49 (m, 3H), 3.45 (td, J = 9.5, 2.8 Hz, 1H), 3.39 (td, J = 10.2, 3.7 Hz, 2H), 3.33 (d, J = 4.6 Hz, 
1H), 3.31-3.24 (m, 2H), 3.01-2.90 (m, 2H), 2.60 (s, 3H), 2.20 (dt, J = 9.6, 4.5 Hz, 1H), 2.14-2.02 
(m, 2H), 1.91 (s, 2H), 1.33 (q, J = 12.5 Hz, 1H); 13C NMR (151 MHz, CD4OD) δ 97.02, 94.51, 
94.37, 81.82, 77.02, 76.34, 72.24, 71.46, 71.28, 70.21, 66.58, 64.32, 62.04, 60.98, 60.93, 60.84, 
56.72, 49.31, 33.19, 31.07, 27.70; ESI-HRMS: m/z calcd. for C21H35N11O11 [M+H]
+ 640.2415, 
found: 640.2399. 
N-(Diethylcarbamoyl)-N-methoxyacetamide (189). To a mixture of 1,1-diethyl-3-
methoxyurea172 (500 mg, 3.4 mmol), 4-dimethylaminopyridine (1250 mg, 10.2 mmol ) and DCM 
(5 mL) cooled in an ice-bath was added acetic anhydride (970 L, 10.2 mmol) over 20 min. The 
mixture was stirred for 10 h before diluting with EtOAc. The organic layer washed with 5% 
aqueous HCl, aqueous Na2HCO3 and brine, dried with Na2SO4 and concentrated. The crude 
product was purified using silica gel column chromatography (eluent: 50% EtOAc/hexanes) to 
give 189 (385 mg, 65%) as colorless oil; 1H NMR (400 MHz, CDCl3) δ 3.67 (s, 3H, OCH3), 3.25 
(br s, 4H, 2*NCH2CH3), 2.08 (s, 3H, COCH3), 1.08 (t, J = 7.2 Hz, 6H, 2*NCH2CH3); 
13C NMR 
(101 MHz, CDCL3) δ 170.0 (COCH3), 153.3 (NCON), 63.2 (OCH3), 41.6 (NCH2CH3), 21.9 
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(COCH3), 13.0 (NCH2CH3); ESI-HRMS: m/z calcd. for C8H16N2NaO3 [M+Na]
+ 211.1059; 
found, 211.1050. 
3-O-Formyl-apramycin tetraacetate salt (190). To a stirred solution of 1,2',4''-triazido-
apramycin 188 (15 mg, 0.02 mmol) in water (0.5 mL), N-(diethylcarbamoyl)-N-
methoxyformamide172 (16 L, 0.09 mmol) and triethylamine (2L) were added. The reaction 
mixture was stirred for 48 h and quenched with aqueous ammonium hydroxide (0.5 mL) and 
concentrated. The crude product was purified using silica gel column chromatography (eluent: 
0.5% to 3% ammonical MeOH in DCM). The product-containing fractions was concentrated and 
dissolved in dioxane:water (1:1, 0.4 mL) followed by the addition 1 M P(CH3)3 in THF (0.2 mL), 
and stirred at 50 °C for 2 h. The reaction mixture was then concentrated to dryness and dissolved 
in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a Sephadex column (CM 
Sephadex C-25). The column was flushed with D.I. water (20 mL), then gradient elution of 0.1% 
- 1.0% NH4OH in D.I. water. The fractions containing the product were combined, acidified with 
acetic acid, and lyophilized to afford 190 (5 mg, 25%) as a white solid; [α]D25= +103.2 (c 0.3, 
H2O); Major (trans): Minor (Cis) = 4:3; Major (trans): 
1H NMR (600 MHz, D2O) δ 5.28 (d, J = 
3.5 Hz, 1H, H-1’t), 3.99 – 3.91 (m, 1H, H-3t), 3.04 (dd, J = 8.6, 2.4 Hz, 1H, 7’t) 2.64 (s, 3H, 
NCH3t), 2.08 (dt, J = 13.3, 3.9 Hz, 1H, H-2);
 13C NMR (151 MHz, d2o) δ 163.8 (CHOt), 96.1 (C-
1’t), 81.1 (C-4t), 46.4 (C-3t), 30.2 (C-2t); Minor (Cis): 1H NMR (600 MHz, Deuterium Oxide): δ 
5.20 (d, J = 3.6 Hz, 0.75H, H-1’c), 2.63 (s, 1.5H, NCH3c); 13C NMR (151 MHz, d2o): δ 167.2 
(CHOc), 96.6 (C-1’c), 81.2 (C-4c), 51.0 (C-3c), 31.5 (C-2c); Not resolved rotamers; 1H NMR 
(600 MHz, D2O): δ 8.00 (s, 1H, CHO), 7.93 (s, 1H, CHO), 5.32 (t, J = 4.3 Hz, 1.75H, H-1’’), 
5.04 (t, J = 7.5 Hz, 1.75H, H-8’), 4.27 (s, 1.75H, H-6’), 3.84 – 3.78 (m, 1.75H, H-5’’), 3.78 –  
3.71 (m, 3.5H, H-4’, H-3’’), 3.69 (dd, J = 12.5, 3.3 Hz, 1.75H, H-6’’), 3.62 (dd, J = 12.5, 4.5 Hz, 
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1.75H, H-6’’), 3.59 – 3.51 (m, 3.5H, H-3c, H-4t, H-2’’), 3.50 – 3.39 (m, 6H, H-4c, H-5, H-2’, H-
5’), 3.38 – 3.31 (m, 1.75H, 6), 3.19 – 3.06 (m, 4.25H, H-1, H-4’’, H-7c), 2.19 (ddt, J = 16.3, 8.8, 
4.4 Hz, 2.25H, H-3’, H-2c), 1.59 (q, J = 12.5 Hz, 1.75H, H-2); 13C NMR (151 MHz, D2O): δ 94.4 
(C-1’’), 92.9 and 92.7 (C-8’), 75.5 and 75.2 (C-5), 72.5 (C-6), 70.2 (C-2’’), 69.4 (C-5’’), 69.5 
and 69.0 (C-5’), 68.4 (C-3’’), 65.9 (C-4’), 62.8 and 62.5 (C-6’), 60.3 (C-6’’), 59.6 (C-7’), 52.0 
(C-4’’), 50.1 and 50.0 (C-1), 48.2 and 48.0 (C-2’), 30.1 and 30.0, (NCH3), 27.1 and 26.9 (C-3’); 
ESI-HRMS: m/z calcd. for C22H42N5O10 [M+H]
+ 568.2830; found, 568.2833. 
3-O-Acetyl-apramycin tetraacetate salt (191). To a stirred solution of 1,2',4''-triazido-
apramycin 188 (15 mg, 0.02 mmol) in water (0.5 mL), N-(diethylcarbamoyl)-N-
methoxyacetamide 189 (50 L, 0.26 mmol) was added. The reaction mixture was stirred for 3 h 
and quenched with aqueous ammonium hydroxide (0.5 mL) and concentrated. The crude product 
was purified using silica gel column chromatography (eluent: 0.5% to 3% ammonical MeOH in 
DCM). The crude product was dissolved in dioxane:water:glacial acetic acid = 1:2:0.2 (0.3 mL) 
and 10% Pd/C (20 mg, 1 equiv.) was added. The reaction was stirred at room temperature under 
1 atm of hydrogen (balloon) for 1 h. After completion, the reaction mixture was filtered over 
Celite® and filtrate concentrated to dryness. The reaction mixture was then concentrated to 
dryness and dissolved in aqueous acetic acid solution (pH 4, 1 mL) before it was charged to a 
Sephadex column (CM Sephadex C-25). The column was flushed with D.I. water (20 mL), then 
gradient elution of 0.1% - 1.0% NH4OH in D.I. water. The fractions containing the product were 
combined, acidified with acetic acid, and lyophilized to afford 191 (3 mg, 15%) as a white solid; 
[α]D25= +113.0 (c 0.1, H2O);1H NMR (600 MHz, D2O): δ 5.41 (d, J = 3.3 Hz, 1H, H-1’), 5.36 (d, 
J = 4.0 Hz, 1H, H-1’’), 5.07 (d, J = 8.4 Hz, 1H, H-8’), 4.33 (s, 1H, H-6’), 3.89 (ddd, J = 12.5, 
9.6, 4.4 Hz, 1H, H-3), 3.84 – 3.74 (m, 3H, H-4’, H-3’’, H-5’’), 3.71 (dd, J = 12.5, 3.3 Hz, 1H, H-
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6’’), 3.64 (dd, J = 12.4, 4.7 Hz, 1H, H-6’’), 3.57 (dd, J = 9.8, 4.0 Hz, 1H, H-2’’), 3.54 – 3.44 (m, 
2H, H-4, H-5), 3.44 – 3.34 (m, 2H, H-2’, H-5’), 3.35 (t, J = 9.7 Hz, 1H, H-6), 3.17 – 3.07 (m, 
3H, H-1, H-7’, H-4’’), 2.65 (s, 3H, NCH3), 2.19 (dt, J = 11.1, 4.7 Hz, 1H, H-3’), 2.08 (dt, J = 
12.9, 4.4 Hz, 1H, H-2), 1.89 (s, 3H, COCH3), 1.74 (q, J = 11.9 Hz, 1H, H-3’), 1.53 (q, J = 12.7 
Hz, 1H, H-2); 13C NMR (151 MHz, D2O): δ 173.4 (C=O), 95.3 (C-1’), 94.3 (C-1’’), 92.9 (C-8’), 
79.6 (C-4), 75.8 (C-5), 72.7 (C-6), 70.2 (C-2’’), 69.6 (C-5’’), 69.5 (C-5’), 68.5 (C-3’’), 65.9 (C-
4’), 62.9 (C-6’), 60.3 (C-6’’), 59.8 (C-7’), 52.1 (C-4’’), 50.1 (C-1), 48.3 (C-2’), 47.5 (C-3), 30.3 
(C-2), 30.1 (NCH3), 26.8 (C-3’), 22.4 (COCH3); ESI-HRMS: m/z calcd. for C23H44N5O12 
[M+H]+ 582.2986; found, 582.2983.  
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ABSTRACT 
SYNTHESIS OF NETILMICIN AND APRAMYCIN DERIVATIVES FOR THE 
TREATMENT OF MULTIDRUG-RESISTANT INFECTIOUS DISEASES  
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Degree: Doctor of Philosophy 
The ever-growing bacterial resistance to existing antibiotics is alarming to humanity. 
Many researchers decided to revisit aminoglycosides with renewed emphasis on chemical 
modification as they have long been used as highly potent antibiotics for treating severe bacterial 
infections. The bactericidal effect of aminoglycosides is mainly due to protein synthesis 
inhibition by binding to the A-site of the bacterial ribosomes. However, the high potency and the 
broad spectrum of aminoglycosides has been outweighed by their side effects, especially 
ototoxicity, and by the resistance of pathogens. The goal of this research was the modification of 
existing aminoglycosides to develop derivatives which are less toxic and that evade resistance. 
The chapters in the thesis discuss the chemical synthesis as well as the biological evaluation of 
the newly synthesized analogs. This study has focused on the modification of aminoglycosides 
netilmicin and apramycin. 
Chapter one introduces the MDR bacterial infection problem and its influence. Chapter 
one also introduces the aminoglycosides elaborating their history, classifications, and their 
mechanism of action. The resistance mechanisms against aminoglycosides and their adverse 
effects, as well as the ways to prevent them are briefly explained. 
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Chapter two discusses modifications of netilmicin at the 4’-position conducted with a 
view to reducing the ototoxicity but not the antibiotic activity, as was previously done in the 4,5-
series with paromomycin. The antibacterial activity and antiribosomal activity of the six 
netilmicin derivatives synthesized were determined. The 4’-position is more sensitive to 
modification in 4,6-series than in the 4,5-series to the extent that such modifications are 
ineffective. Chapter two also highlights the use of phenyl triazenes as selective protecting groups 
for secondary amines in the presence of primary amines. Several polyamine substrates were 
selectively protected as phenyl triazenes, and primary amines were subsequently protected as 
azides, benzyloxy carbamates, or fluorenylmethyl carbamates. Phenyl triazenes enabled the 
synthesis of plazomicin, an aminoglycoside in phase III clinical trials, in fewer steps and higher 
yield than previously reported. 
Chapter three describes derivatization and modification of apramycin at the 5-position. 
The influence of these modifications was investigated using cell-free translation assays and 
antibacterial assays. An apramycin-paromomycin hybrid was synthesized with the aim of 
combining paromomycin’s high activity with apramycin’s low ototoxicity. Eighteen compounds 
were synthesized with modifications mainly at the 5-position leading to the development of a 
potent derivative that was more active than apramycin against all bacterial strains tested and 
which also showed better ribosomal selectivity. This investigation affords proof of concept for 
the development of more potent and selective aminoglycosides in the apramycin class. 
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